{
  "items": "466",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "What's Going On With Acadia Pharmaceuticals Stock? - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/12/36220214/whats-going-on-with-acadia-pharmaceuticals-stock",
      "time_published": "20231213T174440",
      "authors": [
        "Erica Kollmann"
      ],
      "summary": "Acadia Pharmaceuticals Inc. ACAD shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. According to court documents, Acadia won the the judgment over MSN Laboratories regarding its patent of Nuplazid.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/acadia_pharmaceuticals_stock_acad_shares.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.273462,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.932163",
          "ticker_sentiment_score": "0.356249",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/03/31338344/acadia-pharmaceuticals-gets-price-target-bumps-by-analysts-after-fda-approval-of-rett-syndrome-drug",
      "time_published": "20230314T122819",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "The FDA approved Acadia Pharmaceuticals Inc's ACAD Daybue ( trofinetide ) for Rett syndrome in adult and pediatric patients two years of age and older. Daybue is the first and only drug approved for treating Rett syndrome, a rare genetic neurological and developmental disorder that causes a ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/14/image19_1.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.035903,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CCORF",
          "relevance_score": "0.350564",
          "ticker_sentiment_score": "0.218282",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.930964",
          "ticker_sentiment_score": "0.195674",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.350564",
          "ticker_sentiment_score": "0.248583",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "StockNews.com Upgrades ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  to Buy",
      "url": "https://reporter.am/2022/09/07/stocknews-com-upgrades-acadia-pharmaceuticals-nasdaqacad-to-buy.html",
      "time_published": "20220907T112115",
      "authors": [
        "AM Reporter Staff"
      ],
      "summary": "ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) was upgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Monday. ACAD has been the topic of a number of other research reports.",
      "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg&w=240&h=240&zc=2",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "reporter.am",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.223522,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NMR",
          "relevance_score": "0.073098",
          "ticker_sentiment_score": "0.169861",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PRU",
          "relevance_score": "0.145583",
          "ticker_sentiment_score": "0.211562",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.918687",
          "ticker_sentiment_score": "0.385407",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.073098",
          "ticker_sentiment_score": "0.087621",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZO",
          "relevance_score": "0.073098",
          "ticker_sentiment_score": "0.015217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.073098",
          "ticker_sentiment_score": "0.087621",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is a Surprise Coming for Acadia Pharmaceuticals  ( ACAD )  This Earnings Season?",
      "url": "https://www.zacks.com/stock/news/2011920/is-a-surprise-coming-for-acadia-pharmaceuticals-acad-this-earnings-season",
      "time_published": "20221101T140400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4b/2087.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998287"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.447479,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.911063",
          "ticker_sentiment_score": "0.692805",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Downgraded by StockNews.com to Hold",
      "url": "https://reporter.am/2022/09/14/acadia-pharmaceuticals-nasdaqacad-downgraded-by-stocknews-com-to-hold.html",
      "time_published": "20220914T073643",
      "authors": [
        "AM Reporter Staff"
      ],
      "summary": "StockNews.com lowered shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) from a buy rating to a hold rating in a report published on Tuesday.",
      "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg&w=240&h=240&zc=2",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "reporter.am",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.126794,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FIVE",
          "relevance_score": "0.06623",
          "ticker_sentiment_score": "-0.004021",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JEF",
          "relevance_score": "0.06623",
          "ticker_sentiment_score": "0.003014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.174236",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.903497",
          "ticker_sentiment_score": "0.222287",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.174236",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.06623",
          "ticker_sentiment_score": "0.003014",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded at StockNews.com",
      "url": "https://www.etfdailynews.com/2022/09/21/acadia-pharmaceuticals-nasdaqacad-upgraded-at-stocknews-com/",
      "time_published": "20220921T061047",
      "authors": [
        "MarketBeat News"
      ],
      "summary": "ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Wednesday. ACAD has been the subject of a number of other research reports.",
      "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg&w=240&h=240&zc=2",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.etfdailynews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999967"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.186821,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ROKU",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "-0.032125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RUTH",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "-0.032125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.891347",
          "ticker_sentiment_score": "0.321724",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "0.053158",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "0.053158",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.063933",
          "ticker_sentiment_score": "0.053158",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Stock Rating Lowered by StockNews.com",
      "url": "https://www.etfdailynews.com/2022/11/11/acadia-pharmaceuticals-nasdaqacad-stock-rating-lowered-by-stocknews-com-2/",
      "time_published": "20221111T081645",
      "authors": [
        "MarketBeat News"
      ],
      "summary": "StockNews.com lowered shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) from a buy rating to a hold rating in a research report report published on Friday morning.",
      "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=ACAD",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.etfdailynews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.692272"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.195087,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "C",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "0.050989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBS",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.186741",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CPNG",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "-0.02505",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.862496",
          "ticker_sentiment_score": "0.332296",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "0.001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "0.050989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HBI",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "-0.02505",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Stock Rating Lowered by StockNews.com",
      "url": "https://www.etfdailynews.com/2022/11/02/acadia-pharmaceuticals-nasdaqacad-stock-rating-lowered-by-stocknews-com/",
      "time_published": "20221102T074242",
      "authors": [
        "MarketBeat News"
      ],
      "summary": "StockNews.com lowered shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) from a buy rating to a hold rating in a research note released on Tuesday morning.",
      "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=ACAD",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.etfdailynews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.723405"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.249122,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WMG",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "0.058012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AWK",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "0.058012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.859573",
          "ticker_sentiment_score": "0.416883",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "0.058012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded to \"Buy\" by StockNews.com",
      "url": "https://reporter.am/2022/09/22/acadia-pharmaceuticals-nasdaqacad-upgraded-to-buy-by-stocknews-com.html",
      "time_published": "20220922T074242",
      "authors": [
        "AM Reporter Staff"
      ],
      "summary": "StockNews.com upgraded shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) from a hold rating to a buy rating in a report published on Wednesday morning. A number of other equities research analysts also recently issued reports on the stock.",
      "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg&w=240&h=240&zc=2",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "reporter.am",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.186059,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JEF",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.015033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.84342",
          "ticker_sentiment_score": "0.315298",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.015033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCORF",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.015033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.015033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.066414",
          "ticker_sentiment_score": "-0.015033",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia: Q1 Earnings Snapshot",
      "url": "https://apnews.com/article/business-earnings-san-diego-acadia-pharmaceuticals-inc-19f4526c075f8d94dd093e44f850f5d8",
      "time_published": "20220504T211132",
      "authors": [],
      "summary": "Acadia: Q1 Earnings Snapshot The Associated Press - en Espa\u00f1ol",
      "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png",
      "source": "Associated Press",
      "category_within_source": "Business",
      "source_domain": "apnews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": -0.320032,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.829759",
          "ticker_sentiment_score": "-0.123047",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Downgraded by StockNews.com to Hold",
      "url": "https://www.etfdailynews.com/2022/11/11/acadia-pharmaceuticals-nasdaqacad-downgraded-by-stocknews-com-to-hold/",
      "time_published": "20221111T081645",
      "authors": [
        "MarketBeat News"
      ],
      "summary": "ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating ) was downgraded by equities researchers at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research report issued on Friday. Other research analysts also recently issued reports about the stock.",
      "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=ACAD",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.etfdailynews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.20013,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "UBS",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "0.199594",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CPNG",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "-0.02502",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.823212",
          "ticker_sentiment_score": "0.306054",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "-0.037937",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "0.037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "0.037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HBI",
          "relevance_score": "0.056674",
          "ticker_sentiment_score": "-0.02502",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "StockNews.com Downgrades ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  to Hold",
      "url": "https://www.defenseworld.net/2023/11/07/stocknews-com-downgrades-acadia-pharmaceuticals-nasdaqacad-to-hold.html",
      "time_published": "20231107T092444",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "StockNews.com Downgrades ACADIA Pharmaceuticals ( NASDAQ ... Defense World ...",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.271282,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "STT",
          "relevance_score": "0.103554",
          "ticker_sentiment_score": "0.209233",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.806919",
          "ticker_sentiment_score": "0.441519",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MNGPF",
          "relevance_score": "0.103554",
          "ticker_sentiment_score": "0.209233",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.051886",
          "ticker_sentiment_score": "0.061788",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "StockNews.com Downgrades ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  to Hold",
      "url": "https://www.defenseworld.net/2023/12/02/stocknews-com-downgrades-acadia-pharmaceuticals-nasdaqacad-to-hold-2.html",
      "time_published": "20231202T065047",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "StockNews.com Downgrades ACADIA Pharmaceuticals ( NASDAQ ... Defense World ...",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.256051,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.081024",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.802624",
          "ticker_sentiment_score": "0.417992",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.081024",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded by StockNews.com to Buy",
      "url": "https://www.defenseworld.net/2023/12/09/acadia-pharmaceuticals-nasdaqacad-upgraded-by-stocknews-com-to-buy.html",
      "time_published": "20231210T020749",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "StockNews.com upgraded shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Free Report ) from a hold rating to a buy rating in a research note published on Friday. ACAD has been the subject of a number of other reports. UBS Group began coverage on shares of ACADIA Pharmaceuticals in a report on ...",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.273483,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JPM",
          "relevance_score": "0.047749",
          "ticker_sentiment_score": "0.087406",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.791422",
          "ticker_sentiment_score": "0.403363",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Looking At ACADIA Pharmaceuticals's Recent Whale Trades",
      "url": "https://www.benzinga.com/markets/options/22/06/27725846/looking-at-acadia-pharmaceuticalss-recent-whale-trades",
      "time_published": "20220615T173217",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on ACADIA Pharmaceuticals. Looking at options history for ACADIA Pharmaceuticals ACAD we detected 18 strange trades.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/movers_image_6881.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": -0.036858,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.765876",
          "ticker_sentiment_score": "-0.037842",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is ACADIA Pharmaceuticals  ( ACAD )  Stock Outpacing Its Medical Peers This Year?",
      "url": "https://www.zacks.com/stock/news/2125346/is-acadia-pharmaceuticals-acad-stock-outpacing-its-medical-peers-this-year",
      "time_published": "20230721T134010",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.211199,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.753462",
          "ticker_sentiment_score": "0.300153",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded to \"Strong-Buy\" by StockNews.com",
      "url": "https://www.defenseworld.net/2024/07/12/acadia-pharmaceuticals-nasdaqacad-upgraded-to-strong-buy-by-stocknews-com.html",
      "time_published": "20240712T110848",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "StockNews.com upgraded shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Free Report ) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday.",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.236051,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.74287",
          "ticker_sentiment_score": "0.312612",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.09495",
          "ticker_sentiment_score": "0.100006",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.047559",
          "ticker_sentiment_score": "0.021783",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.047559",
          "ticker_sentiment_score": "0.021783",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.047559",
          "ticker_sentiment_score": "0.021783",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBS",
          "relevance_score": "0.09495",
          "ticker_sentiment_score": "0.144225",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded to Buy by StockNews.com",
      "url": "https://www.defenseworld.net/2023/10/31/acadia-pharmaceuticals-nasdaqacad-upgraded-to-buy-by-stocknews-com.html",
      "time_published": "20231031T070443",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "ACADIA Pharmaceuticals ( NASDAQ:ACAD ) Upgraded to Buy by ... Defense World ...",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972476"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.289192,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDNDF",
          "relevance_score": "0.04303",
          "ticker_sentiment_score": "0.166234",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.742825",
          "ticker_sentiment_score": "0.45444",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.04303",
          "ticker_sentiment_score": "0.066627",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACAD or TECH: Which Is the Better Value Stock Right Now?",
      "url": "https://www.zacks.com/stock/news/2348436/acad-or-tech-which-is-the-better-value-stock-right-now",
      "time_published": "20241009T154015",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ACAD vs. TECH: Which Stock Is the Better Value Option?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default107.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.503661,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.7414",
          "ticker_sentiment_score": "0.620624",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Downgraded to \"Hold\" at StockNews.com",
      "url": "https://www.defenseworld.net/2023/12/16/acadia-pharmaceuticals-nasdaqacad-downgraded-to-hold-at-stocknews-com.html",
      "time_published": "20231216T062044",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued on Saturday. Other equities analysts also recently issued research reports about the stock.",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.289876,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.077937",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.739097",
          "ticker_sentiment_score": "0.401923",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.077937",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Are Medical Stocks Lagging ACADIA Pharmaceuticals  ( ACAD )  This Year?",
      "url": "https://www.zacks.com/stock/news/2185974/are-medical-stocks-lagging-acadia-pharmaceuticals-acad-this-year",
      "time_published": "20231117T144007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default336.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.201452,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.381463",
          "ticker_sentiment_score": "0.324311",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.737428",
          "ticker_sentiment_score": "0.278888",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Stock Upgrades: ACADIA Pharmaceuticals Shows Rising Relative Strength",
      "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-acadia-pharmaceuticals-shows-rising-relative-strength-7/",
      "time_published": "20231011T070000",
      "authors": [
        "INVESTOR'S BUSINESS DAILY",
        "Investor's Business Daily"
      ],
      "summary": "Stock Upgrades: ACADIA Pharmaceuticals Shows Rising Relative ... Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.372608,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KNSA",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.124621",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.726435",
          "ticker_sentiment_score": "0.564905",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HCM",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.124621",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded to \"Strong-Buy\" at StockNews.com",
      "url": "https://www.americanbankingnews.com/2024/07/13/acadia-pharmaceuticals-nasdaqacad-upgraded-to-strong-buy-at-stocknews-com.html",
      "time_published": "20240713T061935",
      "authors": [
        "ABMN Staff"
      ],
      "summary": "ACADIA Pharmaceuticals ( NASDAQ:ACAD - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a note issued to investors on Thursday. ACAD has been the subject of several other reports.",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo-1200x675.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.americanbankingnews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.82617"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.269115,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BEN",
          "relevance_score": "0.087027",
          "ticker_sentiment_score": "0.218288",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.725561",
          "ticker_sentiment_score": "0.422058",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.087027",
          "ticker_sentiment_score": "0.090695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBCPF",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "0.027339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "0.027339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "0.027339",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  Upgraded by StockNews.com to Buy",
      "url": "https://www.defenseworld.net/2024/01/31/acadia-pharmaceuticals-nasdaqacad-upgraded-by-stocknews-com-to-buy.html",
      "time_published": "20240131T083845",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "StockNews.com upgraded shares of ACADIA Pharmaceuticals ( NASDAQ:ACAD - Free Report ) from a hold rating to a buy rating in a research report released on Tuesday. Other equities analysts also recently issued research reports about the stock. Robert W.",
      "banner_image": "https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo.jpg?v=20221122152651",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "www.defenseworld.net",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.274242,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.047371",
          "ticker_sentiment_score": "0.067584",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.715069",
          "ticker_sentiment_score": "0.389339",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "KMDA or ACAD: Which Is the Better Value Stock Right Now?",
      "url": "https://www.zacks.com/stock/news/2563501/kmda-or-acad-which-is-the-better-value-stock-right-now",
      "time_published": "20250704T154003",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "KMDA vs. ACAD: Which Stock Is the Better Value Option?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default68.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.518588,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KMDA",
          "relevance_score": "0.802099",
          "ticker_sentiment_score": "0.615027",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.69701",
          "ticker_sentiment_score": "0.588897",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "KMDA vs. ACAD: Which Stock Is the Better Value Option?",
      "url": "https://www.zacks.com/stock/news/2511135/kmda-vs-acad-which-stock-is-the-better-value-option",
      "time_published": "20250618T154006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada ( KMDA Quick QuoteKMDA - ) or Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default55.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.489359,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KMDA",
          "relevance_score": "0.794423",
          "ticker_sentiment_score": "0.600572",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.688777",
          "ticker_sentiment_score": "0.573832",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Almacenes Exito  ( NYSE:EXTO ) ",
      "url": "https://www.benzinga.com/24/12/42744885/acadia-pharmaceuticals-ftai-aviation-and-other-big-stocks-moving-higher-on-tuesday",
      "time_published": "20241231T165110",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Tuesday. Shares of ACADIA Pharmaceuticals Inc. ACAD rose sharply during Tuesday's session. Acadia Pharmaceuticals will replace Independent Bank Group in S&P SmallCap 600, effective prior to opening of trading on ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/31/Amazon--Crowdstrike--Autodesk--Dell--And.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.361392,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SPNT",
          "relevance_score": "0.550532",
          "ticker_sentiment_score": "0.74539",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ZSPC",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.726936",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FTAI",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.405558",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.686739",
          "ticker_sentiment_score": "0.475462",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GT",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXTO",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.562368",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HTZ",
          "relevance_score": "0.38588",
          "ticker_sentiment_score": "0.726936",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "IBTX",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.23662",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Acadia Pharmaceuticals Stock Is Rising Today",
      "url": "https://www.fool.com/investing/2023/10/10/why-acadia-pharmaceuticals-stock-is-rising-today/",
      "time_published": "20231010T144914",
      "authors": [
        "George Budwell"
      ],
      "summary": "An analyst upgrade is sparking a rally in the drugmaker's shares today.",
      "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.285214,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JPM",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.150173",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.680008",
          "ticker_sentiment_score": "0.430668",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "HRMY or ACAD: Which Is the Better Value Stock Right Now?",
      "url": "https://www.zacks.com/stock/news/2205798/hrmy-or-acad-which-is-the-better-value-stock-right-now",
      "time_published": "20240104T164010",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "HRMY vs. ACAD: Which Stock Is the Better Value Option?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.480083,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.678673",
          "ticker_sentiment_score": "0.573377",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HRMY",
          "relevance_score": "0.73545",
          "ticker_sentiment_score": "0.589203",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Stocks Showing Improving Market Leadership: ACADIA Pharmaceuticals Earns 84 RS Rating",
      "url": "https://www.investors.com/ibd-data-stories/stocks-showing-improving-market-leadership-acadia-pharmaceuticals-earns-84-rs-rating/",
      "time_published": "20230123T080000",
      "authors": [
        "Investor's Business Daily",
        "INVESTOR'S BUSINESS DAILY"
      ],
      "summary": "Stocks Showing Improving Market Leadership: ACADIA ... Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.328131,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMAB",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.644033",
          "ticker_sentiment_score": "0.374205",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/22/04/26696473/analysts-say-acadias-negative-pain-data-increases-focus-on-pimavanserin-for-alzheim",
      "time_published": "20220419T194909",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Acadia Pharmaceuticals Inc  ( NASDAQ: ACAD )  announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. \nRBC Capital Markets writes that although trends of pain redu",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/04/19/aapharma_13.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": -0.074644,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.643441",
          "ticker_sentiment_score": "-0.079442",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees",
      "url": "https://www.benzinga.com/news/earnings/22/08/28416093/acadia-pharmaceuticals-faces-several-price-target-cuts-after-q2-results-but-this-analyst-disagrees",
      "time_published": "20220809T123308",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "ACADIA Pharmaceuticals Inc. ACAD reported upbeat results for its second quarter after the closing bell on Monday. ACADIA Pharmaceuticals posted a quarterly loss of $0.21 per share on sales of $134.56 million. Analysts, however, were expecting a loss of $0.25 per share on sales of $130.43 million.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/09/image-acadia-pharmaceuticals.jpg?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.122298,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.162255",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.643211",
          "ticker_sentiment_score": "0.051845",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These Analysts Boost Their Forecasts On Acadia Pharmaceuticals - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/25/05/45491578/these-analysts-boost-their-forecasts-on-acadia-pharmaceuticals",
      "time_published": "20250519T122520",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday. The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia's '721 formulation patent for NUPLAZID ( pimavanserin ) , a treatment for Parkinson's Disease Psychosis.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/19/Analyst-Woman-Working-With-Information-D.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.321481,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.639616",
          "ticker_sentiment_score": "0.477021",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "GSK or ACAD: Which Is the Better Value Stock Right Now?",
      "url": "https://www.zacks.com/stock/news/2474138/gsk-or-acad-which-is-the-better-value-stock-right-now",
      "time_published": "20250519T154006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GSK vs. ACAD: Which Stock Is the Better Value Option?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default252.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.481846,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.630514",
          "ticker_sentiment_score": "0.472641",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis",
      "url": "https://www.benzinga.com/analyst-stock-ratings/analyst-color/22/06/27799706/this-analyst-sees-beyond-acadias-alzheimers-disease-psychosis",
      "time_published": "20220621T194412",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc's ACAD perhaps marks the end of the Alzheimer's disease psychosis ( ADP ) story for now.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/acadia_pharmaceuticals.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": -0.190875,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.610806",
          "ticker_sentiment_score": "-0.065762",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Implied Volatility Surging for ACADIA Pharmaceuticals  ( ACAD )  Stock Options",
      "url": "https://www.zacks.com/stock/news/2378091/implied-volatility-surging-for-acadia-pharmaceuticals-acad-stock-options",
      "time_published": "20241203T133200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.069035,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.597963",
          "ticker_sentiment_score": "0.102136",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals  ( ACAD )  Stock?",
      "url": "https://www.zacks.com/stock/news/2415187/is-the-options-market-predicting-a-spike-in-acadia-pharmaceuticals-acad-stock",
      "time_published": "20250213T133000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.054935,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.592742",
          "ticker_sentiment_score": "0.080896",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why ACADIA Pharmaceuticals  ( ACAD )  Shares Are Trading Higher - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/04/31834077/why-acadia-pharmaceuticals-acad-shares-are-trading-higher",
      "time_published": "20230417T151504",
      "authors": [
        "Henry Khederian"
      ],
      "summary": "ACADIA Pharmaceuticals Inc ACAD shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. ACADIA says DAYBUE has demonstrated the potential to improve the signs and symptoms of Rett syndrome.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/17/eye-6318412.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.190019,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.591019",
          "ticker_sentiment_score": "0.007099",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Stock Upgrades: ACADIA Pharmaceuticals Shows Rising Relative Strength",
      "url": "https://www.investors.com/ibd-data-stories/stock-upgrades-acadia-pharmaceuticals-shows-rising-relative-strength-8/",
      "time_published": "20231129T080000",
      "authors": [
        "Investor's Business Daily",
        "INVESTOR'S BUSINESS DAILY"
      ],
      "summary": "Stock Upgrades: ACADIA Pharmaceuticals Shows Rising Relative ... Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.34656,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMGN",
          "relevance_score": "0.31282",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.579393",
          "ticker_sentiment_score": "0.611927",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.31282",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Leads Biotech Rally With 35% Jump On Patent Win",
      "url": "https://www.investors.com/news/technology/acad-stock-launches-after-snapping-up-a-patent-win-for-nuplazid/",
      "time_published": "20231213T211400",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "ACAD Stock Launches 35% After Snapping Up A Patent Win For Nuplazid Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Acadia-Pharma-01-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        }
      ],
      "overall_sentiment_score": 0.197141,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.578948",
          "ticker_sentiment_score": "0.259228",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Stock Explodes 26% After Patent Court Victory - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/25/05/45476079/acadia-pharmaceuticals-acad-stock-explodes-26-after-patent-court-victory",
      "time_published": "20250516T195055",
      "authors": [
        "Henry Khederian"
      ],
      "summary": "ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/16/doctor-563429.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        }
      ],
      "overall_sentiment_score": 0.365784,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.577527",
          "ticker_sentiment_score": "0.492026",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Acadia Leads Biotech Rally With 36% Jump On Patent Win",
      "url": "https://www.investors.com/all-categories/acad-stock-launches-after-snapping-up-a-patent-win-for-nuplazid/",
      "time_published": "20231213T181300",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "ACAD Stock Launches 36% After Snapping Up A Patent Win For Nuplazid Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Acadia-Pharma-01-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        }
      ],
      "overall_sentiment_score": 0.197097,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.577173",
          "ticker_sentiment_score": "0.255375",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Stocks Showing Market Leadership: ACADIA Pharmaceuticals Earns 94 RS Rating",
      "url": "https://www.investors.com/ibd-data-stories/stocks-showing-market-leadership-acadia-pharmaceuticals-earns-94-rs-rating/",
      "time_published": "20230621T070000",
      "authors": [
        "INVESTOR'S BUSINESS DAILY",
        "Investor's Business Daily"
      ],
      "summary": "Stocks Showing Market Leadership: ACADIA Pharmaceuticals ... Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.367323,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ARCT",
          "relevance_score": "0.310843",
          "ticker_sentiment_score": "0.120934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KNSA",
          "relevance_score": "0.310843",
          "ticker_sentiment_score": "0.120934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.576289",
          "ticker_sentiment_score": "0.597337",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals Gets Relative Strength Rating Upgrade",
      "url": "https://www.investors.com/ibd-data-stories/acadia-pharmaceuticals-gets-relative-strength-rating-upgrade/",
      "time_published": "20240207T080000",
      "authors": [
        "INVESTOR'S BUSINESS DAILY",
        "Investor's Business Daily"
      ],
      "summary": "The Relative Strength ( RS ) Rating for ACADIA Pharmaceuticals ( ACAD ) climbed into a new percentile Wednesday, as it got a lift from 70 to 76. X When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.331393,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALKS",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMGN",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.573213",
          "ticker_sentiment_score": "0.403735",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade",
      "url": "https://www.investors.com/ibd-data-stories/acadia-pharmaceuticals-earns-relative-strength-rating-upgrade-3/",
      "time_published": "20240227T080000",
      "authors": [
        "Investor's Business Daily",
        "INVESTOR'S BUSINESS DAILY"
      ],
      "summary": "The Relative Strength ( RS ) Rating for ACADIA Pharmaceuticals ( ACAD ) jumped into a new percentile Tuesday, as it got a lift from 61 to 71. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.306889,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.570165",
          "ticker_sentiment_score": "0.279406",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.156461",
          "ticker_sentiment_score": "0.173392",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade",
      "url": "https://www.investors.com/ibd-data-stories/acadia-pharmaceuticals-scores-relative-strength-rating-upgrade/",
      "time_published": "20220323T080000",
      "authors": [
        "Investor's Business Daily",
        "INVESTOR'S BUSINESS DAILY"
      ],
      "summary": "Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade Investor's Business Daily",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.243052,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.305437",
          "ticker_sentiment_score": "0.174634",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.567746",
          "ticker_sentiment_score": "0.308375",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.155652",
          "ticker_sentiment_score": "0.264819",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Implied Volatility Surging for ACADIA Pharmaceuticals  ( ACAD )  Stock Options",
      "url": "https://www.zacks.com/stock/news/2328729/implied-volatility-surging-for-acadia-pharmaceuticals-acad-stock-options",
      "time_published": "20240829T123000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.066725,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.56296",
          "ticker_sentiment_score": "0.095551",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating",
      "url": "https://www.investors.com/news/technology/acadia-pharmaceuticals-stock-shows-market-leadership-with-jump-to-91-rs-rating/",
      "time_published": "20220325T182600",
      "authors": [
        "JULIE MAK",
        "INVESTOR'S BUSINESS DAILY",
        "Investor's Business Daily"
      ],
      "summary": "Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating Investor's Business Daily",
      "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU33.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.09238,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.554172",
          "ticker_sentiment_score": "0.10673",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Implied Volatility Surging for On ACADIA Pharmaceuticals  ( ACAD )  Stock Options",
      "url": "https://www.zacks.com/stock/news/2185208/implied-volatility-surging-for-on-acadia-pharmaceuticals-acad-stock-options",
      "time_published": "20231116T134200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.073923,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.551295",
          "ticker_sentiment_score": "0.111068",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's Going On With ACADIA Pharmaceuticals Stock? - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/24/09/41011838/whats-going-on-with-acadia-pharmaceuticals-stock",
      "time_published": "20240924T174428",
      "authors": [
        "Henry Khederian"
      ],
      "summary": "ACADIA Pharmaceuticals Inc ACAD shares are trading lower by 4.11% to $15.62 during Tuesday's session after the company appointed Catherine Owen Adams as CEO. What Happened: Acadia Pharmaceuticals announced that Catherine Owen Adams has succeeded Steve Davis as CEO and joined the board of ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/24/doctor-2568481.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.332435,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.530253",
          "ticker_sentiment_score": "0.375724",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NYMT",
          "relevance_score": "0.095899",
          "ticker_sentiment_score": "0.101963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.095899",
          "ticker_sentiment_score": "0.164443",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.095899",
          "ticker_sentiment_score": "0.164443",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is GSK PLC Sponsored ADR  ( GSK )  Stock Outpacing Its Medical Peers This Year?",
      "url": "https://www.zacks.com/stock/news/2192952/is-gsk-plc-sponsored-adr-gsk-stock-outpacing-its-medical-peers-this-year",
      "time_published": "20231204T144008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.186306,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.52706",
          "ticker_sentiment_score": "0.18988",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is CRISPR Therapeutics  ( CRSP )  Stock Outpacing Its Medical Peers This Year?",
      "url": "https://www.zacks.com/stock/news/2071846/is-crispr-therapeutics-crsp-stock-outpacing-its-medical-peers-this-year",
      "time_published": "20230329T134011",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.267831,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.508593",
          "ticker_sentiment_score": "0.22487",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRSP",
          "relevance_score": "0.784481",
          "ticker_sentiment_score": "0.436693",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Acadia Pharma Shares Are Plunging Today",
      "url": "https://www.benzinga.com/general/biotech/22/06/27792099/fda-adcomm-gives-thumbs-down-to-acadias-pimavanserin-in-alzheimers-related-psychosis",
      "time_published": "20220621T122707",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's ACAD pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-related psychosis.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/aapharma_2.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.143928,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.493128",
          "ticker_sentiment_score": "-0.162502",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Is OraSure Technologies  ( OSUR )  Outperforming Other Medical Stocks This Year?",
      "url": "https://www.zacks.com/stock/news/2082734/is-orasure-technologies-osur-outperforming-other-medical-stocks-this-year",
      "time_published": "20230421T134009",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default315.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.219589,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OSUR",
          "relevance_score": "0.76367",
          "ticker_sentiment_score": "0.374436",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.489394",
          "ticker_sentiment_score": "0.216382",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Are Medical Stocks Lagging Amphastar Pharmaceuticals  ( AMPH )  This Year?",
      "url": "https://www.zacks.com/stock/news/2163395/are-medical-stocks-lagging-amphastar-pharmaceuticals-amph-this-year",
      "time_published": "20231010T134008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default160.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.240466,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMPH",
          "relevance_score": "0.761617",
          "ticker_sentiment_score": "0.4337",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.487546",
          "ticker_sentiment_score": "0.16638",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is Medpace  ( MEDP )  Outperforming Other Medical Stocks This Year?",
      "url": "https://www.zacks.com/stock/news/2176301/is-medpace-medp-outperforming-other-medical-stocks-this-year",
      "time_published": "20231101T134009",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.204856,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.757528",
          "ticker_sentiment_score": "0.333774",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.483888",
          "ticker_sentiment_score": "0.214931",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia Surges; 'No Major Surprises' In Nuplazid Papers, But No Gifts Either",
      "url": "https://www.investors.com/news/technology/acad-stock-surges-no-major-surprises-for-nuplazid-but-no-major-gifts-either/",
      "time_published": "20220615T163600",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "Acadia Surges. 'No Major Surprises' In Nuplazid Papers, But No Gifts Either Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Acadia-Pharma-01-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.014134,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.47619",
          "ticker_sentiment_score": "0.017323",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/general/biotech/23/03/31321513/acadia-pharmas-rett-syndrome-drug-becomes-first-fda-approved-treatment",
      "time_published": "20230313T145654",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "The FDA has approved Acadia Pharmaceuticals Inc's ACAD Daybue ( trofinetide ) for Rett syndrome in adult and pediatric patients two years of age and older. Daybue is the first and only drug approved for treating Rett syndrome, a rare genetic neurological and developmental disorder that causes ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/13/acad.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.164868,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.167322",
          "ticker_sentiment_score": "0.038348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.47379",
          "ticker_sentiment_score": "0.209582",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Are Acadia Pharmaceuticals Shares Trading Higher Today? - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/general/biotech/23/07/33230863/why-are-acadia-pharmaceuticals-shares-trading-higher-today",
      "time_published": "20230714T134422",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Acadia Pharmaceuticals Inc ACAD shares are trading higher after the company expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/acad.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.145421,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.249125",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.470894",
          "ticker_sentiment_score": "0.473863",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals Shows Market Leadership With Jump To 84 RS Rating",
      "url": "https://www.investors.com/ibd-data-stories/acadia-pharmaceuticals-shows-market-leadership-with-jump-to-84-rs-rating/",
      "time_published": "20231024T070000",
      "authors": [
        "Investor's Business Daily",
        "INVESTOR'S BUSINESS DAILY"
      ],
      "summary": "ACADIA Pharmaceuticals Shows Market Leadership With Jump To ... Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.326184,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.468029",
          "ticker_sentiment_score": "0.502693",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HCM",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "After Yo-Yoing, Acadia Crashes To 4-Year Low Following FDA Vote",
      "url": "https://www.investors.com/news/technology/acad-stock-plummets-after-fda-experts-shoot-down-its-alzheimers-drug/",
      "time_published": "20220621T140600",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "ACAD Stock Plummets After FDA Experts Shoot Down Its Alzheimer's Drug Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/07/stock-pharmaceutical-opioids-01-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        }
      ],
      "overall_sentiment_score": -0.087181,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.45743",
          "ticker_sentiment_score": "-0.14274",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGEN",
          "relevance_score": "0.080837",
          "ticker_sentiment_score": "0.598747",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Top Biotech Obliterates Sales Estimates And Soars To Two-Year High",
      "url": "https://www.investors.com/news/technology/acad-stock-hits-two-year-high-after-obliterating-sales-expectations/",
      "time_published": "20230714T154000",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "ACAD Stock Hits Two-Year High After Obliterating Sales Expectations Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Acadia-02-IBD.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999864"
        }
      ],
      "overall_sentiment_score": 0.217109,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.151119",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.442522",
          "ticker_sentiment_score": "0.301694",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Energy Transfer  ( NYSE:ET ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/05/32574025/over-5m-bet-on-southwest-gas-check-out-these-4-stocks-insiders-are-buying",
      "time_published": "20230525T131748",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Although US stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/25/southwest_gas_-_logo.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.262758,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HHC",
          "relevance_score": "0.43303",
          "ticker_sentiment_score": "0.292059",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.43303",
          "ticker_sentiment_score": "0.011681",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWX",
          "relevance_score": "0.43303",
          "ticker_sentiment_score": "0.556462",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ET",
          "relevance_score": "0.43303",
          "ticker_sentiment_score": "0.187848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "10 Biggest Price Target Changes For Tuesday",
      "url": "https://www.benzinga.com/analyst-stock-ratings/price-target/22/06/27791891/10-biggest-price-target-changes-for-tuesday",
      "time_published": "20220621T114059",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Goldman Sachs cut SunPower Corporation. SPWR price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading. Morgan Stanley lowered Adobe Inc. ADBE price target from $591 to $362. Adobe shares fell 0.3% to $359.60 in pre-market trading.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/price_targets.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": -0.012556,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "JPM",
          "relevance_score": "0.151064",
          "ticker_sentiment_score": "0.000146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.151064",
          "ticker_sentiment_score": "-0.000336",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMT",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.000146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NOVA",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "-0.002229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRGRF",
          "relevance_score": "0.296761",
          "ticker_sentiment_score": "-0.003027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.296761",
          "ticker_sentiment_score": "-0.002575",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UA",
          "relevance_score": "0.296761",
          "ticker_sentiment_score": "0.009705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMED",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.006804",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.000655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADBE",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "-0.000336",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.007964",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.009378",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EME",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.001305",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPWR",
          "relevance_score": "0.296761",
          "ticker_sentiment_score": "-0.003027",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Acadia Pharma Shares Are Falling Today",
      "url": "https://www.benzinga.com/general/biotech/22/04/26682019/why-acadia-pharma-shares-are-falling-today",
      "time_published": "20220419T101045",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Acadia Pharmaceuticals Inc  ( NASDAQ: ACAD )  announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. \nThe primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg ",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/04/19/aapharma_0.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.044858,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.430576",
          "ticker_sentiment_score": "0.032751",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?",
      "url": "https://www.benzinga.com/general/biotech/22/06/27726921/why-are-acadia-pharmaceuticals-shares-trading-higher-today",
      "time_published": "20220615T185544",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Ahead of Acadia Pharmaceuticals Inc's ACAD FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/15/aapharma_7.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.074928,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.427666",
          "ticker_sentiment_score": "-0.007945",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why Acadia Pharmaceuticals  ( ACAD )  is a Strong Momentum Stock",
      "url": "https://www.zacks.com/stock/news/2368932/heres-why-acadia-pharmaceuticals-acad-is-a-strong-momentum-stock",
      "time_published": "20241112T145011",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default130.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.371005,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.427184",
          "ticker_sentiment_score": "0.272221",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "J&J  ( JNJ )  Seeks Expanded Use of Lung Cancer Drug Rybrevant",
      "url": "https://www.zacks.com/stock/news/2187470/jj-jnj-seeks-expanded-use-of-lung-cancer-drug-rybrevant",
      "time_published": "20231121T174100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ed/4040.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9973"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.201274,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.356609",
          "ticker_sentiment_score": "0.177221",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.421485",
          "ticker_sentiment_score": "0.129066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.356609",
          "ticker_sentiment_score": "0.167325",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "-0.044802",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday - Archer-Daniels-Midland  ( NYSE:ADM ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/25/05/45490633/netflix-to-1220-here-are-10-top-analyst-forecasts-for-monday",
      "time_published": "20250519T115308",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised ACADIA Pharmaceuticals Inc. ACAD price target from $27 to $30.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/19/Netflix.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.846708"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.282904,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.281422",
          "ticker_sentiment_score": "0.260819",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WSM",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.20896",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.142989",
          "ticker_sentiment_score": "0.159458",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.142989",
          "ticker_sentiment_score": "0.00381",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MQ",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.367098",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HP",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.005041",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADM",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.220181",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.411176",
          "ticker_sentiment_score": "0.16532",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.20896",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DAL",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.285234",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Expands Existing Licensing Deal With Neuren",
      "url": "https://www.zacks.com/stock/news/2121199/acadia-acad-expands-existing-licensing-deal-with-neuren",
      "time_published": "20230714T120300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2e/972.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.057746,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKRO",
          "relevance_score": "0.260004",
          "ticker_sentiment_score": "0.037748",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.309539",
          "ticker_sentiment_score": "0.043365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIX",
          "relevance_score": "0.309539",
          "ticker_sentiment_score": "0.079175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.052918",
          "ticker_sentiment_score": "0.032038",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.404563",
          "ticker_sentiment_score": "0.103207",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Vertex Pharmaceuticals  ( NASDAQ:VRTX ) ",
      "url": "https://www.benzinga.com/news/24/06/39523582/this-vertex-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for",
      "time_published": "20240627T124140",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/27/xrdDAFzgn8dVBs2-j9120197723021318877-t23.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.18446,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.397098",
          "ticker_sentiment_score": "0.127197",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KD",
          "relevance_score": "0.397098",
          "ticker_sentiment_score": "0.142929",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.397098",
          "ticker_sentiment_score": "0.144661",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.397098",
          "ticker_sentiment_score": "0.140089",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GRAB",
          "relevance_score": "0.271274",
          "ticker_sentiment_score": "0.014796",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32860825/strategic-fit-of-acp-101-promises-future-revenue-growth-for-acadia-pharmaceuticals-",
      "time_published": "20230614T185941",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Tuesday, Acadia Pharmaceuticals Inc ACAD announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 ( intranasal carbetocin ) , for hyperphagia ( a false and unrelenting state of starvation ) in Prader-Willi syndrome.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/14/acad.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.128653,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.382925",
          "ticker_sentiment_score": "-0.302196",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Bayer  ( BAYRY )  Cuts 2023 Outlook, Reports Preliminary Q2 Results",
      "url": "https://www.zacks.com/stock/news/2127789/bayer-bayry-cuts-2023-outlook-reports-preliminary-q2-results",
      "time_published": "20230726T125200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bayer (BAYRY) lowers its full-year financial performance guidance for 2023 and reports preliminary earnings results for the second quarter of 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8e/2706.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999973"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.06443,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADCT",
          "relevance_score": "0.378094",
          "ticker_sentiment_score": "0.050415",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.378094",
          "ticker_sentiment_score": "0.0661",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Analysts See Steady Growth For Acadia Pharma's Nuplazid - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/02/31097856/analysts-see-steady-growth-for-acadia-pharmas-nuplazid",
      "time_published": "20230228T190036",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Acadia Pharmaceuticals Inc ACAD reported a Q4 EPS loss of $ ( 0.26 ) , missing the consensus of $ ( 0.24 ) and sales of $136.49 million, beating the consensus of $134.07 million. For FY23, the company expects Nuplazid sales of $520-$550 million compared to a consensus of $569.16 million.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/28/acad_logo_light__1eb578dd5218f06affd93c334493da6d.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.148201,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.373378",
          "ticker_sentiment_score": "-0.261121",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Soars 24.7%: Is Further Upside Left in the Stock?",
      "url": "https://www.zacks.com/stock/news/2121799/acadia-acad-soars-247-is-further-upside-left-in-the-stock",
      "time_published": "20230717T065300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.233786,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TNGX",
          "relevance_score": "0.4499",
          "ticker_sentiment_score": "-0.072429",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.069343",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.367412",
          "ticker_sentiment_score": "0.331637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Notable Insider Move: Owen Catherine Adams Takes Part In Options Exercise At ACADIA Pharmaceuticals - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/insights/news/24/09/41049602/notable-insider-move-owen-catherine-adams-takes-part-in-options-exercise-at-acadia-pharmaceuticals",
      "time_published": "20240926T150044",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "A large exercise of company stock options by Owen Catherine Adams, Chief Executive Officer at ACADIA Pharmaceuticals ACAD was disclosed in a new SEC filing on September 25, as part of an insider exercise. What Happened: The latest Form 4 filing on Wednesday with the U.S.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.993856"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998682"
        }
      ],
      "overall_sentiment_score": 0.280073,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.363009",
          "ticker_sentiment_score": "0.370697",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Stock Jumps 6.1%: Will It Continue to Soar?",
      "url": "https://www.zacks.com/stock/news/2443317/acadia-acad-stock-jumps-61-will-it-continue-to-soar",
      "time_published": "20250410T133100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default240.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.223392,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KNSA",
          "relevance_score": "0.567746",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.362505",
          "ticker_sentiment_score": "0.223297",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Reassuring Market Adoption of Daybue Fuels Acadia's Strategic Advancements, Analysts Boost Price Targets - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33233666/reassuring-market-adoption-of-daybue-fuels-acadias-strategic-advancements-analysts-",
      "time_published": "20230714T184735",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Acadia Pharmaceuticals Inc ACAD expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. For Q2, the company expects interim Daybue sales of $21-$23 million and Nuplazid sales of $140-$144 million.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/acad_0.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.311697,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.174019",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "0.354929",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Here's Why Acadia  ( ACAD )  Looks Ripe for Bottom Fishing",
      "url": "https://www.zacks.com/stock/news/2135064/heres-why-acadia-acad-looks-ripe-for-bottom-fishing",
      "time_published": "20230810T135504",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "After losing some value lately, a hammer chart pattern has been formed for Acadia (ACAD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.203573,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.359707",
          "ticker_sentiment_score": "0.329761",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Ocular Therapeutix  ( NASDAQ:OCUL ) ",
      "url": "https://www.benzinga.com/news/24/03/37610301/acadia-pharmaceuticals-ocular-therapeutix-asana-and-other-big-stocks-moving-lower-in-tuesdays-pre-ma",
      "time_published": "20240312T093605",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA Pharmaceuticals Inc ACAD fell sharply in today's pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/12/image31_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999922"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.041757,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NN",
          "relevance_score": "0.359014",
          "ticker_sentiment_score": "0.010506",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHI",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "-0.314067",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AEVA",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "0.013786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASAN",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "-0.097003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LXRX",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "0.11181",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.359014",
          "ticker_sentiment_score": "-0.300687",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "0.008611",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OCUL",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "-0.07365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XPDB",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "-0.086259",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Acadia Pharmaceuticals Stock Trading Lower On Tuesday? - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/general/biotech/24/03/37612311/trial-setback-for-acadia-pharmaceuticals-late-stage-schizophrenia-trial-details",
      "time_published": "20240312T111900",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Monday, Acadia Pharmaceuticals Inc ACAD released top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for negative symptoms of schizophrenia.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/pharma-lab-worker-ai_6.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.045589,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "-0.207501",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate",
      "url": "https://www.benzinga.com/general/biotech/22/07/28107505/acadia-seeks-fda-approval-for-genetic-neurological-disorder-candidate",
      "time_published": "20220718T205302",
      "authors": [
        "Ragothaman Srinivasan"
      ],
      "summary": "Acadia Pharmaceuticals Inc. ACAD has submitted a New Drug Application ( NDA ) to the U.S. Food and Drug Administration ( FDA ) for trofinetide for the treatment of Rett syndrome.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/07/18/bz-pharma.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.117482,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.353059",
          "ticker_sentiment_score": "-0.162364",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday - Aehr Test Systems  ( NASDAQ:AEHR ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/earnings/23/07/33232154/unitedhealth-elanco-animal-health-and-other-big-stocks-moving-higher-on-friday",
      "time_published": "20230714T144835",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Chijet Motor Company, Inc. CJET shares surged 21.1% to $3.7738. Chijet Motor Company's majority-owned subsidiary achieved a breakthrough in export model. TMC the metals company Inc. TMC shares gained 16.7% to $2.1250. ACADIA Pharmaceuticals Inc. ACAD shares rose 15.6% to $29.83.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/unitedhealth_-_logo.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.266547,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AEHR",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "0.252938",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ELAN",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.121037",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NKLA",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "0.52665",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GKOS",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "-0.299613",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TMC",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "0.741659",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ARCT",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "-0.290872",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "LUNR",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.421833",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ORGO",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFWL",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "-0.416133",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.239305",
          "ticker_sentiment_score": "0.609855",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Thrives on Nuplazid, Overdependence a Concern",
      "url": "https://www.zacks.com/stock/news/1991007/acadia-acad-thrives-on-nuplazid-overdependence-a-concern",
      "time_published": "20221012T145700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.179866,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ORIC",
          "relevance_score": "0.351558",
          "ticker_sentiment_score": "0.23052",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.351558",
          "ticker_sentiment_score": "0.314162",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.351558",
          "ticker_sentiment_score": "0.23052",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.144708",
          "ticker_sentiment_score": "0.055562",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACAD Signs License Deal With Saniona for Rights to Neurology Drug",
      "url": "https://www.zacks.com/stock/news/2376102/acad-signs-license-deal-with-saniona-for-rights-to-neurology-drug",
      "time_published": "20241127T150600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.176115,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.223659",
          "ticker_sentiment_score": "0.070958",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.350564",
          "ticker_sentiment_score": "0.187569",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.223659",
          "ticker_sentiment_score": "0.134864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.135347",
          "ticker_sentiment_score": "0.091055",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Plummets After Placebo Effect Torpedoes Schizophrenia Study",
      "url": "https://www.investors.com/news/technology/acadia-stock-acadia-pharmaceuticals-advance-2-nuplazid-schizophrenia/",
      "time_published": "20240312T131249",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "Acadia stock crashed to an 11-month low Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients. Acadia Pharmaceuticals ( ACAD ) had been hoping its antipsychotic, Nuplazid, would make a difference for people with the negative symptoms ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.032095,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "-0.335892",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.345674",
          "ticker_sentiment_score": "0.297432",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Rises More Than 14% in 3 Months: Here's Why",
      "url": "https://www.zacks.com/stock/news/1988870/acadia-acad-rises-more-than-14-in-3-months-heres-why",
      "time_published": "20221006T173600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.163094,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ORIC",
          "relevance_score": "0.341857",
          "ticker_sentiment_score": "0.185666",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.341857",
          "ticker_sentiment_score": "0.057877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.341857",
          "ticker_sentiment_score": "0.185666",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.140485",
          "ticker_sentiment_score": "0.054603",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ardelyx  ( ARDX )  Up on Xphozah's Orphan Tag for Hyperphosphatemia",
      "url": "https://www.zacks.com/stock/news/2185902/ardelyx-ardx-up-on-xphozahs-orphan-tag-for-hyperphosphatemia",
      "time_published": "20231117T140000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.103058,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ANIX",
          "relevance_score": "0.463192",
          "ticker_sentiment_score": "0.115068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "0.141711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "0.177871",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARDX",
          "relevance_score": "0.519739",
          "ticker_sentiment_score": "0.229959",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Anixa  ( ANIX )  Falls 25% Despite Positive Breast Cancer Study Data",
      "url": "https://www.zacks.com/stock/news/2080544/anixa-anix-falls-25-despite-positive-breast-cancer-study-data",
      "time_published": "20230418T154300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/845.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.048642,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "0.137553",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIX",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "-0.196976",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "-0.022223",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "0.084124",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Begins Alzheimer's Disease Psychosis Study",
      "url": "https://www.zacks.com/stock/news/2190144/acadia-acad-begins-alzheimers-disease-psychosis-study",
      "time_published": "20231128T125100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.028636,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.391486",
          "ticker_sentiment_score": "0.15226",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.391486",
          "ticker_sentiment_score": "0.024566",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.188763",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.339356",
          "ticker_sentiment_score": "-0.098258",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "MorphoSys  ( MOR )  Down 22% on Mixed Data From Myelofibrosis Study",
      "url": "https://www.zacks.com/stock/news/2188101/morphosys-mor-down-22-on-mixed-data-from-myelofibrosis-study",
      "time_published": "20231122T184800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.060198,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ANAB",
          "relevance_score": "0.229691",
          "ticker_sentiment_score": "-0.048981",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.284861",
          "ticker_sentiment_score": "0.165816",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MOR",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "-0.002854",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.13773",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alnylam  ( ALNY )  to Co-Develop Hypertension Drug With Roche",
      "url": "https://www.zacks.com/stock/news/2126411/alnylam-alny-to-co-develop-hypertension-drug-with-roche",
      "time_published": "20230724T172000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.216046,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.390613",
          "ticker_sentiment_score": "0.425775",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "-0.007342",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.009768",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Agios  ( AGIO )  Meets Clinical Proof-of-Concept in Anemia Treatment",
      "url": "https://www.zacks.com/stock/news/2187358/agios-agio-meets-clinical-proof-of-concept-in-anemia-treatment",
      "time_published": "20231121T155600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.102042,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ANAB",
          "relevance_score": "0.229149",
          "ticker_sentiment_score": "-0.012663",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AGIO",
          "relevance_score": "0.229149",
          "ticker_sentiment_score": "0.101406",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.337811",
          "ticker_sentiment_score": "0.185528",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Horizon's  ( HZNP )  Daxdilimab Fails to Meet Goal in Lupus Study",
      "url": "https://www.zacks.com/stock/news/2126230/horizons-hznp-daxdilimab-fails-to-meet-goal-in-lupus-study",
      "time_published": "20230724T151200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.016817,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADCT",
          "relevance_score": "0.337811",
          "ticker_sentiment_score": "0.046462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.337811",
          "ticker_sentiment_score": "0.063333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.172919",
          "ticker_sentiment_score": "0.063711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.389744",
          "ticker_sentiment_score": "-0.192868",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Repare Therapeutics  ( RPTX )  Rises 34% in a Week: Here's Why",
      "url": "https://www.zacks.com/stock/news/2186488/repare-therapeutics-rptx-rises-34-in-a-week-heres-why",
      "time_published": "20231120T131900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.002412,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.456107",
          "ticker_sentiment_score": "0.151992",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.271274",
          "ticker_sentiment_score": "0.225356",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.335367",
          "ticker_sentiment_score": "0.130911",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPTX",
          "relevance_score": "0.335367",
          "ticker_sentiment_score": "-0.317613",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Begins Alzheimer's Disease Psychosis Study  ( Revised ) ",
      "url": "https://www.zacks.com/stock/news/2191207/acadia-acad-begins-alzheimers-disease-psychosis-study-revised",
      "time_published": "20231130T084400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.033424,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.382088",
          "ticker_sentiment_score": "0.149645",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.382088",
          "ticker_sentiment_score": "0.024143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.331024",
          "ticker_sentiment_score": "0.025812",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.174662",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods - e.l.f. Beauty  ( NYSE:ELF ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/08/40575289/jim-cramer-believes-in-dell-ceo-doesnt-like-b-g-foods",
      "time_published": "20240827T124014",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer called e.l.f. Beauty, Inc. ELF \"without a doubt, one of the most shorted stocks in the market.\" \"And every time anything bad happens in the cosmetic group, people come down on it, but then you have to buy,\" he said. Cramer said he doesn't like ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/Dell-Technologies.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.244793,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LCID",
          "relevance_score": "0.330286",
          "ticker_sentiment_score": "0.530071",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.330286",
          "ticker_sentiment_score": "0.190538",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DELL",
          "relevance_score": "0.223866",
          "ticker_sentiment_score": "0.373905",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SYM",
          "relevance_score": "0.330286",
          "ticker_sentiment_score": "0.019877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BGS",
          "relevance_score": "0.330286",
          "ticker_sentiment_score": "0.302184",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.330286",
          "ticker_sentiment_score": "0.033397",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia stock rallies on drug news as Roivant also climbs, while Leslie's, Theseus shares plunge and more moving stocks",
      "url": "https://www.marketwatch.com/story/acadia-stock-rallies-on-drug-news-as-roivant-also-climbs-while-leslies-theseus-shares-plunge-and-more-moving-stocks-a1e7ace2",
      "time_published": "20230714T090700",
      "authors": [
        "MarketWatch"
      ],
      "summary": "Acadia Pharmaceuticals, Roivant, Leslie's, Nokia and Ericsson were among the biggest moving shares ahead of Friday's market open.",
      "banner_image": "https://images.mktw.net/im-817113/social",
      "source": "MarketWatch",
      "category_within_source": "Top Stories",
      "source_domain": "www.marketwatch.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.053078,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LESL",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.035706",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "0.248502",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "-0.248502",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NOK",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "0.084691",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ROIV",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "0.1472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRBU",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "0.415296",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "THRX",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "-0.236631",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Astria  ( ATXS )  Rises 5% on Fast Track Tag for Angioedema Drug",
      "url": "https://www.zacks.com/stock/news/2125236/astria-atxs-rises-5-on-fast-track-tag-for-angioedema-drug",
      "time_published": "20230721T114400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.110769,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ATXS",
          "relevance_score": "0.275246",
          "ticker_sentiment_score": "-0.078131",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.327366",
          "ticker_sentiment_score": "0.042897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.327366",
          "ticker_sentiment_score": "0.059355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKYA",
          "relevance_score": "0.327366",
          "ticker_sentiment_score": "-0.019279",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Agenus  ( AGEN )  Rises on Fast Track Tag for Cancer Combo Drug",
      "url": "https://www.zacks.com/stock/news/2080511/agenus-agen-rises-on-fast-track-tag-for-cancer-combo-drug",
      "time_published": "20230418T152000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.012235,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.325637",
          "ticker_sentiment_score": "0.186296",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.686739",
          "ticker_sentiment_score": "-0.182336",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.325637",
          "ticker_sentiment_score": "-0.021459",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.263231",
          "ticker_sentiment_score": "0.079062",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent",
      "url": "https://www.zacks.com/stock/news/2474014/acad-stock-soars-as-us-court-rules-in-favor-of-key-nuplazid-patent",
      "time_published": "20250519T133200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.234041,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HALO",
          "relevance_score": "0.142005",
          "ticker_sentiment_score": "0.156372",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.323684",
          "ticker_sentiment_score": "0.128542",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTLA",
          "relevance_score": "0.18856",
          "ticker_sentiment_score": "0.020139",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Karuna  ( KRTX )  Posts Upbeat Safety Data on Schizophrenia Drug",
      "url": "https://www.zacks.com/stock/news/2186086/karuna-krtx-posts-upbeat-safety-data-on-schizophrenia-drug",
      "time_published": "20231117T163200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.097689,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.268589",
          "ticker_sentiment_score": "0.127456",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANAB",
          "relevance_score": "0.216376",
          "ticker_sentiment_score": "-0.012059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KRTX",
          "relevance_score": "0.268589",
          "ticker_sentiment_score": "0.100902",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.319587",
          "ticker_sentiment_score": "0.166438",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down as Schizophrenia Study on Nuplazid Fails",
      "url": "https://www.zacks.com/stock/news/2239365/acadia-acad-down-as-schizophrenia-study-on-nuplazid-fails",
      "time_published": "20240312T150600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.029105,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.316846",
          "ticker_sentiment_score": "0.204365",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FGEN",
          "relevance_score": "0.266246",
          "ticker_sentiment_score": "-0.030545",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.316846",
          "ticker_sentiment_score": "0.106715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACET",
          "relevance_score": "0.266246",
          "ticker_sentiment_score": "-0.028501",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Surges 15.5%: Is This an Indication of Further Gains?",
      "url": "https://www.zacks.com/stock/news/1939806/acadia-acad-surges-155-is-this-an-indication-of-further-gains",
      "time_published": "20220616T124100",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": -0.018829,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKYA",
          "relevance_score": "0.315763",
          "ticker_sentiment_score": "-0.012329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.315763",
          "ticker_sentiment_score": "0.001911",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Surges 8.3%: Is This an Indication of Further Gains?",
      "url": "https://www.zacks.com/stock/news/2156844/acadia-acad-surges-83-is-this-an-indication-of-further-gains",
      "time_published": "20230928T093900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default253.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.146808,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CUE",
          "relevance_score": "0.500753",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.31482",
          "ticker_sentiment_score": "0.169869",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Vor Bio  ( VOR )  Up on Positive Update From AML Cell Therapy Study",
      "url": "https://www.zacks.com/stock/news/2212665/vor-bio-vor-up-on-positive-update-from-aml-cell-therapy-study",
      "time_published": "20240119T132200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.195646,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VOR",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.212902",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.426567",
          "ticker_sentiment_score": "0.146062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.116968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.166657",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Olema Pharmaceuticals  ( OLMA )  Skyrockets 471% YTD: Here's Why",
      "url": "https://www.zacks.com/stock/news/2189936/olema-pharmaceuticals-olma-skyrockets-471-ytd-heres-why",
      "time_published": "20231127T175400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.026537,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OLMA",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "0.164337",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.106541",
          "ticker_sentiment_score": "0.005572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.312158",
          "ticker_sentiment_score": "0.176988",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Zymeworks Inc.  ( ZYME )  Surges 23.2%: Is This an Indication of Further Gains?",
      "url": "https://www.zacks.com/stock/news/1913145/zymeworks-inc-zyme-surges-232-is-this-an-indication-of-further-gains",
      "time_published": "20220502T103600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default240.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": -0.027668,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZYME",
          "relevance_score": "0.496534",
          "ticker_sentiment_score": "0.001139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.311894",
          "ticker_sentiment_score": "-0.048893",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merck  ( MRK )  Gets FDA Nod for Keytruda Expansion in Gastric Cancer",
      "url": "https://www.zacks.com/stock/news/2186122/merck-mrk-gets-fda-nod-for-keytruda-expansion-in-gastric-cancer",
      "time_published": "20231117T162900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7e/42272.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.995869"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.237355,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.259451",
          "ticker_sentiment_score": "0.125953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANAB",
          "relevance_score": "0.208914",
          "ticker_sentiment_score": "-0.011744",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "0.16436",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ligand  ( LGND )  Offers $15M in Cash to Acquire All Novan Assets",
      "url": "https://www.zacks.com/stock/news/2123037/ligand-lgnd-offers-15m-in-cash-to-acquire-all-novan-assets",
      "time_published": "20230718T150400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.060339,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADCT",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "0.043294",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.357049",
          "ticker_sentiment_score": "0.027902",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "0.016039",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKYA",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "-0.018443",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NOVN",
          "relevance_score": "0.533678",
          "ticker_sentiment_score": "0.246173",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Strength Seen in Acadia  ( ACAD ) : Can Its 5.0% Jump Turn into More Strength?",
      "url": "https://www.zacks.com/stock/news/2065828/strength-seen-in-acadia-acad-can-its-50-jump-turn-into-more-strength",
      "time_published": "20230315T064300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default58.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.249014,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EYPT",
          "relevance_score": "0.491255",
          "ticker_sentiment_score": "-0.076711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.308246",
          "ticker_sentiment_score": "0.367248",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Moderna  ( MRNA )  to Report Q2 Earnings: Will It Beat Estimates?",
      "url": "https://www.zacks.com/stock/news/2130052/moderna-mrna-to-report-q2-earnings-will-it-beat-estimates",
      "time_published": "20230731T165000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6f/3484.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999985"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.042895,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.606558",
          "ticker_sentiment_score": "0.095348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.207127",
          "ticker_sentiment_score": "0.05546",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.306325",
          "ticker_sentiment_score": "0.073131",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q2 Earnings & Revenues Beat Estimates, '23 View Up",
      "url": "https://www.zacks.com/stock/news/2131843/acadia-acad-q2-earnings-revenues-beat-estimates-23-view-up",
      "time_published": "20230803T120200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/2110.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.995869"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.148194,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.192081",
          "ticker_sentiment_score": "0.138139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.22951",
          "ticker_sentiment_score": "0.034129",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.03878",
          "ticker_sentiment_score": "0.035806",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.302708",
          "ticker_sentiment_score": "0.11268",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biotech Dives As Seasonality Rocks Its Most High-Profile Launch",
      "url": "https://www.investors.com/news/technology/acadia-stock-acad-stock-fourth-quarter-daybue-launch/",
      "time_published": "20240228T161600",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "Acadia Stock Plummets As Seasonality Rocks Its High-Profile Launch Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2019/12/stock-Acadia-Pharma-01-shutter.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999612"
        }
      ],
      "overall_sentiment_score": 0.10273,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.300946",
          "ticker_sentiment_score": "-0.116203",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Gain Therapeutics  ( GANX )  Down 25% on Issue of New Common Stock",
      "url": "https://www.zacks.com/stock/news/2188012/gain-therapeutics-ganx-down-25-on-issue-of-new-common-stock",
      "time_published": "20231122T165800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999862"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.123462,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.247838",
          "ticker_sentiment_score": "0.123233",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANAB",
          "relevance_score": "0.199447",
          "ticker_sentiment_score": "-0.011326",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.295273",
          "ticker_sentiment_score": "0.156528",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GANX",
          "relevance_score": "0.51278",
          "ticker_sentiment_score": "0.12902",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Atara Biotherapeutics  ( ATRA )  Slumps 57% in a Month: Here's Why",
      "url": "https://www.zacks.com/stock/news/2189268/atara-biotherapeutics-atra-slumps-57-in-a-month-heres-why",
      "time_published": "20231124T172900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.125627,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.245835",
          "ticker_sentiment_score": "0.118709",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANAB",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "-0.011248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.292922",
          "ticker_sentiment_score": "0.155508",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.144084",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Wall Street Analysts Predict a 37.65% Upside in Acadia  ( ACAD ) : Here's What You Should Know",
      "url": "https://www.zacks.com/stock/news/2186662/wall-street-analysts-predict-a-3765-upside-in-acadia-acad-heres-what-you-should-know",
      "time_published": "20231120T145522",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The mean of analysts' price targets for Acadia (ACAD) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.22059,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.289576",
          "ticker_sentiment_score": "0.361866",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Growth Stocks I'd Buy on the Dip",
      "url": "https://www.fool.com/investing/2023/09/30/2-growth-stocks-id-buy-on-the-dip/",
      "time_published": "20230930T143000",
      "authors": [
        "George Budwell"
      ],
      "summary": "These two growth stocks could be worthwhile buy-and-holds.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749303%2Fu-turn.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.178641,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TLRY",
          "relevance_score": "0.422268",
          "ticker_sentiment_score": "0.284667",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.289462",
          "ticker_sentiment_score": "0.158669",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "How Much Upside is Left in Acadia  ( ACAD ) ? Wall Street Analysts Think 38.62%",
      "url": "https://www.zacks.com/stock/news/2173761/how-much-upside-is-left-in-acadia-acad-wall-street-analysts-think-3862",
      "time_published": "20231027T135505",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The consensus price target hints at a 38.6% upside potential for Acadia (ACAD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default266.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.252013,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.287537",
          "ticker_sentiment_score": "0.369389",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down More Than 30% in Past 3 Months: Here's Why",
      "url": "https://www.zacks.com/stock/news/1949933/acadia-acad-down-more-than-30-in-past-3-months-heres-why",
      "time_published": "20220708T151400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.125683,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGLE",
          "relevance_score": "0.354572",
          "ticker_sentiment_score": "0.233817",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.2872",
          "ticker_sentiment_score": "0.12278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DTIL",
          "relevance_score": "0.354572",
          "ticker_sentiment_score": "0.290584",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LPTX",
          "relevance_score": "0.354572",
          "ticker_sentiment_score": "0.226524",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Avita  ( RCEL )  Falls 19% on Lowered 2023 Revenue Guidance",
      "url": "https://www.zacks.com/stock/news/2187726/avita-rcel-falls-19-on-lowered-2023-revenue-guidance",
      "time_published": "20231122T133300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99237"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.17566,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.391486",
          "ticker_sentiment_score": "0.024554",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.12259",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.115451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RCEL",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "-0.019725",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Microsoft To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Friday - Albany Intl  ( NYSE:AIN ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/07/33229739/microsoft-to-rally-around-17-here-are-10-other-analyst-forecasts-for-friday",
      "time_published": "20230714T120255",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Keybanc boosted the price target for Spotify Technology S.A. SPOT from $180 to $205. Keybanc analyst Justin Patterson maintained an Overweight rating. Spotify shares rose 0.9% to $172.68 in pre-market trading. Morgan Stanley boosted Boyd Gaming Corporation BYD price target from $69 to $75.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/microsoft_-_logo.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.21992,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OUST",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.379882",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MDNDF",
          "relevance_score": "0.191929",
          "ticker_sentiment_score": "-0.137315",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPOT",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.137148",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AIN",
          "relevance_score": "0.191929",
          "ticker_sentiment_score": "0.327017",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.191929",
          "ticker_sentiment_score": "-0.235573",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.191929",
          "ticker_sentiment_score": "0.321249",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BYD",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.425144",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.11518",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.425144",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NOV",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.19835",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.103649",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "T",
          "relevance_score": "0.191929",
          "ticker_sentiment_score": "-0.235573",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.372496",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Wall Street Analysts Believe Acadia  ( ACAD )  Could Rally 26%: Here's is How to Trade",
      "url": "https://www.zacks.com/stock/news/1974073/wall-street-analysts-believe-acadia-acad-could-rally-26-heres-is-how-to-trade",
      "time_published": "20220830T135510",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default152.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.21129,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.2842",
          "ticker_sentiment_score": "0.316983",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Kellogg, Spirit Airlines rise; Acadia, ODP fall",
      "url": "https://apnews.com/article/elon-musk-tesla-inc-acadia-pharmaceuticals-lennar-corp-41d553c104c8f48cf259f8f97077769e",
      "time_published": "20220621T202002",
      "authors": [],
      "summary": "Kellogg, Spirit Airlines rise. Acadia, ODP fall The Associated Press - en ...",
      "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png",
      "source": "Associated Press",
      "category_within_source": "Business",
      "source_domain": "apnews.com",
      "topics": [
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.001176,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.283542",
          "ticker_sentiment_score": "0.000955",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAVE",
          "relevance_score": "0.283542",
          "ticker_sentiment_score": "0.001397",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dermata  ( DRMA )  Up on FDA Nod to Begin Pivotal Study of Acne Drug",
      "url": "https://www.zacks.com/stock/news/2185908/dermata-drma-up-on-fda-nod-to-begin-pivotal-study-of-acne-drug",
      "time_published": "20231117T140600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.160596,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ANIX",
          "relevance_score": "0.388018",
          "ticker_sentiment_score": "0.10204",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DRMA",
          "relevance_score": "0.282886",
          "ticker_sentiment_score": "0.281923",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.228073",
          "ticker_sentiment_score": "0.121672",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.282886",
          "ticker_sentiment_score": "0.153989",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Acadia Pharmaceuticals Stock Is Crashing Today",
      "url": "https://www.fool.com/investing/2022/06/21/why-acadia-pharmaceuticals-stock-is-crashing-today/",
      "time_published": "20220621T160712",
      "authors": [
        "Keith Speights"
      ],
      "summary": "An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.",
      "banner_image": "https://g.foolcdn.com/editorial/images/685222/scientist-examines-cultures-in-lab.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": -0.378445,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.282234",
          "ticker_sentiment_score": "-0.464242",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Acadia's  ( ACAD )  Rett Syndrome Drug NDA Gets FDA Priority Review",
      "url": "https://www.zacks.com/stock/news/1979811/acadias-acad-rett-syndrome-drug-nda-gets-fda-priority-review",
      "time_published": "20220913T124400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.179312,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ORIC",
          "relevance_score": "0.347614",
          "ticker_sentiment_score": "0.237637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.022575",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.281422",
          "ticker_sentiment_score": "0.215255",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "APTO",
          "relevance_score": "0.347614",
          "ticker_sentiment_score": "0.237637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.347614",
          "ticker_sentiment_score": "0.237637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Innate Pharma  ( IPHA )  Gains as FDA Lifts Hold on Lymphoma Study",
      "url": "https://www.zacks.com/stock/news/2205860/innate-pharma-ipha-gains-as-fda-lifts-hold-on-lymphoma-study",
      "time_published": "20240104T174000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99246"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.088649,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.383765",
          "ticker_sentiment_score": "0.184477",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IPHA",
          "relevance_score": "0.383765",
          "ticker_sentiment_score": "0.024123",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.279653",
          "ticker_sentiment_score": "0.072139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.225425",
          "ticker_sentiment_score": "0.123662",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Electronic Arts  ( NASDAQ:EA ) ",
      "url": "https://www.benzinga.com/news/23/10/35160321/electronic-arts-to-rally-over-20-here-are-10-other-analyst-forecasts-for-tuesday",
      "time_published": "20231010T122321",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "JP Morgan increased ACADIA Pharmaceuticals Inc. ACAD price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares rose 0.3% to close at $21.74 on Monday. Raymond James cut the price target for Tractor Supply Company TSCO ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/10/electronic_arts_-_logo_copy.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999995"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.009848,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "0.16079",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HOG",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.006295",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RRC",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.147045",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.524949",
          "ticker_sentiment_score": "-0.167072",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NTST",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "-0.180339",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.366061",
          "ticker_sentiment_score": "-0.016109",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWKS",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "-0.144869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSCO",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.00657",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEE",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.12169",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLW",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "-0.301408",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "0.22575",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NEP",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "-0.165241",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.270547",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EA",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.300672",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "QRVO",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "-0.178031",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Alnylam  ( ALNY )  Soars 5.3%: Is Further Upside Left in the Stock?",
      "url": "https://www.zacks.com/stock/news/2291930/alnylam-alny-soars-53-is-further-upside-left-in-the-stock",
      "time_published": "20240624T104900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default55.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.307085,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.277958",
          "ticker_sentiment_score": "0.397065",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.277958",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday - Amylyx Pharma  ( NASDAQ:AMLX ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/03/31337920/jabil-to-rally-around-23-here-are-10-other-analyst-forecasts-for-tuesday",
      "time_published": "20230314T121138",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Raymond James raised the price target for Jabil Inc. JBL from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on Monday. Canaccord Genuity boosted the price target for ACADIA Pharmaceuticals Inc. ACAD from $24 to $26.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/14/image_3.jpg?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.211375,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WSM",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "0.182635",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.114507",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.236145",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CLBT",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "-0.045829",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JBL",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "0.12442",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMLX",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "0.317171",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OPRT",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "0.232073",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LU",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "-0.157072",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NKE",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.114507",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "0.103761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGEN",
          "relevance_score": "0.276909",
          "ticker_sentiment_score": "0.284993",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CCORF",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "0.076325",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Acadia Pharmaceuticals Spiked Today",
      "url": "https://www.fool.com/investing/2022/06/15/why-acadia-pharmaceuticals-spiked-today/",
      "time_published": "20220615T170728",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "Regulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.",
      "banner_image": "https://g.foolcdn.com/editorial/images/658602/acadia.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.26532,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.276648",
          "ticker_sentiment_score": "0.008659",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals  ( NASDAQ:ACAD )  - U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review",
      "url": "https://www.benzinga.com/news/22/09/28829615/u-s-fda-accepts-acadias-filing-for-rett-syndrome-candidate-under-priority-review",
      "time_published": "20220912T131545",
      "authors": [
        "Ragothaman Srinivasan"
      ],
      "summary": "The U.S. Food and Drug Administration ( FDA ) has accepted for filing Acadia Pharmaceuticals' ACAD New Drug Application ( NDA ) of trofinetide for the treatment of Rett syndrome. The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/09/12/bz-pharma_0.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.159693,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.27432",
          "ticker_sentiment_score": "0.006226",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Novartis  ( NVS )  Chronic Myeloid Leukemia Drug Approved by EC",
      "url": "https://www.zacks.com/stock/news/1974178/novartis-nvs-chronic-myeloid-leukemia-drug-approved-by-ec",
      "time_published": "20220830T161700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.202178,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALC",
          "relevance_score": "0.0699",
          "ticker_sentiment_score": "0.187108",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.27432",
          "ticker_sentiment_score": "0.190856",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Aptorum Gr  ( NASDAQ:APM ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/24/12/42745148/crude-oil-rises-1-sangamo-therapeutics-shares-plummet",
      "time_published": "20241231T170149",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.05% to 42,554.24 while the NASDAQ fell 0.23% to 19,441.37. The S&P 500 also fell, dropping, 0.12% to 5,899.74. In trading on Tuesday, utilities shares ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/31/Crude-Oil-6--logo.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.039072,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RR",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "0.312807",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SGMO",
          "relevance_score": "0.273807",
          "ticker_sentiment_score": "-0.132987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COCP",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "-0.22177",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.273807",
          "ticker_sentiment_score": "0.463542",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "APM",
          "relevance_score": "0.273807",
          "ticker_sentiment_score": "0.155601",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ONCO",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "0.247198",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.184598",
          "ticker_sentiment_score": "-0.097747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBTX",
          "relevance_score": "0.092927",
          "ticker_sentiment_score": "0.257194",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Anavex  ( AVXL )  Up 12% on Regulatory Update for Alzheimer's Drug",
      "url": "https://www.zacks.com/stock/news/2187113/anavex-avxl-up-12-on-regulatory-update-for-alzheimers-drug",
      "time_published": "20231121T131900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.088143,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.373911",
          "ticker_sentiment_score": "0.034257",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.219312",
          "ticker_sentiment_score": "0.117956",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.272181",
          "ticker_sentiment_score": "0.111114",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVXL",
          "relevance_score": "0.272181",
          "ticker_sentiment_score": "0.004124",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HLN vs. LMAT: Which Stock Should Value Investors Buy Now?",
      "url": "https://www.zacks.com/stock/news/2302726/hln-vs-lmat-which-stock-should-value-investors-buy-now",
      "time_published": "20240716T154020",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "HLN vs. LMAT: Which Stock Is the Better Value Option?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default318.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.105405,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADPT",
          "relevance_score": "0.118452",
          "ticker_sentiment_score": "0.016365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARQT",
          "relevance_score": "0.196132",
          "ticker_sentiment_score": "0.063215",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.271921",
          "ticker_sentiment_score": "0.061115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.07913",
          "ticker_sentiment_score": "0.029958",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia's  ( ACAD )  Nuplazid Drives Growth, Pipeline Setbacks a Woe",
      "url": "https://www.zacks.com/stock/news/2302781/acadias-acad-nuplazid-drives-growth-pipeline-setbacks-a-woe",
      "time_published": "20240716T142800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/2216.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.105405,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADPT",
          "relevance_score": "0.118452",
          "ticker_sentiment_score": "0.016365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARQT",
          "relevance_score": "0.196132",
          "ticker_sentiment_score": "0.063215",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.271921",
          "ticker_sentiment_score": "0.061115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.07913",
          "ticker_sentiment_score": "0.029958",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Aptorum Gr  ( NASDAQ:APM ) ",
      "url": "https://www.benzinga.com/24/12/42748000/dow-dips-over-100-points-cocrystal-pharma-shares-slide",
      "time_published": "20241231T192135",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.26% to 42,461.52 while the NASDAQ fell 0.91% to 19,308.99. The S&P 500 also fell, dropping, 0.55% to 5,874.24.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/31/wall-street-chart-shutter2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.03906,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RR",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.31041",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SGMO",
          "relevance_score": "0.270773",
          "ticker_sentiment_score": "-0.131814",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COCP",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "-0.21999",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.270773",
          "ticker_sentiment_score": "0.46005",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "APM",
          "relevance_score": "0.270773",
          "ticker_sentiment_score": "0.154291",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ONCO",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.245243",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "-0.096938",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBTX",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "0.256526",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?",
      "url": "https://www.zacks.com/stock/news/2268837/watch-these-5-drug-stocks-for-q1-earnings-beat-or-miss",
      "time_published": "20240506T144000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.071681,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.270202",
          "ticker_sentiment_score": "-0.016202",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "-0.123117",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.117678",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.378285",
          "ticker_sentiment_score": "0.073358",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.378285",
          "ticker_sentiment_score": "0.078744",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bellus Health  ( BLU )  Stock Up 99% on $2B Buyout Offer From GSK",
      "url": "https://www.zacks.com/stock/news/2081392/bellus-health-blu-stock-up-99-on-2b-buyout-offer-from-gsk",
      "time_published": "20230419T134400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.161519,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLU",
          "relevance_score": "0.369163",
          "ticker_sentiment_score": "0.380709",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.268589",
          "ticker_sentiment_score": "-0.020551",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.216376",
          "ticker_sentiment_score": "0.07446",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.463325",
          "ticker_sentiment_score": "0.326657",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Can-Fite  ( CANF )  Up on Liver Cancer Study Update of Namodenoson",
      "url": "https://www.zacks.com/stock/news/2187671/can-fite-canf-up-on-liver-cancer-study-update-of-namodenoson",
      "time_published": "20231122T122300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/54831.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.12496,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.368383",
          "ticker_sentiment_score": "0.036509",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.118224",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.268",
          "ticker_sentiment_score": "0.111772",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  to Begin Study on ACP-101 for Hyperphagia in PWS",
      "url": "https://www.zacks.com/stock/news/2108261/acadia-acad-to-begin-study-on-acp-101-for-hyperphagia-in-pws",
      "time_published": "20230614T132600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) is set to begin a pivotal study evaluating a new developmental candidate, ACP-101, in the treatment of hyperphagia associated with Prader-Willi syndrome.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.095505,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.330876",
          "ticker_sentiment_score": "0.213429",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AKRO",
          "relevance_score": "0.391923",
          "ticker_sentiment_score": "0.142656",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.267559",
          "ticker_sentiment_score": "-0.083802",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADAP",
          "relevance_score": "0.391923",
          "ticker_sentiment_score": "0.134888",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q1 Earnings Surpass Estimates, Revenues Miss",
      "url": "https://www.zacks.com/stock/news/2271128/acadia-acad-q1-earnings-surpass-estimates-revenues-miss",
      "time_published": "20240509T095900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99237"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.05998,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ANIP",
          "relevance_score": "0.308062",
          "ticker_sentiment_score": "0.184962",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.179121",
          "ticker_sentiment_score": "0.143982",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.265859",
          "ticker_sentiment_score": "-0.069523",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANVS",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "-0.026474",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down More Than 30% in Past 3 Months: Here's Why",
      "url": "https://www.zacks.com/stock/news/1949933/acadia-acad-down-more-than-30-in-past-3-months-heres-why",
      "time_published": "20220708T151400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.00175,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGLE",
          "relevance_score": "0.327975",
          "ticker_sentiment_score": "0.012751",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.265161",
          "ticker_sentiment_score": "0.016033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DTIL",
          "relevance_score": "0.327975",
          "ticker_sentiment_score": "0.000607",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPTX",
          "relevance_score": "0.327975",
          "ticker_sentiment_score": "0.005508",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACAD: Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now",
      "url": "https://stocknews.com/news/acad-amrx-optn-buy-alert-3-pharma-stocks-under-20-to-invest-in/",
      "time_published": "20240502T132844",
      "authors": [
        "StockNews.com Staff"
      ],
      "summary": "In the ever-evolving landscape of pharmaceutical sector, the ascent of Pharma 4.0 heralds a transformative era. Besides, the growing interest among investors in pharmaceutical stocks is highlighted by the impressive performance of the Invesco Dynamic Pharmaceuticals ETF ( PJP ) , which has seen a ...",
      "banner_image": "https://stocknews.com/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "stocknews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999987"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.142162,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.265089",
          "ticker_sentiment_score": "-0.108111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.265089",
          "ticker_sentiment_score": "0.108078",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.027011",
          "ticker_sentiment_score": "0.199431",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OPTN",
          "relevance_score": "0.187359",
          "ticker_sentiment_score": "0.095778",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aeglea  ( AGLE )  Plunges 26% After Rare Disorder Drug Study Fails",
      "url": "https://www.zacks.com/stock/news/2078294/aeglea-agle-plunges-26-after-rare-disorder-drug-study-fails",
      "time_published": "20230413T134400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.0455,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.265089",
          "ticker_sentiment_score": "0.158525",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGLE",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "-0.175446",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.265089",
          "ticker_sentiment_score": "-0.018251",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.066858",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adial  ( ADIL )  Shares Up 43% in the Past Week: Here's Why",
      "url": "https://www.zacks.com/stock/news/2123690/adial-adil-shares-up-43-in-the-past-week-heres-why",
      "time_published": "20230719T135900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/4018.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.234736,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADIL",
          "relevance_score": "0.30211",
          "ticker_sentiment_score": "0.331677",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.260652",
          "ticker_sentiment_score": "0.035823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.260652",
          "ticker_sentiment_score": "0.049557",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKYA",
          "relevance_score": "0.260652",
          "ticker_sentiment_score": "-0.016117",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zymeworks  ( ZYME )  Up on Licensing Deal With Jazz Pharmaceuticals",
      "url": "https://www.zacks.com/stock/news/1995256/zymeworks-zyme-up-on-licensing-deal-with-jazz-pharmaceuticals",
      "time_published": "20221020T173600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.129724,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.260189",
          "ticker_sentiment_score": "0.10577",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BGNE",
          "relevance_score": "0.260189",
          "ticker_sentiment_score": "0.100967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.269043",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ZYME",
          "relevance_score": "0.903189",
          "ticker_sentiment_score": "0.249873",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth  ( Revised ) ",
      "url": "https://www.zacks.com/stock/news/2424877/acadias-q4-earnings-miss-nuplazid-daybue-drive-revenue-growth-revised",
      "time_published": "20250304T090900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.236128,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMRN",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "0.146254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOLD",
          "relevance_score": "0.150357",
          "ticker_sentiment_score": "0.063719",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.259925",
          "ticker_sentiment_score": "0.106069",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.150357",
          "ticker_sentiment_score": "0.2101",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ultragenyx  ( RARE )  Posts Update From AS Study of GTX-102",
      "url": "https://www.zacks.com/stock/news/2205510/ultragenyx-rare-posts-update-from-as-study-of-gtx-102",
      "time_published": "20240104T131200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.995921"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.0551,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.356317",
          "ticker_sentiment_score": "0.17476",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.2589",
          "ticker_sentiment_score": "0.100701",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RARE",
          "relevance_score": "0.2589",
          "ticker_sentiment_score": "-0.034111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.116295",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Do Options Traders Know Something About Acadia  ( ACAD )  Stock We Don't?",
      "url": "https://www.zacks.com/stock/news/2355082/do-options-traders-know-something-about-acadia-acad-stock-we-dont",
      "time_published": "20241022T150500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to Acadia (ACAD) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.078584,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "-0.138198",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD",
      "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmaceuticals-inc---acad-302075277.html",
      "time_published": "20240303T151500",
      "authors": [
        "Pomerantz LLP"
      ],
      "summary": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals ... PR ...",
      "banner_image": "https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.067813,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.138198",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Theseus  ( THRX )  Up 57% in a Month on Strategic Restructuring Plan",
      "url": "https://www.zacks.com/stock/news/2189784/theseus-thrx-up-57-in-a-month-on-strategic-restructuring-plan",
      "time_published": "20231127T151600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.103953,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.230007",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.257805",
          "ticker_sentiment_score": "0.102471",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.126389",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "THRX",
          "relevance_score": "0.354862",
          "ticker_sentiment_score": "-0.068076",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday - Oracle  ( NYSE:ORCL ) ",
      "url": "https://www.benzinga.com/news/24/03/37618463/oracle-to-rally-around-40-here-are-10-top-analyst-forecasts-for-tuesday",
      "time_published": "20240312T131719",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer cut the price target for ACADIA Pharmaceuticals Inc. ACAD from $25 to $19.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/12/oracle_-_logo_0.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999897"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.155478,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PCVX",
          "relevance_score": "0.256538",
          "ticker_sentiment_score": "0.065344",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASAN",
          "relevance_score": "0.256538",
          "ticker_sentiment_score": "-0.136479",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DG",
          "relevance_score": "0.256538",
          "ticker_sentiment_score": "0.405295",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "S",
          "relevance_score": "0.172713",
          "ticker_sentiment_score": "0.141236",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.172713",
          "ticker_sentiment_score": "0.007447",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "H",
          "relevance_score": "0.172713",
          "ticker_sentiment_score": "-0.028725",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MU",
          "relevance_score": "0.172713",
          "ticker_sentiment_score": "0.165026",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NKE",
          "relevance_score": "0.172713",
          "ticker_sentiment_score": "0.007447",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ORCL",
          "relevance_score": "0.256538",
          "ticker_sentiment_score": "0.234063",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.256538",
          "ticker_sentiment_score": "0.128542",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data",
      "url": "https://www.benzinga.com/general/biotech/22/08/28422620/acadia-terminates-painkiller-cancer-candidate-after-disappointing-data",
      "time_published": "20220809T172450",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Acadia Pharmaceuticals Inc ACAD stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's VRTX non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/09/aapharma_12.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.124759,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.007386",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.116442",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Akouos  ( AKUS )  Surges on $610M Buyout Deal With Eli Lilly",
      "url": "https://www.zacks.com/stock/news/1994344/akouos-akus-surges-on-610m-buyout-deal-with-eli-lilly",
      "time_published": "20221019T154200",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.163935,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.48268",
          "ticker_sentiment_score": "0.434065",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AKUS",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.386867",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.253866",
          "ticker_sentiment_score": "0.151464",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ACADIA SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals, Inc.  ( NASDAQ: ACAD )  and Encourages Long-Term ACAD Investors to Contact the Firm - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/pressreleases/23/12/g36169807/acadia-shareholder-alert-kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-nas",
      "time_published": "20231210T211325",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "PHILADELPHIA, Dec. 10, 2023 ( GLOBE NEWSWIRE ) -- Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. ( \"Acadia\" ) ACAD on behalf the company's long-term investors.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.986714"
        }
      ],
      "overall_sentiment_score": 0.077065,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.252114",
          "ticker_sentiment_score": "0.120677",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February - Cencora  ( NYSE:COR ) ",
      "url": "https://www.benzinga.com/news/large-cap/24/05/39010333/after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stol",
      "time_published": "20240524T160024",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "U.S. drug wholesaler Cencora Inc COR, formerly AmerisourceBergen, is notifying affected individuals about their personal and highly sensitive medical information stolen during a cyberattack earlier this year.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/24/Crypto-hack-Photo-by-Bits-And-Splits-on-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.108839,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SSTK",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.798255",
          "ticker_sentiment_score": "0.148167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "-0.036372",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Altice USA  ( NYSE:ATUS ) ",
      "url": "https://www.benzinga.com/news/23/12/36427310/expedia-to-rally-around-10-here-are-10-top-analyst-forecasts-for-friday",
      "time_published": "20231229T142013",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Nomura raised Uber Technologies, Inc. UBER price target from $59 to $62.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/29/expedia_group_-_logo.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.232874,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NTRA",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.321031",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OTLK",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.196022",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.116718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.079193",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXPE",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.408917",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NEO",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.003972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.081327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.058549",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKNG",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.415471",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "-0.038119",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATUS",
          "relevance_score": "0.249531",
          "ticker_sentiment_score": "0.142605",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Adicet  ( ACET )  Stock Rallies 130% in a Month: Here's Why",
      "url": "https://www.zacks.com/stock/news/2210403/adicet-acet-stock-rallies-130-in-a-month-heres-why",
      "time_published": "20240115T184200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.142029,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.343619",
          "ticker_sentiment_score": "0.17008",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.249361",
          "ticker_sentiment_score": "0.034137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACET",
          "relevance_score": "0.249361",
          "ticker_sentiment_score": "0.022813",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.249361",
          "ticker_sentiment_score": "0.17067",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia's  ( ACAD )  Nuplazid Sales Drive Growth Amid Competition",
      "url": "https://www.zacks.com/stock/news/2203852/acadias-acad-nuplazid-sales-drive-growth-amid-competition",
      "time_published": "20231229T175100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.181417,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.248682",
          "ticker_sentiment_score": "0.089435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.248682",
          "ticker_sentiment_score": "0.115629",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.084127",
          "ticker_sentiment_score": "-0.027572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.167322",
          "ticker_sentiment_score": "0.108719",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions",
      "url": "https://www.benzinga.com/general/biotech/22/08/28371718/fda-asks-for-additional-study-for-acadias-pimavanserin-in-alzheimers-associated-delusions",
      "time_published": "20220805T115553",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "The FDA has issued a Complete Response Letter ( CRL ) to Acadia Pharmaceuticals Inc ACAD regarding its supplemental marketing application for pimavanserin in hallucinations and delusions associated with Alzheimer's disease psychosis ( ADP ) .",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/05/aapharma_1.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.176415,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.248682",
          "ticker_sentiment_score": "0.077104",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q3 Earnings and Sales Beat Estimates, Stock Up",
      "url": "https://www.zacks.com/stock/news/2177987/acadia-acad-q3-earnings-and-sales-beat-estimates-stock-up",
      "time_published": "20231103T121200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/2216.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.045373,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.206509",
          "ticker_sentiment_score": "-0.013388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVAX",
          "relevance_score": "0.165883",
          "ticker_sentiment_score": "0.131772",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.041755",
          "ticker_sentiment_score": "0.037949",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.246582",
          "ticker_sentiment_score": "-0.039014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACET",
          "relevance_score": "0.165883",
          "ticker_sentiment_score": "0.035266",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Gets FDA Approval for Daybue for Rett Syndrome",
      "url": "https://www.zacks.com/stock/news/2064814/acadia-acad-gets-fda-approval-for-daybue-for-rett-syndrome",
      "time_published": "20230313T141900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.081687,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "0.166548",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.246582",
          "ticker_sentiment_score": "0.057558",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANVS",
          "relevance_score": "0.186259",
          "ticker_sentiment_score": "0.108414",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.186259",
          "ticker_sentiment_score": "0.044002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVXL",
          "relevance_score": "0.124809",
          "ticker_sentiment_score": "-0.07702",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q4 Earnings Miss, Nuplazid Sales Boost Revenues",
      "url": "https://www.zacks.com/stock/news/2059780/acadia-acad-q4-earnings-miss-nuplazid-sales-boost-revenues",
      "time_published": "20230228T141400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording wider-than-expected loss per share and better-than-expected revenue figures owing to the sales of Nuplazid.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.036346,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.099476",
          "ticker_sentiment_score": "0.052918",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.061945",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.049835",
          "ticker_sentiment_score": "0.080318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.07012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.049835",
          "ticker_sentiment_score": "0.080318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRN",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.001319",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/pressreleases/24/02/g37277718/acadia-pharmaceuticals-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses",
      "time_published": "20240223T011610",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises ACADIA Pharmaceuticals Inc. ( \"ACADIA\" or the \"Company\" ) ACAD investors that the law firm has initiated an investigation on ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": -0.024249,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "0.055712",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top 5 Health Care Stocks That Should Keep You Up At Night - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/05/32527927/top-5-health-care-stocks-that-should-keep-you-up-at-night",
      "time_published": "20230523T123345",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/23/image_6.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.290477,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CERE",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.122489",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMSI",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.302318",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.271445",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CTIC",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "-0.04317",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYGR",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.210092",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.082111",
          "ticker_sentiment_score": "0.11536",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45822460/jpmorgan-lifts-acadia-price-target-after-nuplazid-patent-victory",
      "time_published": "20250606T193455",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Court ruling secures Nuplazid's 34 mg formulation patent protection through 2038. JPMorgan hikes Acadia target from $26 to $30, citing strong patent outlook. Get access to the leaderboards pointing to tomorrow's biggest stock movers. In May, the U.S.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/06/Acadia-Pharmaceuticals.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.281441,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.242084",
          "ticker_sentiment_score": "0.091619",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nektar Therapeutics  ( NKTR )  Q2 Loss Narrows, Sales Miss",
      "url": "https://www.zacks.com/stock/news/2134281/nektar-therapeutics-nktr-q2-loss-narrows-sales-miss",
      "time_published": "20230809T132500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.028569,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.193078",
          "ticker_sentiment_score": "0.035708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.240014",
          "ticker_sentiment_score": "0.079349",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.240014",
          "ticker_sentiment_score": "0.080237",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NKTR",
          "relevance_score": "0.458799",
          "ticker_sentiment_score": "-0.078625",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/pressreleases/24/03/g37545915/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmace",
      "time_published": "20240307T210747",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ( \"ACADIA\" or the \"Company\" ) ACAD. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.029041,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/pressreleases/24/02/g37374845/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmace",
      "time_published": "20240228T201000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ( \"ACADIA\" or the \"Company\" ) ACAD. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.029041,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/pressreleases/24/02/g37261841/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmace",
      "time_published": "20240222T142235",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ( \"ACADIA\" or the \"Company\" ) ACAD. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.029041,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "bluebird  ( BLUE )  Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues",
      "url": "https://www.zacks.com/stock/news/2134411/bluebird-blue-q2-earnings-top-zynteglo-skysona-fuel-revenues",
      "time_published": "20230809T153600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/33314.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.090709,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FOLD",
          "relevance_score": "0.236396",
          "ticker_sentiment_score": "0.090659",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVAX",
          "relevance_score": "0.178459",
          "ticker_sentiment_score": "0.091079",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.236396",
          "ticker_sentiment_score": "0.010871",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.401331",
          "ticker_sentiment_score": "0.09826",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q2 Earnings Beat, Product Sales Drive Revenues",
      "url": "https://www.zacks.com/stock/news/2317917/acadia-acad-q2-earnings-beat-product-sales-drive-revenues",
      "time_published": "20240807T121600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.105294,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKRO",
          "relevance_score": "0.189298",
          "ticker_sentiment_score": "0.106918",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIX",
          "relevance_score": "0.280615",
          "ticker_sentiment_score": "0.037983",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.235366",
          "ticker_sentiment_score": "-0.016461",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANVS",
          "relevance_score": "0.189298",
          "ticker_sentiment_score": "-0.026643",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NeuBase  ( NBSE )  Up on Restructuring Plan, Set to Lower Workforce",
      "url": "https://www.zacks.com/stock/news/1992939/neubase-nbse-up-on-restructuring-plan-set-to-lower-workforce",
      "time_published": "20221017T155700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.123172,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ORIC",
          "relevance_score": "0.381755",
          "ticker_sentiment_score": "0.286306",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGLE",
          "relevance_score": "0.381755",
          "ticker_sentiment_score": "0.211367",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NBSE",
          "relevance_score": "0.235062",
          "ticker_sentiment_score": "0.159871",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.235062",
          "ticker_sentiment_score": "0.23365",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults",
      "url": "https://www.zacks.com/stock/news/1992112/gsks-rsv-vaccine-candidate-shows-high-efficacy-in-older-adults",
      "time_published": "20221014T133700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.168726,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ORIC",
          "relevance_score": "0.381755",
          "ticker_sentiment_score": "0.203768",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.235062",
          "ticker_sentiment_score": "0.169009",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.450165",
          "ticker_sentiment_score": "0.352647",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.309864",
          "ticker_sentiment_score": "0.209801",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Acadia Pharmaceuticals Stock Is Soaring Today",
      "url": "https://www.fool.com/investing/2023/07/14/why-acadia-pharmaceuticals-stock-is-soaring-today/",
      "time_published": "20230714T154117",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Investors are cheering Acadia's latest news.",
      "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.115701,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.118647",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.234684",
          "ticker_sentiment_score": "0.108643",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth",
      "url": "https://www.zacks.com/stock/news/2422991/acadias-q4-earnings-miss-nuplazid-daybue-drive-revenue-growth",
      "time_published": "20250227T154800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.227539,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BMRN",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.148451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOLD",
          "relevance_score": "0.156207",
          "ticker_sentiment_score": "0.065267",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.232439",
          "ticker_sentiment_score": "0.064974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.156207",
          "ticker_sentiment_score": "0.214966",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pharvaris  ( PHVS )  Up as FDA Lifts Clinical Hold on HAE Program",
      "url": "https://www.zacks.com/stock/news/2214182/pharvaris-phvs-up-as-fda-lifts-clinical-hold-on-hae-program",
      "time_published": "20240123T143400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.052263,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PHVS",
          "relevance_score": "0.493965",
          "ticker_sentiment_score": "-0.019019",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.342487",
          "ticker_sentiment_score": "0.110471",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.232439",
          "ticker_sentiment_score": "0.07575",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.232439",
          "ticker_sentiment_score": "0.156399",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday",
      "url": "https://www.benzinga.com/news/22/08/28412963/nvidia-to-240-here-are-5-other-price-target-changes-for-tuesday",
      "time_published": "20220809T104442",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Raymond James cut the price target on NVIDIA Corporation NVDA from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to $172.92 in pre-market trading. Piper Sandler boosted monday.com Ltd. MNDY price target from $150 to $180.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/09/image-nvidia.png?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.109027,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BC",
          "relevance_score": "0.232069",
          "ticker_sentiment_score": "0.366052",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.232069",
          "ticker_sentiment_score": "0.003781",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.232069",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRSP",
          "relevance_score": "0.155954",
          "ticker_sentiment_score": "0.004028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.232069",
          "ticker_sentiment_score": "-0.263814",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.155954",
          "ticker_sentiment_score": "-0.198975",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Novo Nordisk's  ( NVO )  Phase III Diabetes Study Meets Primary Goal",
      "url": "https://www.zacks.com/stock/news/2207561/novo-nordisks-nvo-phase-iii-diabetes-study-meets-primary-goal",
      "time_published": "20240109T162600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.090054,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.319488",
          "ticker_sentiment_score": "0.163131",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.231332",
          "ticker_sentiment_score": "0.061906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.007722",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.231332",
          "ticker_sentiment_score": "0.162542",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Begins Study on ACP-101 for Hyperphagia in PWS",
      "url": "https://www.zacks.com/stock/news/2192107/acadia-acad-begins-study-on-acp-101-for-hyperphagia-in-pws",
      "time_published": "20231201T135700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.043382,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.392362",
          "ticker_sentiment_score": "0.136345",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.392362",
          "ticker_sentiment_score": "0.024526",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.230782",
          "ticker_sentiment_score": "0.032047",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.230782",
          "ticker_sentiment_score": "0.159198",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Up on FDA Briefing Document for Nuplazid sNDA",
      "url": "https://www.zacks.com/stock/news/1939943/acadia-acad-up-on-fda-briefing-document-for-nuplazid-snda",
      "time_published": "20220616T144200",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.012065,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.230235",
          "ticker_sentiment_score": "0.000248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DTIL",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.00311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPTX",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.002167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLPG",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.011372",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Signature Bank, Johnson & Johnson rise; Acadia, Netgear fall",
      "url": "https://apnews.com/article/business-johnson-and-acadia-pharmaceuticals-inc-super-micro-computer-signature-bank-d29432bed924698470816c45f2d781f3",
      "time_published": "20220419T201544",
      "authors": [],
      "summary": "Signature Bank, Johnson & Johnson rise; Acadia, Netgear fall The Associated Press - en Espa\u00f1ol",
      "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png",
      "source": "Associated Press",
      "category_within_source": "Business",
      "source_domain": "apnews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.046937,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACC",
          "relevance_score": "0.228717",
          "ticker_sentiment_score": "5.2e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.228717",
          "ticker_sentiment_score": "0.002719",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FLGT",
          "relevance_score": "0.228717",
          "ticker_sentiment_score": "0.000912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.228717",
          "ticker_sentiment_score": "0.000113",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMCI",
          "relevance_score": "0.228717",
          "ticker_sentiment_score": "0.100222",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biogen  ( BIIB )  Beats on Q2 Earnings & Sales, Announces Job Cuts",
      "url": "https://www.zacks.com/stock/news/2127098/biogen-biib-beats-on-q2-earnings-sales-announces-job-cuts",
      "time_published": "20230725T152100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999953"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.021731,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.228073",
          "ticker_sentiment_score": "0.028693",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.264761",
          "ticker_sentiment_score": "0.169739",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ESALF",
          "relevance_score": "0.03853",
          "ticker_sentiment_score": "0.077855",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.228073",
          "ticker_sentiment_score": "-0.05759",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth",
      "url": "https://www.zacks.com/stock/news/2465350/acadia-q1-earnings-beat-nuplazid-daybue-sales-drive-revenue-growth",
      "time_published": "20250508T144000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999756"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.20573,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BEAM",
          "relevance_score": "0.152983",
          "ticker_sentiment_score": "0.033293",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.152983",
          "ticker_sentiment_score": "0.137463",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.227716",
          "ticker_sentiment_score": "0.138776",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Mirati  ( MRTX )  Q2 Earnings Beat, Stock Up on Solid Krazati Sales",
      "url": "https://www.zacks.com/stock/news/2134320/mirati-mrtx-q2-earnings-beat-stock-up-on-solid-krazati-sales",
      "time_published": "20230809T134200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. The stock climbs 9%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.021535,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MRTX",
          "relevance_score": "0.181477",
          "ticker_sentiment_score": "-0.075433",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZLAB",
          "relevance_score": "0.045743",
          "ticker_sentiment_score": "0.035771",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.22574",
          "ticker_sentiment_score": "0.077405",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia's  ( ACAD )  Q2 Earnings & Revenues Surpass Estimates",
      "url": "https://www.zacks.com/stock/news/1966196/acadias-acad-q2-earnings-revenues-surpass-estimates",
      "time_published": "20220809T150600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9d/2473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.073649,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TECH",
          "relevance_score": "0.225425",
          "ticker_sentiment_score": "0.19741",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.225425",
          "ticker_sentiment_score": "-0.038908",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DTIL",
          "relevance_score": "0.279653",
          "ticker_sentiment_score": "0.243356",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.279653",
          "ticker_sentiment_score": "0.197395",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Perrigo  ( PRGO )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2175755/perrigo-prgo-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231031T152700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.134082,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.113597",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "-0.056946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "0.112403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.290095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Regeneron's  ( REGN )  Eylea sBLA Gets FDA's Priority Review",
      "url": "https://www.zacks.com/stock/news/1991735/regenerons-regn-eylea-sbla-gets-fdas-priority-review",
      "time_published": "20221013T165600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.167231,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ORIC",
          "relevance_score": "0.366061",
          "ticker_sentiment_score": "0.234776",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "0.195642",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.151064",
          "ticker_sentiment_score": "0.099614",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.075874",
          "ticker_sentiment_score": "0.244523",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "BioNTech  ( BNTX )  to Report Q4 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2064231/biontech-bntx-to-report-q4-earnings-whats-in-the-cards",
      "time_published": "20230310T152900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999682"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.111188,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "-0.050399",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "-0.205425",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.121402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.478692",
          "ticker_sentiment_score": "0.171505",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "BioNTech  ( BNTX )  to Report Q4 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2064231/biontech-bntx-to-report-q4-earnings-whats-in-the-cards",
      "time_published": "20230310T142900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999682"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.111188,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "-0.050399",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "-0.205425",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.121402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.478692",
          "ticker_sentiment_score": "0.171505",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Stocks making the biggest moves in the premarket: Netgear, Zendesk, WeWork and more",
      "url": "https://www.cnbc.com/2022/04/19/stocks-making-the-biggest-moves-in-the-premarket-netgear-zendesk-wework-and-more.html",
      "time_published": "20220419T114506",
      "authors": [
        "Peter Schacknow"
      ],
      "summary": "The stocks making the biggest moves in premarket trading include Netgear, Zendesk, WeWork, and more.",
      "banner_image": "https://image.cnbcfm.com/api/v1/image/107045008-Traders-OB-Photo-20220411-DN-384-PRESS-4.jpg?v=1649700049&w=1920&h=1080",
      "source": "CNBC",
      "category_within_source": "Market Insider",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": -0.061368,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APO",
          "relevance_score": "0.149285",
          "ticker_sentiment_score": "-0.019685",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACC",
          "relevance_score": "0.222293",
          "ticker_sentiment_score": "-0.000144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAL",
          "relevance_score": "0.362012",
          "ticker_sentiment_score": "-0.016138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZEN",
          "relevance_score": "0.293389",
          "ticker_sentiment_score": "0.07053",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTGR",
          "relevance_score": "0.293389",
          "ticker_sentiment_score": "-0.176883",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.149285",
          "ticker_sentiment_score": "-0.000144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TWTR",
          "relevance_score": "0.222293",
          "ticker_sentiment_score": "-0.019685",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.222293",
          "ticker_sentiment_score": "-0.380217",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.222293",
          "ticker_sentiment_score": "-0.007405",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLUG",
          "relevance_score": "0.149285",
          "ticker_sentiment_score": "0.018172",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WE",
          "relevance_score": "0.149285",
          "ticker_sentiment_score": "0.092705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.149285",
          "ticker_sentiment_score": "0.018172",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates",
      "url": "https://www.zacks.com/stock/news/2083259/4-pharma-biotech-stocks-poised-to-beat-q1-earnings-estimates",
      "time_published": "20230424T123800",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.178822,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.222022",
          "ticker_sentiment_score": "-0.046605",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.190761",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.348103",
          "ticker_sentiment_score": "0.075985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "-0.001252",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.222022",
          "ticker_sentiment_score": "0.025583",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Archer Aviation  ( NYSE:ACHR ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/25/05/45470960/evolv-technologies-quantum-computing-acadia-pharmaceuticals-and-other-big-stocks-moving-higher-on-friday",
      "time_published": "20250516T150148",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's session after the company announced preliminary first-quarter financial results. The company said it expects revenue growth of 40%+ in the ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/16/Section-Of-A-Financial-Newspaper-Titled-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.283022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.110462",
          "ticker_sentiment_score": "0.248133",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SMLR",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NWTN",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.220695",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BULL",
          "relevance_score": "0.110462",
          "ticker_sentiment_score": "-0.046984",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "-0.071189",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGC",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.140388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QUBT",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.381697",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CRWV",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.366345",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACHR",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADV",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.536134",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "APLD",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.536134",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "-0.026653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVLV",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.199877",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HALO",
          "relevance_score": "0.218817",
          "ticker_sentiment_score": "0.536134",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "VIPS",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "-0.227296",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q1 Earnings & Revenues Fall Shy of Estimates",
      "url": "https://www.zacks.com/stock/news/1916899/acadia-acad-q1-earnings-revenues-fall-shy-of-estimates",
      "time_published": "20220505T140600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9d/2473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": -0.118423,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.164918",
          "ticker_sentiment_score": "0.022043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.218669",
          "ticker_sentiment_score": "-0.317118",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.164918",
          "ticker_sentiment_score": "0.00096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYGR",
          "relevance_score": "0.271395",
          "ticker_sentiment_score": "-0.077223",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth",
      "url": "https://www.zacks.com/stock/news/2366506/acadias-q3-earnings-beat-nuplazid-daybue-drive-revenue-growth",
      "time_published": "20241107T150400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.203437,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.142217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.06073",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.21803",
          "ticker_sentiment_score": "-0.022391",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "0.055636",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Intra-Cellular's  ( ITCI )  Caplyta Aids Sales, Overreliance a Woe",
      "url": "https://www.zacks.com/stock/news/2082867/intra-cellulars-itci-caplyta-aids-sales-overreliance-a-woe",
      "time_published": "20230421T152800",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/2110.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.10352,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.2138",
          "ticker_sentiment_score": "-0.017116",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.2138",
          "ticker_sentiment_score": "0.176025",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.17179",
          "ticker_sentiment_score": "0.059752",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.0864",
          "ticker_sentiment_score": "0.117735",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?",
      "url": "https://www.fool.com/investing/2023/08/22/can-this-red-hot-biotech-stock-keep-beating-the-br/",
      "time_published": "20230822T123000",
      "authors": [
        "George Budwell"
      ],
      "summary": "This biotech stock has been on fire in 2023.",
      "banner_image": "https://media.ycharts.com/charts/911600125422ece49c11a5ce5e48b20e.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.295633,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.213674",
          "ticker_sentiment_score": "0.260841",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.072",
          "ticker_sentiment_score": "-0.130901",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "U.S. Markets Open Higher; Lennar Earnings Top Views",
      "url": "https://www.benzinga.com/news/earnings/22/06/27796597/u-s-markets-open-higher-lennar-earnings-top-views",
      "time_published": "20220621T142310",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1.70% to 30,395.65 while the NASDAQ rose 2.88% to 11,109.85. The S&P also rose, gaining, 2.38% to 3,762.25.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/mid-morning-market-update.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.000486,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BKSY",
          "relevance_score": "0.143116",
          "ticker_sentiment_score": "0.081981",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNVY",
          "relevance_score": "0.143116",
          "ticker_sentiment_score": "-4.3e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEON",
          "relevance_score": "0.143116",
          "ticker_sentiment_score": "-0.002862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LEN",
          "relevance_score": "0.213235",
          "ticker_sentiment_score": "0.132271",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALN",
          "relevance_score": "0.213235",
          "ticker_sentiment_score": "0.017881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHWY",
          "relevance_score": "0.143116",
          "ticker_sentiment_score": "0.006062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ODP",
          "relevance_score": "0.213235",
          "ticker_sentiment_score": "-0.200174",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.213235",
          "ticker_sentiment_score": "-0.023476",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MULN",
          "relevance_score": "0.143116",
          "ticker_sentiment_score": "0.006062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.071849",
          "ticker_sentiment_score": "0.017881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.213235",
          "ticker_sentiment_score": "0.003733",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates",
      "url": "https://www.zacks.com/stock/news/2462159/5-drugbiotech-stocks-likely-to-outperform-q1-earnings-estimates",
      "time_published": "20250505T131300",
      "authors": [
        "Ahan Chakraborty"
      ],
      "summary": "Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.157137,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.142777",
          "ticker_sentiment_score": "-0.051097",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.247119",
          "ticker_sentiment_score": "0.023928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DNLI",
          "relevance_score": "0.212736",
          "ticker_sentiment_score": "-0.005018",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.212736",
          "ticker_sentiment_score": "0.022866",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCRX",
          "relevance_score": "0.177933",
          "ticker_sentiment_score": "-0.001433",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.035875",
          "ticker_sentiment_score": "-0.018242",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.035875",
          "ticker_sentiment_score": "-0.018242",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.035875",
          "ticker_sentiment_score": "-0.018242",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why These 2 Biotech Stocks Made Big Moves Late Thursday",
      "url": "https://www.fool.com/investing/2023/07/13/why-these-2-biotech-stocks-made-big-moves-late-thu/",
      "time_published": "20230713T231100",
      "authors": [
        "Dan Caplinger"
      ],
      "summary": "Markets kept powering higher on the day.",
      "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.1305,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "THRX",
          "relevance_score": "0.212425",
          "ticker_sentiment_score": "-0.321345",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.07157",
          "ticker_sentiment_score": "0.004076",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.212425",
          "ticker_sentiment_score": "-0.174976",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Atea Pharma  ( AVIR )  Gains on Upbeat Initial Data From HCV Study",
      "url": "https://www.zacks.com/stock/news/2208247/atea-pharma-avir-gains-on-upbeat-initial-data-from-hcv-study",
      "time_published": "20240110T143000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99246"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.127224,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AVIR",
          "relevance_score": "0.212301",
          "ticker_sentiment_score": "0.043294",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.293841",
          "ticker_sentiment_score": "0.150659",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.212301",
          "ticker_sentiment_score": "0.057793",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.212301",
          "ticker_sentiment_score": "0.150321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Reasons to Add Acadia  ( ACAD )  Stock to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2165037/reasons-to-add-acadia-acad-stock-to-your-portfolio-now",
      "time_published": "20231012T155100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.145901,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASLN",
          "relevance_score": "0.312158",
          "ticker_sentiment_score": "-0.013898",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "0.225082",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.26224",
          "ticker_sentiment_score": "-0.040419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NRIX",
          "relevance_score": "0.312158",
          "ticker_sentiment_score": "-0.013894",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sana Bio  ( SANA )  Stock Rallies 105% in 3 Months: Here's Why",
      "url": "https://www.zacks.com/stock/news/2212223/sana-bio-sana-stock-rallies-105-in-3-months-heres-why",
      "time_published": "20240118T152400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.986564"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.179407,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.291347",
          "ticker_sentiment_score": "0.109742",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.210457",
          "ticker_sentiment_score": "0.085322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.210457",
          "ticker_sentiment_score": "0.147683",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SANA",
          "relevance_score": "0.251247",
          "ticker_sentiment_score": "0.298229",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet",
      "url": "https://www.benzinga.com/news/earnings/22/06/27800993/nasdaq-rises-2-5-acadia-pharmaceuticals-shares-plummet",
      "time_published": "20220621T184259",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday. The Dow traded up 2.09% to 30,445.81 while the NASDAQ rose 2.58% to 11,076.53. The S&P also rose, gaining, 2.44% to 3,764.68. Also check this: US Existing Home Sales And Other Macro Issues ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/mid-afternoon-market-update.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": -0.006116,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CNVY",
          "relevance_score": "0.140937",
          "ticker_sentiment_score": "-0.000476",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LEN",
          "relevance_score": "0.210031",
          "ticker_sentiment_score": "0.132271",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALN",
          "relevance_score": "0.210031",
          "ticker_sentiment_score": "0.020249",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BHAT",
          "relevance_score": "0.210031",
          "ticker_sentiment_score": "0.001214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EGY",
          "relevance_score": "0.140937",
          "ticker_sentiment_score": "0.066359",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPT",
          "relevance_score": "0.140937",
          "ticker_sentiment_score": "0.066359",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LEXX",
          "relevance_score": "0.140937",
          "ticker_sentiment_score": "0.003265",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ODP",
          "relevance_score": "0.210031",
          "ticker_sentiment_score": "-0.273448",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.210031",
          "ticker_sentiment_score": "-0.03198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.070746",
          "ticker_sentiment_score": "0.020249",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.210031",
          "ticker_sentiment_score": "0.003733",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher",
      "url": "https://www.benzinga.com/news/earnings/22/06/27798870/dow-jumps-550-points-convey-health-solutions-shares-spike-higher",
      "time_published": "20220621T161648",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday. The Dow traded up 1.86% to 30,445.81 while the NASDAQ rose 3.15% to 11,138.32. The S&P also rose, gaining, 2.56% to 3,768.74. Also check this: US Existing Home Sales And Other Macro Issues ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/mid-day-market-update.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": -0.011876,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CNVY",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-4.3e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LEN",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.132271",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALN",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.02214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BHAT",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.001198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARVL",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.016634",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LEXX",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.002492",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ODP",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "-0.305911",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "-0.018834",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MULN",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.016634",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.070725",
          "ticker_sentiment_score": "0.02214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:EUR",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.003733",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Add Xenon  ( XENE )  to Your Portfolio Now",
      "url": "https://www.zacks.com/stock/news/2214046/heres-why-you-should-add-xenon-xene-to-your-portfolio-now",
      "time_published": "20240123T133600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.995921"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.186701,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.289381",
          "ticker_sentiment_score": "0.115456",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.209004",
          "ticker_sentiment_score": "0.0571",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XENE",
          "relevance_score": "0.209004",
          "ticker_sentiment_score": "0.158172",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.209004",
          "ticker_sentiment_score": "0.148537",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "BioMarin  ( BMRN )  Hemophilia Gene Therapy BLA Gets FDA Acceptance",
      "url": "https://www.zacks.com/stock/news/1991732/biomarin-bmrn-hemophilia-gene-therapy-bla-gets-fda-acceptance",
      "time_published": "20221013T165100",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.116912,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMRN",
          "relevance_score": "0.208764",
          "ticker_sentiment_score": "0.143338",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ORIC",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "0.26431",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.208764",
          "ticker_sentiment_score": "0.21497",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "0.26431",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect",
      "url": "https://www.zacks.com/stock/news/2363525/arcturus-gears-up-to-report-q3-earnings-heres-what-to-expect",
      "time_published": "20241104T150500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999953"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.165866,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "0.117398",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "-0.034914",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRSP",
          "relevance_score": "0.1568",
          "ticker_sentiment_score": "-0.005445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARCT",
          "relevance_score": "0.531716",
          "ticker_sentiment_score": "0.058789",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Q1 Earnings & Sales Miss Estimates",
      "url": "https://www.zacks.com/stock/news/2092434/acadia-pharmaceuticals-acad-q1-earnings-sales-miss-estimates",
      "time_published": "20230509T144000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.061703,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.041296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.258351",
          "ticker_sentiment_score": "0.110605",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIX",
          "relevance_score": "0.1568",
          "ticker_sentiment_score": "0.087208",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "-0.068229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.05257",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ligand Pharmaceuticals  ( LGND )  Tops Q1 Earnings Estimates",
      "url": "https://www.zacks.com/stock/news/2270022/ligand-pharmaceuticals-lgnd-tops-q1-earnings-estimates",
      "time_published": "20240507T214006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Ligand (LGND) delivered earnings and revenue surprises of 6.19% and 4.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default354.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.180474,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.139265",
          "ticker_sentiment_score": "0.096077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alnylam  ( ALNY )  Posts Preliminary Q4 & Full-Year '23 Revenues",
      "url": "https://www.zacks.com/stock/news/2207180/alnylam-alny-posts-preliminary-q4-full-year-23-revenues",
      "time_published": "20240108T184900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.993856"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.165468,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.166743",
          "ticker_sentiment_score": "0.083972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.287441",
          "ticker_sentiment_score": "0.148003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.055145",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.144508",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Blueprint Medicines  ( BPMC )  Reports Q4 Loss, Misses Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/2415188/blueprint-medicines-bpmc-reports-q4-loss-misses-revenue-estimates",
      "time_published": "20250213T132506",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -12.86% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default256.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999892"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.110308,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.20698",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.400265",
          "ticker_sentiment_score": "0.106251",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision",
      "url": "https://www.benzinga.com/news/earnings/22/03/26159949/a-peek-into-the-markets-us-stock-futures-gain-all-eyes-on-fed-decision",
      "time_published": "20220316T100935",
      "authors": [],
      "summary": "Pre-open movers\nU.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results from  Jabil Inc.   ( NYSE: JBL ) ,  Williams-Sonoma, Inc.   ( NYSE: WSM )  and  Lennar Corporation  ( NYSE: LEN ) .\nData on",
      "banner_image": "https://cdn.benzinga.com/files/imagecache/story_image_685x375C/images/story/2012/peek_into_the_marketnew_385.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": -0.010208,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WSM",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "0.006733",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LEN",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "0.006733",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JBL",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "0.006733",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NIO",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "-0.002772",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATHM",
          "relevance_score": "0.069414",
          "ticker_sentiment_score": "-0.002772",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GM",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "0.00181",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KSFTF",
          "relevance_score": "0.069414",
          "ticker_sentiment_score": "-0.003491",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KC",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "-0.003491",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.206157",
          "ticker_sentiment_score": "0.019572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCORF",
          "relevance_score": "0.069414",
          "ticker_sentiment_score": "0.026224",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAL",
          "relevance_score": "0.138304",
          "ticker_sentiment_score": "0.195348",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Moderna  ( MRNA )  Q2 Earnings and Revenues Beat Estimates",
      "url": "https://www.zacks.com/stock/news/1962732/moderna-mrna-q2-earnings-and-revenues-beat-estimates",
      "time_published": "20220803T122508",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default229.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.146506,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.397098",
          "ticker_sentiment_score": "0.108149",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.205225",
          "ticker_sentiment_score": "0.099261",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "bluebird bio  ( BLUE )  Stock Gains 25.6% in a Month: Here's How",
      "url": "https://www.zacks.com/stock/news/2192021/bluebird-bio-blue-stock-gains-256-in-a-month-heres-how",
      "time_published": "20231201T124100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default270.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.218134,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.270523",
          "ticker_sentiment_score": "0.131404",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.204647",
          "ticker_sentiment_score": "0.070686",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRDA",
          "relevance_score": "0.204647",
          "ticker_sentiment_score": "0.070686",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.33446",
          "ticker_sentiment_score": "0.321557",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Airbnb  ( NASDAQ:ABNB ) ",
      "url": "https://www.benzinga.com/news/24/08/40219934/airbnb-reports-weak-earnings-joins-cryoport-tripadvisor-lyft-and-other-big-stocks-moving-lower-in-we",
      "time_published": "20240807T125652",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday. Shares of Airbnb, Inc. ABNB dipped 15.8% to $109.68 after the company reported worse-than-expected second-quarter EPS results and issued third-quarter revenue guidance below estimates.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/airbnb-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.993856"
        }
      ],
      "overall_sentiment_score": -0.024334,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVRO",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.064017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRIP",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.247191",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CYRX",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.064823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PGNY",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.247191",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "EXPE",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.556745",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "RIVN",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABNB",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.261037",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ZI",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.232696",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EYE",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.303735",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ASH",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.376746",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "-0.008422",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REAL",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss",
      "url": "https://www.zacks.com/stock/news/2134469/fate-q2-earnings-beat-on-lower-expenses-revenues-miss",
      "time_published": "20230809T161200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.0024,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FOLD",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.082363",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVAX",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.115903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.009673",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FATE",
          "relevance_score": "0.253514",
          "ticker_sentiment_score": "-0.149918",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPHLF",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.054047",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pacira  ( PCRX )  Preliminary '23 Revenues Solid, Exparel Strong",
      "url": "https://www.zacks.com/stock/news/2206478/pacira-pcrx-preliminary-23-revenues-solid-exparel-strong",
      "time_published": "20240105T172100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default26.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.07344,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.269033",
          "ticker_sentiment_score": "0.085254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.2035",
          "ticker_sentiment_score": "0.070378",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCRX",
          "relevance_score": "0.136499",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRDA",
          "relevance_score": "0.2035",
          "ticker_sentiment_score": "0.070378",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AVEO Pharmaceuticals  ( AVEO )  Inks Deal to be Acquired by LG Chem",
      "url": "https://www.zacks.com/stock/news/1994386/aveo-pharmaceuticals-aveo-inks-deal-to-be-acquired-by-lg-chem",
      "time_published": "20221019T160200",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.164352,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AVEO",
          "relevance_score": "0.732119",
          "ticker_sentiment_score": "0.235032",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.201803",
          "ticker_sentiment_score": "0.163166",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PLRX",
          "relevance_score": "0.201803",
          "ticker_sentiment_score": "0.212712",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Denali  ( DNLI )  Q2 Earnings Beat on Higher Collaboration Revenues",
      "url": "https://www.zacks.com/stock/news/2135288/denali-dnli-q2-earnings-beat-on-higher-collaboration-revenues",
      "time_published": "20230810T160200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/33314.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.077496,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.01123",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.434349",
          "ticker_sentiment_score": "0.180364",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DNLI",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.060107",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why You Should Add Acadia  ( ACAD )  Stock to Your Portfolio",
      "url": "https://www.zacks.com/stock/news/2075603/heres-why-you-should-add-acadia-acad-stock-to-your-portfolio",
      "time_published": "20230406T141900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/4018.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.20016,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.100634",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.050894",
          "ticker_sentiment_score": "0.004999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.138696",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.0705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVXL",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "0.014186",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Q4 Earnings Lag Estimates  ( Revised ) ",
      "url": "https://www.zacks.com/stock/news/2425672/acadia-pharmaceuticals-acad-q4-earnings-lag-estimates-revised",
      "time_published": "20250305T113600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.171305,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.201244",
          "ticker_sentiment_score": "0.175139",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.201244",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant  ( IMVT )  Set to Develop Lead Candidate Batoclimab",
      "url": "https://www.zacks.com/stock/news/1995262/immunovant-imvt-set-to-develop-lead-candidate-batoclimab",
      "time_published": "20221020T175600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.052753,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.688096",
          "ticker_sentiment_score": "0.25619",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ORIC",
          "relevance_score": "0.326499",
          "ticker_sentiment_score": "0.251481",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGLE",
          "relevance_score": "0.326499",
          "ticker_sentiment_score": "0.183929",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.199584",
          "ticker_sentiment_score": "0.201536",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Rises 35% on Positive Patent Ruling for Nuplazid",
      "url": "https://www.zacks.com/stock/news/2197873/acadia-acad-rises-35-on-positive-patent-ruling-for-nuplazid",
      "time_published": "20231214T134700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ed/4119.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990786"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.185564,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.338913",
          "ticker_sentiment_score": "0.175354",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.338913",
          "ticker_sentiment_score": "0.026915",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.097459",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.09307",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bayer  ( BAYRY )  Elinzanetant Meets Goals in Late-Stage Studies",
      "url": "https://www.zacks.com/stock/news/2207070/bayer-bayry-elinzanetant-meets-goals-in-late-stage-studies",
      "time_published": "20240108T162600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.146346,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.068331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.259037",
          "ticker_sentiment_score": "0.191192",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TRDA",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.068331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.065866",
          "ticker_sentiment_score": "0.183478",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Aehr Test Systems  ( NASDAQ:AEHR ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/07/33230027/why-aehr-test-systems-shares-are-trading-higher-here-are-20-stocks-moving-premarket",
      "time_published": "20230714T121649",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Ainos, Inc. AIMD shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday. Intuitive Machines, Inc. LUNR shares gained 29.1% to $11.02 in pre-market trading. Intuitive Machines is closing in on delivering its Nova-C lunar lander to Florida for launch.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/image9.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.110743,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AIMD",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.311535",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JZXN",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "-0.051722",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TAOP",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "-0.107321",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NOK",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.049954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EMMLD",
          "relevance_score": "0.065866",
          "ticker_sentiment_score": "0.016207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LUNR",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.257778",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARBB",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.184975",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AEHR",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.219075",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LESL",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.07934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NKLA",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.286722",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EVGN",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "-0.015524",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GTBP",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "0.441941",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "-0.163665",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "THRX",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "-0.11088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARDS",
          "relevance_score": "0.131284",
          "ticker_sentiment_score": "-0.055925",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Gilead's  ( GILD )  Yescarta Gets EC Nod for New Cancer Indication",
      "url": "https://www.zacks.com/stock/news/1993697/gileads-gild-yescarta-gets-ec-nod-for-new-cancer-indication",
      "time_published": "20221018T164400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.2267,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MGNX",
          "relevance_score": "0.319725",
          "ticker_sentiment_score": "0.332027",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ORIC",
          "relevance_score": "0.319725",
          "ticker_sentiment_score": "0.178797",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.195287",
          "ticker_sentiment_score": "0.146438",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.130926",
          "ticker_sentiment_score": "0.04679",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "InMode  ( INMD )  to Post Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2170702/inmode-inmd-to-post-q3-earnings-whats-in-the-cards",
      "time_published": "20231024T115300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/41955.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.26593,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PODD",
          "relevance_score": "0.256314",
          "ticker_sentiment_score": "0.079031",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.193723",
          "ticker_sentiment_score": "0.126736",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.193723",
          "ticker_sentiment_score": "0.11313",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INMD",
          "relevance_score": "0.317254",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Files an NDA for Its Rett Syndrome Candidate",
      "url": "https://www.zacks.com/stock/news/1954526/acadia-acad-files-an-nda-for-its-rett-syndrome-candidate",
      "time_published": "20220719T152200",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.204837,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BEAM",
          "relevance_score": "0.307731",
          "ticker_sentiment_score": "0.212574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ANIK",
          "relevance_score": "0.307731",
          "ticker_sentiment_score": "0.253289",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NURPF",
          "relevance_score": "0.063091",
          "ticker_sentiment_score": "0.022245",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.187705",
          "ticker_sentiment_score": "0.119186",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FATE",
          "relevance_score": "0.307731",
          "ticker_sentiment_score": "0.21036",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Viatris  ( VTRS )  to Report Q1 Earnings: What's in the Offing?",
      "url": "https://www.zacks.com/stock/news/2090311/viatris-vtrs-to-report-q1-earnings-whats-in-the-offing",
      "time_published": "20230504T161700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999917"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.12459,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKRO",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "-0.002993",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "-0.127423",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ONCT",
          "relevance_score": "0.186738",
          "ticker_sentiment_score": "-0.004528",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.693986",
          "ticker_sentiment_score": "0.269095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Vertex  ( VRTX )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2174363/vertex-vrtx-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231030T130000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Vertex (VRTX) is likely to outperform third-quarter 2023 estimates, driven by the increased international sales of its lead drug, Trikafta/Kaftrio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/667.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999953"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.138299,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.361626",
          "ticker_sentiment_score": "0.020466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.037942",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.061407",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Emergent's  ( EBS )  Cyfendus Anthrax Vaccine Gets FDA Nod",
      "url": "https://www.zacks.com/stock/news/2125437/emergents-ebs-cyfendus-anthrax-vaccine-gets-fda-nod",
      "time_published": "20230721T132100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.060232,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADCT",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "-0.022972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.042058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKYA",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "-0.028569",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "0.228296",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Dynavax  ( DVAX )  to Report Q3 Earnings: Will It Beat Estimates?",
      "url": "https://www.zacks.com/stock/news/2170685/dynavax-dvax-to-report-q3-earnings-will-it-beat-estimates",
      "time_published": "20231024T114500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999985"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.115226,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "-0.060909",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.103042",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DVAX",
          "relevance_score": "0.301686",
          "ticker_sentiment_score": "0.232326",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "-0.00295",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "U.S. FDA approves Acadia's genetic Rett syndrome drug",
      "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-acadias-genetic-rett-syndrome-drug-2023-03-11/",
      "time_published": "20230311T031000",
      "authors": [
        "Reuters"
      ],
      "summary": "March 10 ( Reuters ) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's ( ACAD.O ) drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first-approved drug for the condition.",
      "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XRR76P24JFOS5KOFHRKLM56YBM.jpg",
      "source": "Reuters",
      "category_within_source": "Business",
      "source_domain": "www.reuters.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.072237,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "-0.068289",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Apellis  ( APLS )  Up on Strong Q4 Preliminary Syfovre U.S. Revenues",
      "url": "https://www.zacks.com/stock/news/2207496/apellis-apls-up-on-strong-q4-preliminary-syfovre-us-revenues",
      "time_published": "20240109T150200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.995921"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.158548,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.228287",
          "ticker_sentiment_score": "0.104732",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADMA",
          "relevance_score": "0.272282",
          "ticker_sentiment_score": "0.088118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.183546",
          "ticker_sentiment_score": "0.063071",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.183546",
          "ticker_sentiment_score": "0.130525",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aeterna  ( AEZS )  Falls 5% on US Sales Halt of Growth Hormone Drug",
      "url": "https://www.zacks.com/stock/news/2075598/aeterna-aezs-falls-5-on-us-sales-halt-of-growth-hormone-drug",
      "time_published": "20230406T141500",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136641,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.18343",
          "ticker_sentiment_score": "-0.015072",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AEZS",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.013284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.08165",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.126672",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allogene's  ( ALLO )  Q3 Loss Narrower Than Expected, Sales Miss",
      "url": "https://www.zacks.com/stock/news/2178230/allogenes-allo-q3-loss-narrower-than-expected-sales-miss",
      "time_published": "20231103T151500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997845"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.0,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.779232",
          "ticker_sentiment_score": "-0.121674",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.181591",
          "ticker_sentiment_score": "0.082945",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.407844",
          "ticker_sentiment_score": "0.230225",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.298023",
          "ticker_sentiment_score": "0.024092",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allogene's  ( ALLO )  Q3 Loss Narrower Than Expected, Sales Miss",
      "url": "https://www.zacks.com/stock/news/2178230/allogenes-allo-q3-loss-narrower-than-expected-sales-miss",
      "time_published": "20231103T141500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997845"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.0,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.779232",
          "ticker_sentiment_score": "-0.121674",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.181591",
          "ticker_sentiment_score": "0.082945",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.407844",
          "ticker_sentiment_score": "0.230225",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.298023",
          "ticker_sentiment_score": "0.024092",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bioventus  ( BVS )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2171824/bioventus-bvs-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231025T144800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.035925,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.181137",
          "ticker_sentiment_score": "-0.060241",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.181137",
          "ticker_sentiment_score": "0.103363",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.181137",
          "ticker_sentiment_score": "-0.002918",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BVS",
          "relevance_score": "0.59892",
          "ticker_sentiment_score": "0.158573",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Acadia  ( ACAD )  Could Beat Earnings Estimates Again",
      "url": "https://www.zacks.com/stock/news/2350142/why-acadia-acad-could-beat-earnings-estimates-again",
      "time_published": "20241014T161015",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default148.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999756"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.315919,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.034836",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Roche  ( RHHBY )  SMA Drug Gets Positive CHMP Opinion for Expanded Use",
      "url": "https://www.zacks.com/stock/news/2126145/roche-rhhby-sma-drug-gets-positive-chmp-opinion-for-expanded-use",
      "time_published": "20230724T130400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.10021,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKYA",
          "relevance_score": "0.233556",
          "ticker_sentiment_score": "-0.027465",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "-0.022152",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.040561",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Milestone's  ( MIST )  Tachycardia Study Data Fail to Impress Investors",
      "url": "https://www.zacks.com/stock/news/1993864/milestones-mist-tachycardia-study-data-fail-to-impress-investors",
      "time_published": "20221018T223000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/380.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.209487,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MIST",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.129096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.146292",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLRX",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.190098",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Q4 Earnings Lag, Sales Beat Estimates, Stock Down",
      "url": "https://www.zacks.com/stock/news/2233112/acadia-acad-q4-earnings-lag-sales-beat-estimates-stock-down",
      "time_published": "20240228T141200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99237"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.145678,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.174903",
          "ticker_sentiment_score": "-0.002974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INDV",
          "relevance_score": "0.174903",
          "ticker_sentiment_score": "0.165478",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VNDA",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "0.10993",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.217639",
          "ticker_sentiment_score": "0.143687",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant  ( IMVT )  Q1 Loss Wider Y/Y, Pipeline in Focus",
      "url": "https://www.zacks.com/stock/news/2135878/immunovant-imvt-q1-loss-wider-yy-pipeline-in-focus",
      "time_published": "20230811T152000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8b/382.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.042812,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.621247",
          "ticker_sentiment_score": "-0.017867",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CORT",
          "relevance_score": "0.116631",
          "ticker_sentiment_score": "0.058019",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.174167",
          "ticker_sentiment_score": "0.094003",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.174167",
          "ticker_sentiment_score": "0.063605",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Femasys  ( FEMY )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2170588/femasys-femy-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231024T081300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/44137.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999855"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.154193,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLUE",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "-0.021175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.172097",
          "ticker_sentiment_score": "0.049638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FEMY",
          "relevance_score": "0.653822",
          "ticker_sentiment_score": "0.337725",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Phathom  ( PHAT )  Up 8% on Erosive Esophagitis Drug's CRL Update",
      "url": "https://www.zacks.com/stock/news/2074874/phathom-phat-up-8-on-erosive-esophagitis-drugs-crl-update",
      "time_published": "20230405T123500",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/1887.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.040756,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "0.143286",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLCO",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.048002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.170878",
          "ticker_sentiment_score": "-0.014286",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "0.073587",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHAT",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "0.008882",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Viatris  ( VTRS )  to Report Q3 Earnings: Is a Beat in Store?",
      "url": "https://www.zacks.com/stock/news/2175750/viatris-vtrs-to-report-q3-earnings-is-a-beat-in-store",
      "time_published": "20231031T151700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999985"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.133372,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.169676",
          "ticker_sentiment_score": "-0.002784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.169676",
          "ticker_sentiment_score": "0.119882",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.567965",
          "ticker_sentiment_score": "0.300198",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm",
      "url": "https://markets.businessinsider.com/news/stocks/ongoing-investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-acadia-pharmaceuticals-inc-and-encourages-investors-with-losses-to-contact-the-firm-1033210676",
      "time_published": "20240401T115409",
      "authors": [
        "PRESS RELEASE ACCESSWIRE"
      ],
      "summary": "ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA ... - Markets Insider ...",
      "banner_image": "https://www.accesswire.com/imagelibrary/505b5ef5-03cd-4ff1-a099-cc3b55a06f40/848613/shalllogo.png",
      "source": "Business Insider",
      "category_within_source": "GoogleRSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.146603,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.091609",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket - Cingulate  ( NASDAQ:CING ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/23/03/31318516/why-provention-bio-shares-are-trading-higher-by-over-260-here-are-20-stocks-moving-premarket",
      "time_published": "20230313T121929",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "Provention Bio, Inc. PRVB rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. Tenax Therapeutics, Inc. TENX rose 35.8% to $0.7737 in pre-market trading after gaining 23% on ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/13/image_7.jpg?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.846708"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.004821,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CING",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.223371",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MARA",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSTR",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.185967",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MEDS",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LASE",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.157214",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CZOO",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.240513",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MTEM",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.109099",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRVB",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.271668",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CYTO",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.097607",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLYC",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.37024",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "HYPR",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "-0.330525",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "OBSV",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.114714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYTA",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.0919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FRC",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "METX",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.267615",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RIOT",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "-0.240513",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.036511",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TENX",
          "relevance_score": "0.16849",
          "ticker_sentiment_score": "0.241871",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.204776",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRYPTO:PAY",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.181998",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Axsome  ( AXSM )  Banks on Auvelity & Sunosi to Fuel Growth",
      "url": "https://www.zacks.com/stock/news/2322688/axsome-axsm-banks-on-auvelity-sunosi-to-fuel-growth",
      "time_published": "20240815T150500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity. Stiff competition in the target market is a woe.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.138793,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "JAZZ",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.002797",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.167904",
          "ticker_sentiment_score": "0.047002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.328455",
          "ticker_sentiment_score": "0.149413",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Perrigo  ( PRGO )  Lags on Q3 Earnings & Sales, Lowers '23 View",
      "url": "https://www.zacks.com/stock/news/2180246/perrigo-prgo-lags-on-q3-earnings-sales-lowers-23-view",
      "time_published": "20231107T165300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99989"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.132803,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.328091",
          "ticker_sentiment_score": "-0.069407",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.084029",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.328091",
          "ticker_sentiment_score": "0.207665",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.474763",
          "ticker_sentiment_score": "0.209287",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Tharimmune  ( THAR )  Up on Positive Data From Pipeline Candidate",
      "url": "https://www.zacks.com/stock/news/2190487/tharimmune-thar-up-on-positive-data-from-pipeline-candidate",
      "time_published": "20231128T172400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Tharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.14169,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.220308",
          "ticker_sentiment_score": "0.111419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.102783",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "THAR",
          "relevance_score": "0.470894",
          "ticker_sentiment_score": "0.200615",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.060731",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Puma Biotech  ( PBYI )  Q2 Earnings Beat, Nerlynx Sales Outperform",
      "url": "https://www.zacks.com/stock/news/2132834/puma-biotech-pbyi-q2-earnings-beat-nerlynx-sales-outperform",
      "time_published": "20230804T163600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99998"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": -0.055156,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.019787",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.206862",
          "ticker_sentiment_score": "0.142733",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.206862",
          "ticker_sentiment_score": "0.066121",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.030863",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CRISPR Therapeutics  ( CRSP )  Q3 Loss Narrower Than Expected",
      "url": "https://www.zacks.com/stock/news/2180153/crispr-therapeutics-crsp-q3-loss-narrower-than-expected",
      "time_published": "20231107T151100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976671"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.089891,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.164656",
          "ticker_sentiment_score": "-0.067048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.164656",
          "ticker_sentiment_score": "0.088527",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRSP",
          "relevance_score": "0.322374",
          "ticker_sentiment_score": "-0.018796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.322374",
          "ticker_sentiment_score": "0.215926",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Novo Nordisk  ( NVO )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2176134/novo-nordisk-nvo-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231101T113800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999973"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.208895,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.164656",
          "ticker_sentiment_score": "0.095082",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.164656",
          "ticker_sentiment_score": "0.104658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.164656",
          "ticker_sentiment_score": "0.027625",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.467081",
          "ticker_sentiment_score": "0.391064",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Incyte  ( INCY )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2173871/incyte-incy-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231027T153600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999917"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.189324,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.161349",
          "ticker_sentiment_score": "0.048938",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.722509",
          "ticker_sentiment_score": "0.243069",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.161349",
          "ticker_sentiment_score": "0.146135",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.161349",
          "ticker_sentiment_score": "-0.001342",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Kodiak  ( KOD )  Down as Late-Stage DME Studies Fail",
      "url": "https://www.zacks.com/stock/news/2127050/kodiak-kod-down-as-late-stage-dme-studies-fail",
      "time_published": "20230725T131600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.060084,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "KOD",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.02695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "-0.0208",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "0.038102",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKYA",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "-0.025579",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Axsome Banks on Auvelity & Sunosi to Fuel Growth - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Axsome Therapeutics  ( NASDAQ:AXSM ) ",
      "url": "https://www.benzinga.com/general/biotech/24/08/40400393/axsome-banks-on-auvelity-sunosi-to-fuel-growth",
      "time_published": "20240815T192204",
      "authors": [
        "Zacks"
      ],
      "summary": "Axsome Therapeutics' AXSM first marketed drug, Auvelity ( AXS-05 ) , was launched in the United States in 2022 for the treatment of major depressive disorder, making it the first approved drug in the company's portfolio.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/15/clay-banks-cezmop5ftv4-unsplash.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.164671,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JAZZ",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.004078",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.160099",
          "ticker_sentiment_score": "0.050978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.313817",
          "ticker_sentiment_score": "0.156105",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Viatris  ( VTRS )  to Report Q2 Earnings: What's in the Offing?",
      "url": "https://www.zacks.com/stock/news/2129982/viatris-vtrs-to-report-q2-earnings-whats-in-the-offing",
      "time_published": "20230731T154500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default12.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999917"
        }
      ],
      "overall_sentiment_score": 0.087635,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "-0.102967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "-0.08901",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.652576",
          "ticker_sentiment_score": "0.299192",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Amicus  ( FOLD )  Misses on Q2 Earnings, Raises Revenue Guidance",
      "url": "https://www.zacks.com/stock/news/2134351/amicus-fold-misses-on-q2-earnings-raises-revenue-guidance",
      "time_published": "20230809T132500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.997874"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.137697,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FOLD",
          "relevance_score": "0.31019",
          "ticker_sentiment_score": "0.133351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.158173",
          "ticker_sentiment_score": "-0.020568",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WXXWY",
          "relevance_score": "0.053035",
          "ticker_sentiment_score": "0.039784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.158173",
          "ticker_sentiment_score": "0.088089",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down 0.7% Since Last Earnings Report: Can It Rebound?",
      "url": "https://www.zacks.com/stock/news/2143805/acadia-acad-down-07-since-last-earnings-report-can-it-rebound",
      "time_published": "20230901T153138",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default210.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.129343,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALKS",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.055929",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.157827",
          "ticker_sentiment_score": "0.05613",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains",
      "url": "https://stocknews.com/news/alpmy-acad-spro-3-affordable-pharma-stocks-to-buy-for-portfolio-gains/",
      "time_published": "20240412T101250",
      "authors": [
        "StockNews.com Staff"
      ],
      "summary": "The pharmaceutical industry is undergoing a transformative boom, leveraging digital platforms, big data analytics, cloud computing, and AI to drive innovation. Moreover, the growing demand for personalized drugs and increased R&D activities should give an additional boost to the already ...",
      "banner_image": "https://stocknews.com/wp-content/uploads/2024/01/Neha-Panjwani_Headshot-1.jpeg",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "stocknews.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.846708"
        }
      ],
      "overall_sentiment_score": 0.168476,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SPRO",
          "relevance_score": "0.229149",
          "ticker_sentiment_score": "0.043286",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.025817",
          "ticker_sentiment_score": "0.241688",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.153961",
          "ticker_sentiment_score": "0.0633",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sage Therapeutics  ( SAGE )  Q3 Earnings Lag Estimates, Down 5%",
      "url": "https://www.zacks.com/stock/news/2181116/sage-therapeutics-sage-q3-earnings-lag-estimates-down-5",
      "time_published": "20231108T181100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.009585,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.3007",
          "ticker_sentiment_score": "-0.075896",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.43768",
          "ticker_sentiment_score": "0.083905",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.153145",
          "ticker_sentiment_score": "0.083164",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.252463",
          "ticker_sentiment_score": "0.161541",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SGIOF",
          "relevance_score": "0.05133",
          "ticker_sentiment_score": "0.086485",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hologic  ( HOLX )  Q4 Earnings Might Rise on 7.7% Breast Health Growth",
      "url": "https://www.zacks.com/stock/news/2174620/hologic-holx-q4-earnings-might-rise-on-77-breast-health-growth",
      "time_published": "20231030T140300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/95/44430.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.226492,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.151858",
          "ticker_sentiment_score": "0.100886",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HOLX",
          "relevance_score": "0.344987",
          "ticker_sentiment_score": "0.338837",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.065181",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.151858",
          "ticker_sentiment_score": "0.107304",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?",
      "url": "https://www.zacks.com/stock/news/2349254/will-auvelity-sunosi-fuel-axsomes-growth-amid-stiff-competition",
      "time_published": "20241011T134000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.212915,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JAZZ",
          "relevance_score": "0.151064",
          "ticker_sentiment_score": "0.00261",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.151064",
          "ticker_sentiment_score": "0.046512",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.296761",
          "ticker_sentiment_score": "0.119306",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug",
      "url": "https://www.reuters.com/business/future-of-health/us-fda-declines-approve-expanded-use-acadias-antipsychotic-drug-2022-08-05/",
      "time_published": "20220805T044600",
      "authors": [
        "Reuters"
      ],
      "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly Aug 4 ( Reuters ) - The U.S.",
      "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/JPYRWVWGNBJDPDJJKTUFIEABKA.jpg",
      "source": "Reuters",
      "category_within_source": "Business",
      "source_domain": "www.reuters.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.016718,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.150592",
          "ticker_sentiment_score": "-0.035451",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zoetis  ( ZTS )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2172904/zoetis-zts-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231026T142100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999973"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.129734,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ZTS",
          "relevance_score": "0.621413",
          "ticker_sentiment_score": "0.255778",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.149656",
          "ticker_sentiment_score": "0.025971",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.149656",
          "ticker_sentiment_score": "0.043947",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DICE Therapeutics  ( DICE )  Up on Top-Line Data From Psoriasis Study",
      "url": "https://www.zacks.com/stock/news/1991101/dice-therapeutics-dice-up-on-top-line-data-from-psoriasis-study",
      "time_published": "20221012T161600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2c/285.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.11094,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMCR",
          "relevance_score": "0.29234",
          "ticker_sentiment_score": "0.206445",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.234095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARDS",
          "relevance_score": "0.29234",
          "ticker_sentiment_score": "0.168594",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DICE",
          "relevance_score": "0.488337",
          "ticker_sentiment_score": "0.276422",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Esperion  ( ESPR )  Q3 Earnings Beat, Stock Up on Strong Revenues",
      "url": "https://www.zacks.com/stock/news/2181120/esperion-espr-q3-earnings-beat-stock-up-on-strong-revenues",
      "time_published": "20231108T181600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.993781"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.043189,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.146618",
          "ticker_sentiment_score": "0.018296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APLS",
          "relevance_score": "0.288327",
          "ticker_sentiment_score": "-0.041468",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ESPR",
          "relevance_score": "0.098054",
          "ticker_sentiment_score": "-0.091924",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.04912",
          "ticker_sentiment_score": "-0.010952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.146618",
          "ticker_sentiment_score": "0.083592",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.04912",
          "ticker_sentiment_score": "-0.010952",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Stock Up on FDA's Action Date for Nuplazid sNDA",
      "url": "https://www.zacks.com/stock/news/1880368/acadia-acad-stock-up-on-fdas-action-date-for-nuplazid-snda",
      "time_published": "20220310T165000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.020249,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.216731",
          "ticker_sentiment_score": "0.053408",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.145495",
          "ticker_sentiment_score": "0.001026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATHX",
          "relevance_score": "0.286193",
          "ticker_sentiment_score": "-0.008189",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KLDO",
          "relevance_score": "0.286193",
          "ticker_sentiment_score": "-0.023937",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "VBI Vaccine  ( VBIV )  Inks Deal With Agenus for Brain Cancer Study",
      "url": "https://www.zacks.com/stock/news/1991663/vbi-vaccine-vbiv-inks-deal-with-agenus-for-brain-cancer-study",
      "time_published": "20221013T152300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.043833,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.535653",
          "ticker_sentiment_score": "-0.115575",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMCR",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.200779",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VBIV",
          "relevance_score": "0.535653",
          "ticker_sentiment_score": "0.030277",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.145145",
          "ticker_sentiment_score": "0.232127",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "28 Biggest Movers From Yesterday",
      "url": "https://www.benzinga.com/news/22/04/26584443/28-biggest-movers-from-yesterday",
      "time_published": "20220412T101537",
      "authors": [],
      "summary": "Gainers\nSailPoint Technologies Holdings, Inc.  ( NYSE: SAIL )  shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire the company for $6.9 billion.\nDatto Holding Corp.  ( NYSE: MSP )  shares surged 20.65% to close at $34.65 after Kaseya Ltd",
      "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/04/12/yesterdays_movers.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": -0.006481,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AMRC",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "-0.012263",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GNENY",
          "relevance_score": "0.072633",
          "ticker_sentiment_score": "0.000138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPD",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.002831",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CZOO",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.002243",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LXU",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DRKTF",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001993",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FRGE",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.003514",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONQ",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "-0.003378",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWTX",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001408",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BURL",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EDU",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "-0.003437",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PING",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001615",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAIL",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.00631",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.00163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BILI",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.017028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCRX",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001545",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.072633",
          "ticker_sentiment_score": "0.001214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBLK",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "-0.032085",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STER",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRNS",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.000911",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSP",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.002317",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPEN",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001353",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GGR",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001276",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SST",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.001726",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEWR",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.000948",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRCIF",
          "relevance_score": "0.072633",
          "ticker_sentiment_score": "-0.002556",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEN",
          "relevance_score": "0.144665",
          "ticker_sentiment_score": "0.000472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:GBP",
          "relevance_score": "0.072633",
          "ticker_sentiment_score": "0.001214",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Eton Pharma  ( ETON )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2170070/eton-pharma-eton-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231023T091600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7c/40264.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.224443,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BLUE",
          "relevance_score": "0.144563",
          "ticker_sentiment_score": "-0.018922",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ETON",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.10445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.144563",
          "ticker_sentiment_score": "0.044349",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Agios  ( AGIO )  Reports Narrower-Than-Expected Q3 Loss, Lags Sales",
      "url": "https://www.zacks.com/stock/news/2178282/agios-agio-reports-narrower-than-expected-q3-loss-lags-sales",
      "time_published": "20231103T150600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998917"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.052558,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.096477",
          "ticker_sentiment_score": "0.047241",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AGIO",
          "relevance_score": "0.191549",
          "ticker_sentiment_score": "-0.138179",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.07386",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.328611",
          "ticker_sentiment_score": "0.201185",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.018295",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Up 12% Since Last Earnings Report: Can It Continue?",
      "url": "https://www.zacks.com/stock/news/2105177/acadia-acad-up-12-since-last-earnings-report-can-it-continue",
      "time_published": "20230607T153039",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default33.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.103477,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "KRTX",
          "relevance_score": "0.143843",
          "ticker_sentiment_score": "0.054286",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.143843",
          "ticker_sentiment_score": "0.041011",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.072217",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Gilead  ( GILD )  Gears Up to Report Q2 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2129602/gilead-gild-gears-up-to-report-q2-earnings-whats-in-store",
      "time_published": "20230728T162900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999985"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.08877,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.1437",
          "ticker_sentiment_score": "-0.002513",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.282777",
          "ticker_sentiment_score": "0.297312",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.096091",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.1437",
          "ticker_sentiment_score": "0.07408",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Reports Q1 Loss, Lags Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/2091781/acadia-pharmaceuticals-acad-reports-q1-loss-lags-revenue-estimates",
      "time_published": "20230508T212514",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.121678,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.142144",
          "ticker_sentiment_score": "-0.064878",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Q4 Earnings Lag Estimates",
      "url": "https://www.zacks.com/stock/news/2422255/acadia-pharmaceuticals-acad-q4-earnings-lag-estimates",
      "time_published": "20250226T222505",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default109.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.164502,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.11892",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?",
      "url": "https://www.zacks.com/stock/news/2125615/gsk-gears-up-for-q2-earnings-will-it-surpass-estimates",
      "time_published": "20230721T172200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99998"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.080531,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADCT",
          "relevance_score": "0.234006",
          "ticker_sentiment_score": "-0.07524",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "-0.064814",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.063155",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.407844",
          "ticker_sentiment_score": "0.263068",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Novartis  ( NVS )  Tops Q3 Earnings, Ups Operating Income View",
      "url": "https://www.zacks.com/stock/news/2170903/novartis-nvs-tops-q3-earnings-ups-operating-income-view",
      "time_published": "20231024T130100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.252213,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.141448",
          "ticker_sentiment_score": "0.062369",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.187827",
          "ticker_sentiment_score": "0.170402",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.141448",
          "ticker_sentiment_score": "0.062369",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Tops Q1 Earnings and Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/2464473/acadia-pharmaceuticals-acad-tops-q1-earnings-and-revenue-estimates",
      "time_published": "20250507T213508",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.128044,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.09672",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Oracle  ( NYSE:ORCL ) ",
      "url": "https://www.benzinga.com/news/24/03/37613941/why-oracle-shares-are-trading-higher-by-around-13-here-are-20-stocks-moving-premarket",
      "time_published": "20240312T121102",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Shares of Oracle Corporation ORCL rose sharply in today's pre-market trading after the company reported upbeat earnings for its fiscal third quarter. Oracle's third-quarter revenue increased 7% year-over-year to $13.3 billion, which missed the consensus estimate of $13.306 billion, according to ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/12/oracle_-_logo.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.882182"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.996675"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.18239,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RERE",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.228379",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SGDVV",
          "relevance_score": "0.070725",
          "ticker_sentiment_score": "-0.263178",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.19021",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NXL",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.052999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONM",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.456781",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SGLY",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.358883",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ORCL",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.253999",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "STI",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-0.230838",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "FNCH",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNLX",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.063385",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OCUL",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-0.049533",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PIK",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-0.069769",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LITM",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-0.406757",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "CLRO",
          "relevance_score": "0.20997",
          "ticker_sentiment_score": "0.325402",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MNSO",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.193023",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-0.268894",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "HRTG",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.535242",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "VINO",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Reports Q4 Loss, Tops Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/2059477/acadia-pharmaceuticals-acad-reports-q4-loss-tops-revenue-estimates",
      "time_published": "20230227T222505",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.112644,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "-0.064542",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TBIO",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Q2 Earnings and Revenues Beat Estimates",
      "url": "https://www.zacks.com/stock/news/2131346/acadia-pharmaceuticals-acad-q2-earnings-and-revenues-beat-estimates",
      "time_published": "20230802T212518",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 108.33% and 7.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999892"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.135472,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.140485",
          "ticker_sentiment_score": "-0.02502",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLRX",
          "relevance_score": "0.209365",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Beats Q2 Earnings and Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/2317402/acadia-pharmaceuticals-acad-beats-q2-earnings-and-revenue-estimates",
      "time_published": "20240806T214505",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 25% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.148433,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GTHX",
          "relevance_score": "0.208764",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.096396",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Tops Q1 Earnings Estimates",
      "url": "https://www.zacks.com/stock/news/2270880/acadia-pharmaceuticals-acad-tops-q1-earnings-estimates",
      "time_published": "20240508T211508",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999981"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.132845,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BFRI",
          "relevance_score": "0.208764",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.035146",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Karuna's  ( KRTX )  Q3 Loss Wider-Than-Expected, Sales Miss",
      "url": "https://www.zacks.com/stock/news/2178245/karunas-krtx-q3-loss-wider-than-expected-sales-miss",
      "time_published": "20231103T153400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998917"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.059465,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "KRTX",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.061601",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.070074",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.192203",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.230892",
          "ticker_sentiment_score": "0.019612",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Karuna's  ( KRTX )  Q3 Loss Wider-Than-Expected, Sales Miss",
      "url": "https://www.zacks.com/stock/news/2178245/karunas-krtx-q3-loss-wider-than-expected-sales-miss",
      "time_published": "20231103T143400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998917"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.059465,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "KRTX",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.061601",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.139804",
          "ticker_sentiment_score": "0.070074",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.192203",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.230892",
          "ticker_sentiment_score": "0.019612",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Scholar Rock  ( SRRK )  Up on Pipeline Advancement, Stock Offering",
      "url": "https://www.zacks.com/stock/news/2165827/scholar-rock-srrk-up-on-pipeline-advancement-stock-offering",
      "time_published": "20231013T164500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.062133,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.055841",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.055841",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.055841",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRRK",
          "relevance_score": "0.571516",
          "ticker_sentiment_score": "0.199784",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Q4 Earnings Lag Estimates",
      "url": "https://www.zacks.com/stock/news/2232690/acadia-pharmaceuticals-acad-q4-earnings-lag-estimates",
      "time_published": "20240227T222006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default116.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999892"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.128381,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKYA",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.139265",
          "ticker_sentiment_score": "0.055325",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Beats Q3 Earnings and Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/2365548/acadia-pharmaceuticals-acad-beats-q3-earnings-and-revenue-estimates",
      "time_published": "20241106T221513",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 53.85% and 0.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.139479,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FTRE",
          "relevance_score": "0.206392",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.034909",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Reports Q2 Loss, Tops Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/1965592/acadia-pharmaceuticals-acad-reports-q2-loss-tops-revenue-estimates",
      "time_published": "20220808T213511",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.10111,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.019572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GERN",
          "relevance_score": "0.138066",
          "ticker_sentiment_score": "0.104055",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach",
      "url": "https://www.benzinga.com/pressreleases/24/05/g39070557/lynch-carpenter-investigates-claims-in-cencora-inc-data-breach",
      "time_published": "20240529T174658",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "PITTSBURGH, May 29, 2024 ( GLOBE NEWSWIRE ) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information of at least half a million individuals.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.028843,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DNPUF",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "-0.086454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSUMF",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "-0.086454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.512093",
          "ticker_sentiment_score": "-0.254098",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "-0.086454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "-0.086454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "-0.086454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "-0.086454",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Iovance  ( IOVA )  Doses First Patient in TIL Cancer Therapy Study",
      "url": "https://www.zacks.com/stock/news/1990463/iovance-iova-doses-first-patient-in-til-cancer-therapy-study",
      "time_published": "20221011T154900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.08215,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.201284",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.13083",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARDS",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.121552",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLLS",
          "relevance_score": "0.202932",
          "ticker_sentiment_score": "-0.001734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Tops Q1 Earnings and Revenue Estimates  ( Revised ) ",
      "url": "https://www.zacks.com/stock/news/2466428/acadia-pharmaceuticals-acad-tops-q1-earnings-and-revenue-estimates-revised",
      "time_published": "20250509T222600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default77.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.121496,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.134214",
          "ticker_sentiment_score": "0.094125",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alkermes  ( ALKS )  Q2 Earnings & Revenues Beat Estimates",
      "url": "https://www.zacks.com/stock/news/2128881/alkermes-alks-q2-earnings-revenues-beat-estimates",
      "time_published": "20230727T142400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.125685,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALKS",
          "relevance_score": "0.347492",
          "ticker_sentiment_score": "0.099818",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.13409",
          "ticker_sentiment_score": "-0.050361",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.13409",
          "ticker_sentiment_score": "-0.002436",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "STERIS  ( STE )  Set to Post Q2 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2175759/steris-ste-set-to-post-q2-earnings-whats-in-the-cards",
      "time_published": "20231031T152800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "STERIS' (STE) second-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/69/45495.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.217709,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "0.094002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.177802",
          "ticker_sentiment_score": "0.059386",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "0.099985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STE",
          "relevance_score": "0.386875",
          "ticker_sentiment_score": "0.277297",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/pressreleases/23/12/g36189246/acadia-alert-bragar-eagel-squire-p-c-is-investigating-acadia-pharmaceuticals-inc-on-behalf-of-long",
      "time_published": "20231212T020000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acadia Pharmaceuticals, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": -0.069703,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.13347",
          "ticker_sentiment_score": "-0.061665",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Avidity  ( RNA )  Expands Collaboration With BMY, Shares Rise",
      "url": "https://www.zacks.com/stock/news/2190798/avidity-rna-expands-collaboration-with-bmy-shares-rise",
      "time_published": "20231129T140300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.099446,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.108661",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.132368",
          "ticker_sentiment_score": "0.057851",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNA",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.198818",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.338883",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?",
      "url": "https://www.zacks.com/stock/news/2430290/will-auvelity-other-drugs-aid-axsms-growth-amid-stiff-competition",
      "time_published": "20250314T145500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.241387,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JAZZ",
          "relevance_score": "0.196344",
          "ticker_sentiment_score": "0.100827",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.091244",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.196344",
          "ticker_sentiment_score": "0.118473",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Roche's  ( RHHBY )  MS Drug Reduces Brain Lesions in Phase II Study",
      "url": "https://www.zacks.com/stock/news/2166686/roches-rhhby-ms-drug-reduces-brain-lesions-in-phase-ii-study",
      "time_published": "20231016T163600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.113101,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.071888",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.071888",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Exelixis  ( EXEL )  Posts Preliminary 2023 Results, to Cut 13% Jobs",
      "url": "https://www.zacks.com/stock/news/2207159/exelixis-exel-posts-preliminary-2023-results-to-cut-13-jobs",
      "time_published": "20240108T174300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.112877,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TRDA",
          "relevance_score": "0.131164",
          "ticker_sentiment_score": "0.061129",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.525759",
          "ticker_sentiment_score": "0.074904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.131164",
          "ticker_sentiment_score": "0.061129",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hologic  ( HOLX )  to Report Q1 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2211619/hologic-holx-to-report-q1-earnings-whats-in-the-cards",
      "time_published": "20240117T170700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.268184,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HOLX",
          "relevance_score": "0.416614",
          "ticker_sentiment_score": "0.255298",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MMSI",
          "relevance_score": "0.130689",
          "ticker_sentiment_score": "0.052777",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.130689",
          "ticker_sentiment_score": "0.1628",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "IDEXX Laboratories  ( IDXX )  to Post Q3 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2170074/idexx-laboratories-idxx-to-post-q3-earnings-whats-in-store",
      "time_published": "20231023T101900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/39328.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.309026,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IDXX",
          "relevance_score": "0.257895",
          "ticker_sentiment_score": "0.166201",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.173645",
          "ticker_sentiment_score": "0.058403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.130689",
          "ticker_sentiment_score": "0.0988",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.130689",
          "ticker_sentiment_score": "0.08816",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the First Trust NYSE Arca Biotechnology ETF  ( FBT ) ?",
      "url": "https://www.zacks.com/stock/news/2412442/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt",
      "time_published": "20250210T112006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default207.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.209549,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NTRA",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.070142",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.070142",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.070142",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hologic  ( HOLX )  Q1 Earnings Might Rise on Breast Health Growth",
      "url": "https://www.zacks.com/stock/news/2212288/hologic-holx-q1-earnings-might-rise-on-breast-health-growth",
      "time_published": "20240118T163000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/60/43413.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.29464,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HOLX",
          "relevance_score": "0.485711",
          "ticker_sentiment_score": "0.397288",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MMSI",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.052545",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.156181",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Reports Q1 Loss, Lags Revenue Estimates",
      "url": "https://www.zacks.com/stock/news/1916201/acadia-pharmaceuticals-acad-reports-q1-loss-lags-revenue-estimates",
      "time_published": "20220504T221517",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default320.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": -0.030012,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICPT",
          "relevance_score": "0.191827",
          "ticker_sentiment_score": "-0.142388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.128581",
          "ticker_sentiment_score": "-0.050203",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Albireo  ( ALBO )  Up on Results From Alagille Syndrome Study",
      "url": "https://www.zacks.com/stock/news/1991077/albireo-albo-up-on-results-from-alagille-syndrome-study",
      "time_published": "20221012T160300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.036636,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMCR",
          "relevance_score": "0.253646",
          "ticker_sentiment_score": "0.184819",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.128478",
          "ticker_sentiment_score": "0.216825",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ALBO",
          "relevance_score": "0.253646",
          "ticker_sentiment_score": "0.308426",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARDS",
          "relevance_score": "0.253646",
          "ticker_sentiment_score": "0.150902",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review",
      "url": "https://www.zacks.com/stock/news/2328363/soleno-stock-up-as-fda-accepts-pws-drug-nda-under-priority-review",
      "time_published": "20240828T142500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/61649.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.121547,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.127795",
          "ticker_sentiment_score": "0.10008",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLNO",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.19421",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BVS",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.166986",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FULC",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.095011",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Iovance's  ( IOVA )  Meets Q3 Earnings, Lags Sales Estimates",
      "url": "https://www.zacks.com/stock/news/2180667/iovances-iova-meets-q3-earnings-lags-sales-estimates",
      "time_published": "20231108T125500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        }
      ],
      "overall_sentiment_score": 0.064932,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.127682",
          "ticker_sentiment_score": "0.015658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APLS",
          "relevance_score": "0.252114",
          "ticker_sentiment_score": "-0.063921",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.127682",
          "ticker_sentiment_score": "0.071617",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.169676",
          "ticker_sentiment_score": "-0.077999",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "23 Stocks Moving in Tuesday's Pre-Market Session",
      "url": "https://www.benzinga.com/news/22/04/26682742/23-stocks-moving-in-tuesdays-pre-market-session",
      "time_published": "20220419T103745",
      "authors": [],
      "summary": "Gainers\nToughBuilt Industries, Inc.   ( NASDAQ: TBLT )  rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss.\nSharps Technology, Inc.  ( NASDAQ: STSS )  shares rose 38.4% to $2.92 in pre-market trading after dipping 18% on Monday. The company recently priced its IPO",
      "banner_image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/04/19/premkt_movers.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.910869"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": -0.037242,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SIDU",
          "relevance_score": "0.190117",
          "ticker_sentiment_score": "-0.063452",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZEN",
          "relevance_score": "0.190117",
          "ticker_sentiment_score": "0.004154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFET",
          "relevance_score": "0.190117",
          "ticker_sentiment_score": "0.000845",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.008478",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EPSN",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.002476",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMCI",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.003857",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STSS",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.001666",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SY",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.000244",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNTG",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.000361",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANNX",
          "relevance_score": "0.190117",
          "ticker_sentiment_score": "0.000243",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDVL",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.001319",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOGL",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "6.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QTT",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.000263",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMRA",
          "relevance_score": "0.190117",
          "ticker_sentiment_score": "-0.351467",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "TBLT",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "-0.016348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CASA",
          "relevance_score": "0.190117",
          "ticker_sentiment_score": "0.008478",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SST",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "0.000116",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "-0.007302",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FLNG",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "2.8e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAVA",
          "relevance_score": "0.127422",
          "ticker_sentiment_score": "-0.000277",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA Panel Votes Against Acadia  ( ACAD )  sNDA for Nuplazid",
      "url": "https://www.zacks.com/stock/news/1941270/fda-panel-votes-against-acadia-acad-snda-for-nuplazid",
      "time_published": "20220620T152700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.004853,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGLE",
          "relevance_score": "0.311079",
          "ticker_sentiment_score": "0.012027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.12722",
          "ticker_sentiment_score": "-0.0018",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DTIL",
          "relevance_score": "0.311079",
          "ticker_sentiment_score": "0.006684",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPTX",
          "relevance_score": "0.311079",
          "ticker_sentiment_score": "0.005508",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Novo Nordisk  ( NVO )  to Acquire Hypertension Drug for $1.3B",
      "url": "https://www.zacks.com/stock/news/2167301/novo-nordisk-nvo-to-acquire-hypertension-drug-for-13b",
      "time_published": "20231017T143100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.048247,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.18967",
          "ticker_sentiment_score": "0.043662",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.127119",
          "ticker_sentiment_score": "0.063705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.127119",
          "ticker_sentiment_score": "0.063705",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.528475",
          "ticker_sentiment_score": "-0.04402",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Upgraded to Buy: What Does It Mean for the Stock?",
      "url": "https://www.zacks.com/stock/news/1973014/acadia-acad-upgraded-to-buy-what-does-it-mean-for-the-stock",
      "time_published": "20220826T160007",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.997845"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.692272"
        }
      ],
      "overall_sentiment_score": 0.312314,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.258779",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Week Ahead In Biotech  ( April 3-April 9 ) : BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight",
      "url": "https://www.benzinga.com/general/biotech/22/04/26440198/the-week-ahead-in-biotech-april-3-april-9-bioxcel-fda-decision-neurology-conference-presentations",
      "time_published": "20220403T213322",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.\nLongeveron Inc.  ( NASDAQ: LGVN )  jumped over 100% after the biopha",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2012/biotech6_1.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.067112,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BHVN",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "-0.000757",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRPO",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.021636",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BTAI",
          "relevance_score": "0.188879",
          "ticker_sentiment_score": "0.000312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMLX",
          "relevance_score": "0.188879",
          "ticker_sentiment_score": "-0.536158",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "FULC",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.000556",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STSA",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "-0.000126",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.188879",
          "ticker_sentiment_score": "0.000747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.002863",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.063492",
          "ticker_sentiment_score": "-0.328661",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "LBPH",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.001403",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.000385",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGVN",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.633112",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AKBA",
          "relevance_score": "0.188879",
          "ticker_sentiment_score": "-0.536158",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "4.3e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLVS",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.633112",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "IOBT",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.000385",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.007897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRRK",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.002852",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVNC",
          "relevance_score": "0.126583",
          "ticker_sentiment_score": "0.00243",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the First Trust NYSE Arca Biotechnology ETF  ( FBT ) ?",
      "url": "https://www.zacks.com/stock/news/1878178/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt",
      "time_published": "20220307T112007",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Sector ETF report for FBT",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default158.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.961735"
        }
      ],
      "overall_sentiment_score": 0.032443,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SRPT",
          "relevance_score": "0.126484",
          "ticker_sentiment_score": "0.001549",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.126484",
          "ticker_sentiment_score": "0.001549",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.126484",
          "ticker_sentiment_score": "0.001549",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Axsome  ( AXSM )  Focuses on Auvelity Launch to Fuel Its Growth",
      "url": "https://www.zacks.com/stock/news/2082952/axsome-axsm-focuses-on-auvelity-launch-to-fuel-its-growth",
      "time_published": "20230421T155900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.055283,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.188683",
          "ticker_sentiment_score": "0.099445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.12645",
          "ticker_sentiment_score": "0.012182",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.366961",
          "ticker_sentiment_score": "0.237568",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "scPharmaceuticals  ( SCPH )  Plunges Despite Furoscix's FDA Approval",
      "url": "https://www.zacks.com/stock/news/1990579/scpharmaceuticals-scph-plunges-despite-furoscixs-fda-approval",
      "time_published": "20221011T213200",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/845.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        }
      ],
      "overall_sentiment_score": 0.118777,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMCR",
          "relevance_score": "0.247838",
          "ticker_sentiment_score": "0.181486",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.214463",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ARDS",
          "relevance_score": "0.247838",
          "ticker_sentiment_score": "0.148177",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCPH",
          "relevance_score": "0.614836",
          "ticker_sentiment_score": "0.218949",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings",
      "url": "https://www.benzinga.com/general/biotech/22/07/28113633/the-daily-biotech-pulse-fda-tentatively-approves-avadels-narcolepsy-drug-european-approval-broade",
      "time_published": "20220719T131233",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: The European Commission has approved AstraZeneca Plc AZN and Daiichi Sankyo's DSNKY Enhertu as monotherapy for unresectable or metastatic HER2-positive breast cancer who have received one or more prior ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/07/19/biotech3.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.156616,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AVDL",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.003805",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CELU",
          "relevance_score": "0.187221",
          "ticker_sentiment_score": "0.016951",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RARE",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.187221",
          "ticker_sentiment_score": "0.003166",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CELC",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "-0.126614",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APLS",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.003791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.136409",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.103913",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.053027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.103913",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Labcorp  ( LH )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2170090/labcorp-lh-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231023T102600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/41051.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.211342,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENZ",
          "relevance_score": "0.041901",
          "ticker_sentiment_score": "0.207762",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.166455",
          "ticker_sentiment_score": "0.056734",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.125242",
          "ticker_sentiment_score": "0.096828",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.125242",
          "ticker_sentiment_score": "0.086401",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LH",
          "relevance_score": "0.125242",
          "ticker_sentiment_score": "0.028454",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is First Trust NYSE Arca Biotechnology ETF  ( FBT )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2542468/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now",
      "time_published": "20250624T102002",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default72.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996675"
        }
      ],
      "overall_sentiment_score": 0.267729,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.124809",
          "ticker_sentiment_score": "0.127963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.124809",
          "ticker_sentiment_score": "0.127963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.124809",
          "ticker_sentiment_score": "0.127963",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases: Biotech Daily",
      "url": "https://www.benzinga.com/news/22/08/28377654/biotech-daily-thumbs-down-for-acadias-antipsychotic-drug-akebia-fails-covid-19-study-kazias-encourag",
      "time_published": "20220805T153525",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA cleared Marker Therapeutics Inc's MRKR Investigational New Drug ( IND ) application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/05/brain-g5e2c29340_1920.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.016629,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALDX",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATNX",
          "relevance_score": "0.245339",
          "ticker_sentiment_score": "0.096253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KZIA",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "-0.087217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CYAD",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRKR",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "-0.128172",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHKCF",
          "relevance_score": "0.062271",
          "ticker_sentiment_score": "-0.093978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "-0.22043",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "-0.070292",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKBA",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "-0.23667",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MYOV",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "-0.22043",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COWNL",
          "relevance_score": "0.062271",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OCGN",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Stock Down as Pain Candidate Misses Study Goal",
      "url": "https://www.zacks.com/stock/news/1902477/acadia-acad-stock-down-as-pain-candidate-misses-study-goal",
      "time_published": "20220419T160200",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": -0.065572,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALGS",
          "relevance_score": "0.243681",
          "ticker_sentiment_score": "-0.027326",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APLT",
          "relevance_score": "0.243681",
          "ticker_sentiment_score": "-0.0219",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.123304",
          "ticker_sentiment_score": "0.005815",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYGR",
          "relevance_score": "0.301908",
          "ticker_sentiment_score": "-0.039647",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aldeyra  ( ALDX )  Plummets on Dry Eye Disease Drug's Setback",
      "url": "https://www.zacks.com/stock/news/2167333/aldeyra-aldx-plummets-on-dry-eye-disease-drugs-setback",
      "time_published": "20231017T141300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.021779,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALDX",
          "relevance_score": "0.300946",
          "ticker_sentiment_score": "-0.132577",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLCO",
          "relevance_score": "0.18343",
          "ticker_sentiment_score": "0.133411",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.087968",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Axsome  ( AXSM )  Rides on New Drug Approval & Sunosi Buyout",
      "url": "https://www.zacks.com/stock/news/2033982/axsome-axsm-rides-on-new-drug-approval-sunosi-buyout",
      "time_published": "20221230T143500",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.167901,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SNDX",
          "relevance_score": "0.300946",
          "ticker_sentiment_score": "0.104322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.090273",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.169764",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.357293",
          "ticker_sentiment_score": "0.238797",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will Zimmer Biomet  ( ZBH )  Beat Estimates This Earnings Season?",
      "url": "https://www.zacks.com/stock/news/2174652/will-zimmer-biomet-zbh-beat-estimates-this-earnings-season",
      "time_published": "20231030T153100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/60/43413.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.220525,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZBH",
          "relevance_score": "0.427973",
          "ticker_sentiment_score": "0.250745",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.162802",
          "ticker_sentiment_score": "0.055902",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.122477",
          "ticker_sentiment_score": "0.095867",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.122477",
          "ticker_sentiment_score": "0.081248",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Acadia  ( ACAD )  Up 26.1% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/2487642/why-is-acadia-acad-up-261-since-last-earnings-report",
      "time_published": "20250606T153105",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default81.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.122041,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.203965",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.461699",
          "ticker_sentiment_score": "0.05649",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Anavex  ( AVXL )  Falls 35% on Mixed Rett Syndrome Study Results",
      "url": "https://www.zacks.com/stock/news/2205039/anavex-avxl-falls-35-on-mixed-rett-syndrome-study-results",
      "time_published": "20240103T145100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.218634,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.240093",
          "ticker_sentiment_score": "0.088769",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.121445",
          "ticker_sentiment_score": "0.1422",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVXL",
          "relevance_score": "0.201021",
          "ticker_sentiment_score": "-0.010078",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.16144",
          "ticker_sentiment_score": "0.131515",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA",
      "url": "https://www.zacks.com/stock/news/2348372/slno-stock-rises-on-upbeat-regulatory-update-on-pws-drug-nda",
      "time_published": "20241009T133300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.133305,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.180685",
          "ticker_sentiment_score": "0.073864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIP",
          "relevance_score": "0.296582",
          "ticker_sentiment_score": "0.27009",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.121037",
          "ticker_sentiment_score": "0.097661",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLNO",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.191702",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Regeneron  ( REGN )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2173690/regeneron-regn-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231027T123700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/01/36484.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999989"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.185872,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.120632",
          "ticker_sentiment_score": "-0.00229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.120632",
          "ticker_sentiment_score": "0.098521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.27676",
          "ticker_sentiment_score": "0.246419",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DBTX",
          "relevance_score": "0.040348",
          "ticker_sentiment_score": "0.016915",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.040348",
          "ticker_sentiment_score": "0.036471",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.27676",
          "ticker_sentiment_score": "0.225294",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Novo Nordisk  ( NVO )  Raises Sales Outlook for 2023, Shares Gain",
      "url": "https://www.zacks.com/stock/news/2166475/novo-nordisk-nvo-raises-sales-outlook-for-2023-shares-gain",
      "time_published": "20231016T125200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.227746,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.12013",
          "ticker_sentiment_score": "0.068932",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.34974",
          "ticker_sentiment_score": "0.424589",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.12013",
          "ticker_sentiment_score": "0.068932",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's in Store for Canopy Growth  ( CGC )  in Q2 Earnings?",
      "url": "https://www.zacks.com/stock/news/2171342/whats-in-store-for-canopy-growth-cgc-in-q2-earnings",
      "time_published": "20231025T121800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/44137.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.218382,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PODD",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.055177",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.12003",
          "ticker_sentiment_score": "0.095039",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.12003",
          "ticker_sentiment_score": "0.084805",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CGC",
          "relevance_score": "0.454174",
          "ticker_sentiment_score": "0.229838",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Emergent  ( EBS )  Q2 Earnings Miss Estimates, Revenues Beat",
      "url": "https://www.zacks.com/stock/news/2134353/emergent-ebs-q2-earnings-miss-estimates-revenues-beat",
      "time_published": "20230809T132600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.028731,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADCT",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "-0.016404",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.074312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.312323",
          "ticker_sentiment_score": "-0.054915",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Gilead  ( GILD )  Gears Up to Report Q3 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2174771/gilead-gild-gears-up-to-report-q3-earnings-whats-in-store",
      "time_published": "20231030T155900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999985"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.154909,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.119433",
          "ticker_sentiment_score": "-0.002279",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.119433",
          "ticker_sentiment_score": "0.096879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.236205",
          "ticker_sentiment_score": "0.267495",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Regeneron  ( REGN )  to Report Q2 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2129606/regeneron-regn-to-report-q2-earnings-whats-in-store",
      "time_published": "20230728T164200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999989"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.173286,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.119433",
          "ticker_sentiment_score": "-0.001144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.236205",
          "ticker_sentiment_score": "0.26067",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.079788",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.039944",
          "ticker_sentiment_score": "0.036451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.2741",
          "ticker_sentiment_score": "0.258934",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu",
      "url": "https://www.benzinga.com/general/biotech/22/04/26684117/the-daily-biotech-pulse-regeneron-acquires-checkmate-pharma-modernas-bivalent-booster-covid-19-va",
      "time_published": "20220419T130502",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nStocks In Focus\nRegeneron Buys Cancer-Focused Checkmate Pharmaceuticals For $250M\nRegeneron Pharmaceuticals Inc  ( NASDAQ: REGN )  has agreed to acquire Checkmate Pharmaceuticals Inc  ( NASDAQ: CMPI )  at $10.50 per sh",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/04/19/lab-5740505_1920.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": -0.004961,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "0.003145",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BTAI",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "0.001132",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "0.050904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CMPI",
          "relevance_score": "0.17824",
          "ticker_sentiment_score": "0.005001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "0.002514",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.236109",
          "ticker_sentiment_score": "0.018445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "0.007987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWTX",
          "relevance_score": "0.119383",
          "ticker_sentiment_score": "0.024305",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Acadia  ( ACAD )  Down 11.1% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/2436979/why-is-acadia-acad-down-111-since-last-earnings-report",
      "time_published": "20250328T153040",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default41.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.035865,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "HALO",
          "relevance_score": "0.451494",
          "ticker_sentiment_score": "0.044007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.119235",
          "ticker_sentiment_score": "-0.004688",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Roche  ( RHHBY )  Nine Months' Sales Fall on Lower COVID-19 Test Sale",
      "url": "https://www.zacks.com/stock/news/2169118/roche-rhhby-nine-months-sales-fall-on-lower-covid-19-test-sale",
      "time_published": "20231019T153100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.036244,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.079392",
          "ticker_sentiment_score": "0.052743",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.118842",
          "ticker_sentiment_score": "0.05846",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:CHF",
          "relevance_score": "0.837089",
          "ticker_sentiment_score": "-0.102859",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's in Store for Thermo Fisher  ( TMO )  in Q4 Earnings?",
      "url": "https://www.zacks.com/stock/news/2210929/whats-in-store-for-thermo-fisher-tmo-in-q4-earnings",
      "time_published": "20240116T165700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.211444,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MMSI",
          "relevance_score": "0.11787",
          "ticker_sentiment_score": "0.051519",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.11787",
          "ticker_sentiment_score": "0.149781",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.195182",
          "ticker_sentiment_score": "0.049943",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ADMA Biologics  ( ADMA )  to Report Q2 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2129454/adma-biologics-adma-to-report-q2-earnings-whats-in-store",
      "time_published": "20230728T125900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.208659,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.541149",
          "ticker_sentiment_score": "0.346201",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Hologic  ( HOLX )  to Report Q4 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2173798/hologic-holx-to-report-q4-earnings-whats-in-the-cards",
      "time_published": "20231027T130300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strength in Breast Health and GYN Surgical businesses will likely drive Hologic's (HOLX) Q4 revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/99/45963.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.217539,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HOLX",
          "relevance_score": "0.306484",
          "ticker_sentiment_score": "0.274841",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.156207",
          "ticker_sentiment_score": "0.054433",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.094204",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.08406",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals",
      "url": "https://www.zacks.com/stock/news/2397716/acad-seeks-eu-nod-for-rett-syndrome-drug-outlines-2025-pipeline-goals",
      "time_published": "20250115T174200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.151377,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.088912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.229691",
          "ticker_sentiment_score": "0.030506",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYGR",
          "relevance_score": "0.229691",
          "ticker_sentiment_score": "0.032331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.229691",
          "ticker_sentiment_score": "0.101695",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bristol-Myers  ( BMY )  Q3 Earnings & Sales Beat, Opdivo Sales Grow",
      "url": "https://www.zacks.com/stock/news/2173090/bristol-myers-bmy-q3-earnings-sales-beat-opdivo-sales-grow",
      "time_published": "20231026T161300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998287"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.067216,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DVAX",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.057746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.057746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRTX",
          "relevance_score": "0.076971",
          "ticker_sentiment_score": "0.177528",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.076971",
          "ticker_sentiment_score": "0.175884",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.300854",
          "ticker_sentiment_score": "0.245968",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "CVS Health  ( CVS )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2170688/cvs-health-cvs-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20231024T114800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/56/2031.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.366495,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.586997",
          "ticker_sentiment_score": "0.661038",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.152741",
          "ticker_sentiment_score": "0.05368",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.114865",
          "ticker_sentiment_score": "0.093369",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.114865",
          "ticker_sentiment_score": "0.083317",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Up 0.6% Since Last Earnings Report: Can It Continue?",
      "url": "https://www.zacks.com/stock/news/2285476/acadia-acad-up-06-since-last-earnings-report-can-it-continue",
      "time_published": "20240607T153051",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default106.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.106373,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "0.030936",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.038713",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Crude Oil Down 2%; Citigroup Profit Tops Estimates - Aehr Test Systems  ( NASDAQ:AEHR ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/earnings/23/07/33233430/crude-oil-down-2-citigroup-profit-tops-estimates",
      "time_published": "20230714T161324",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Friday. The Dow traded up 0.31% to 34,501.62 while the NASDAQ rose 0.36% to 14,188.86. The S&P 500, also rose, gaining, 0.19% to 4,518.39. Health care shares climbed by 1.2% on Friday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/citigroup_-_logo_0.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        }
      ],
      "overall_sentiment_score": 0.055618,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AEHR",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.483566",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "LESL",
          "relevance_score": "0.170878",
          "ticker_sentiment_score": "0.094895",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "-0.062486",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FREQ",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.269296",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.02611",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLMD",
          "relevance_score": "0.170878",
          "ticker_sentiment_score": "0.263254",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "THRX",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.078732",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:ETH",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.3381",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Analysts Conflicted on These Healthcare Names: Trulieve Cannabis  ( OtherTCNNF ) , Rallybio  ( RLYB )  and Canopy Growth  ( CGC ) ",
      "url": "https://markets.businessinsider.com/news/stocks/analysts-conflicted-on-these-healthcare-names-trulieve-cannabis-othertcnnf-rallybio-rlyb-and-canopy-growth-cgc-1032808722",
      "time_published": "20231111T072149",
      "authors": [
        "Tipranks"
      ],
      "summary": "Analysts Conflicted on These Healthcare Names: Trulieve Cannabis (OtherTCNNF), Rallybio (RLYB) and Canopy ... - Markets Insider ...",
      "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
      "source": "Business Insider",
      "category_within_source": "GoogleRSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.118592,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MDGL",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.115462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.115462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRAX",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.115462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RLYB",
          "relevance_score": "0.434142",
          "ticker_sentiment_score": "0.079957",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CGC",
          "relevance_score": "0.434142",
          "ticker_sentiment_score": "0.002855",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is SPDR S&P Biotech ETF  ( XBI )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2136620/is-spdr-sp-biotech-etf-xbi-a-strong-etf-right-now",
      "time_published": "20230815T190211",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default87.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999938"
        }
      ],
      "overall_sentiment_score": 0.258964,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BBIO",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.066424",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.057215",
          "ticker_sentiment_score": "0.061943",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.066424",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HALO",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.066424",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aquestive  ( AQST )  to Report Q2 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2127563/aquestive-aqst-to-report-q2-earnings-whats-in-store",
      "time_published": "20230726T105300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999756"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.126928,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ASRT",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.044484",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.113329",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HYPMY",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.058929",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.113329",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IZQVF",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.058929",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AQST",
          "relevance_score": "0.331024",
          "ticker_sentiment_score": "0.142975",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down 10.9% Since Last Earnings Report: Can It Rebound?",
      "url": "https://www.zacks.com/stock/news/2071955/acadia-acad-down-109-since-last-earnings-report-can-it-rebound",
      "time_published": "20230329T153026",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default58.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.059605,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.09093",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.113329",
          "ticker_sentiment_score": "-0.08952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.09093",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug",
      "url": "https://www.zacks.com/stock/news/2436034/slno-stock-rallies-on-fda-approval-of-prader-willi-syndrome-drug",
      "time_published": "20250327T124600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.183156,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLNO",
          "relevance_score": "0.276491",
          "ticker_sentiment_score": "0.179951",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CORT",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.241074",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.094869",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals  ( Revised ) ",
      "url": "https://www.zacks.com/stock/news/2398173/acad-seeks-eu-nod-for-rett-syndrome-drug-outlines-2025-pipeline-goals-revised",
      "time_published": "20250116T142800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.146974,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.087797",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.029779",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYGR",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.03156",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.099272",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's in Store for West Pharmaceutical in Q3 Earnings?",
      "url": "https://www.zacks.com/stock/news/2354076/whats-in-store-for-west-pharmaceutical-in-q3-earnings",
      "time_published": "20241021T135000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.026247,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CURN",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.027009",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.112269",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WST",
          "relevance_score": "0.427726",
          "ticker_sentiment_score": "0.108953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.112269",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.112269",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Nasdaq Stocks on Watch This Week",
      "url": "https://www.fool.com/investing/2023/03/12/3-nasdaq-stocks-on-watch-this-week/",
      "time_published": "20230312T204500",
      "authors": [
        "George Budwell"
      ],
      "summary": "These three Nasdaq stocks are poised to make big moves in the coming week.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F724384%2Finvestor-watching-a-laptop.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.061078,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ROKU",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "0.109599",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.112269",
          "ticker_sentiment_score": "0.054436",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SIVB",
          "relevance_score": "0.112269",
          "ticker_sentiment_score": "-0.068621",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.112269",
          "ticker_sentiment_score": "-0.148782",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alkermes  ( ALKS )  to Report Q2 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2125439/alkermes-alks-to-report-q2-earnings-whats-in-the-cards",
      "time_published": "20230721T133000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999813"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.203605,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALKS",
          "relevance_score": "0.221313",
          "ticker_sentiment_score": "0.198637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ADCT",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Biotech Stocks To Watch During The Week Of June 13",
      "url": "https://www.benzinga.com/general/biotech/22/06/27665644/5-biotech-stocks-to-watch-during-the-week-of-june-13",
      "time_published": "20220613T122520",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a compilation of five stocks that should be on your radar in the week of June 13: Novavax, Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/13/biotech6.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": -0.070092,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RYTM",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.000515",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.025804",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OKYO",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.004932",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STSA",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.002623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.081747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVAX",
          "relevance_score": "0.220108",
          "ticker_sentiment_score": "-0.171668",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.025804",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.025804",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.111127",
          "ticker_sentiment_score": "0.025804",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down",
      "url": "https://www.zacks.com/stock/news/2358968/lower-instruments-sales-to-hurt-txg-q3-earnings-prelim-sales-down",
      "time_published": "20241028T180200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999996"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.104928,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PRVA",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TXG",
          "relevance_score": "0.374714",
          "ticker_sentiment_score": "0.279838",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?",
      "url": "https://www.zacks.com/stock/news/2355052/will-cgm-sensor-demand-continue-to-drive-dexcom-q3-earnings",
      "time_published": "20241022T133200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999994"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.232023,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.423251",
          "ticker_sentiment_score": "0.351876",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.110973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?",
      "url": "https://www.zacks.com/stock/news/2364091/should-you-buy-sell-or-hold-dentsply-sirona-before-q3-earnings",
      "time_published": "20241105T125400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "XRAY's third-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.198636,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.110462",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.110462",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.468029",
          "ticker_sentiment_score": "0.207737",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.110462",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial",
      "url": "https://www.benzinga.com/general/biotech/22/06/27792486/the-daily-biotech-pulse-thumbs-down-for-acadias-pimavanserin-pfizer-buys-stake-in-valneva-astraze",
      "time_published": "20220621T130352",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's ACAD pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/21/biotech8.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.015754,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "KRYS",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.001662",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALN",
          "relevance_score": "0.321743",
          "ticker_sentiment_score": "0.009221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MTP",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.005111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.071198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RXRX",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.000708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.164319",
          "ticker_sentiment_score": "0.006627",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HEPA",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.010985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.071198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EWTX",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.002206",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "-0.260947",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "XBIT",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.00533",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACST",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.005421",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AURA",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.014713",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZEAL",
          "relevance_score": "0.109981",
          "ticker_sentiment_score": "0.007821",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves - ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/general/health-care/23/07/33282038/acadia-pharmaceuticals-a-mid-cap-biotech-making-large-moves",
      "time_published": "20230719T134054",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Shares of Acadia Pharmaceuticals Inc. ACAD jumped nearly 25% on Friday after the San Diego-based company announced preliminary second-quarter results and a pivotal acquisition. The gain was the biggest among all mid- and large cap stocks on the day and more than double that of the next closest ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/19/acadia_rgb_primary_gradient.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.239173,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.196006",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.193447",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What's in Store for Abbott Laboratories  ( ABT )  in Q4 Earnings?",
      "url": "https://www.zacks.com/stock/news/2210532/whats-in-store-for-abbott-laboratories-abt-in-q4-earnings",
      "time_published": "20240116T115800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.259701,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MMSI",
          "relevance_score": "0.109455",
          "ticker_sentiment_score": "0.050113",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.145583",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.109455",
          "ticker_sentiment_score": "0.147863",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq Drops 50 Points; Wells Fargo Earnings Beat Views - Aehr Test Systems  ( NASDAQ:AEHR ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) ",
      "url": "https://www.benzinga.com/news/earnings/23/07/33235248/nasdaq-drops-50-points-wells-fargo-earnings-beat-views",
      "time_published": "20230714T190645",
      "authors": [
        "Lisa Levin"
      ],
      "summary": "U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Friday. The Dow traded up 0.30% to 34,498.91 while the NASDAQ fell 0.36% to 14,087. The S&P 500, also fell, dropping, 0.18% to 4,502.13. Health care shares climbed by 1.6% on Friday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/wells_fargo_-_logo_0.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        }
      ],
      "overall_sentiment_score": 0.046115,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AEHR",
          "relevance_score": "0.109206",
          "ticker_sentiment_score": "0.476479",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "LESL",
          "relevance_score": "0.16317",
          "ticker_sentiment_score": "0.091978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.16317",
          "ticker_sentiment_score": "0.038005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKR",
          "relevance_score": "0.054732",
          "ticker_sentiment_score": "0.066339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FREQ",
          "relevance_score": "0.109206",
          "ticker_sentiment_score": "0.264841",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.109206",
          "ticker_sentiment_score": "0.02558",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLMD",
          "relevance_score": "0.16317",
          "ticker_sentiment_score": "0.255558",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "THRX",
          "relevance_score": "0.109206",
          "ticker_sentiment_score": "0.077416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:ETH",
          "relevance_score": "0.054732",
          "ticker_sentiment_score": "0.338",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will Eliquis, Opdivo Fuel Bristol-Myers  ( BMY )  Q3 Earnings?",
      "url": "https://www.zacks.com/stock/news/1996049/will-eliquis-opdivo-fuel-bristol-myers-bmy-q3-earnings",
      "time_published": "20221024T115500",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have jumped.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default162.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.178523,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EDIT",
          "relevance_score": "0.162802",
          "ticker_sentiment_score": "0.163073",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.169669",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.268",
          "ticker_sentiment_score": "0.17719",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease",
      "url": "https://www.benzinga.com/general/biotech/22/06/27760074/the-daily-biotech-pulse-addex-terminates-parkinsons-study-expanded-use-of-rhythms-obesity-drug-fd",
      "time_published": "20220617T151547",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: Addex Therapeutics Ltd ADXN has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease ( PD-LID ) due to slow recruitment of patients.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/06/17/red-blood-cell-gc6575ac93_1920.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.000869,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OBSV",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "0.038315",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KZIA",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "0.004266",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RYTM",
          "relevance_score": "0.213988",
          "ticker_sentiment_score": "0.002952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADXN",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "0.004174",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRRA",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "0.00255",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "-9.7e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "-0.069847",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CO",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "-0.000932",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DRTS",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "0.006176",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRRK",
          "relevance_score": "0.213988",
          "ticker_sentiment_score": "0.002569",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News",
      "url": "https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news",
      "time_published": "20231214T145500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.255199,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.142989",
          "ticker_sentiment_score": "0.144851",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EDIT",
          "relevance_score": "0.178196",
          "ticker_sentiment_score": "0.174354",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "0.067248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.035929",
          "ticker_sentiment_score": "0.10456",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.091535",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cencora to Report Q4 Earnings: What's in Store for the Stock?",
      "url": "https://www.zacks.com/stock/news/2363707/cencora-to-report-q4-earnings-whats-in-store-for-the-stock",
      "time_published": "20241104T174400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.220536,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PRVA",
          "relevance_score": "0.105604",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.105604",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.105604",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.309539",
          "ticker_sentiment_score": "0.260174",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "1 Top Biotech Stock to Buy in March",
      "url": "https://www.fool.com/investing/2023/03/07/1-top-biotech-stock-to-buy-in-march/",
      "time_published": "20230307T144500",
      "authors": [
        "George Budwell"
      ],
      "summary": "This biotech could land a major regulatory approval this month.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723274%2Fcleanroom.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        }
      ],
      "overall_sentiment_score": 0.146314,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.051663",
          "ticker_sentiment_score": "0.065999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.103109",
          "ticker_sentiment_score": "0.065252",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down 2.9% Since Last Earnings Report: Can It Rebound?",
      "url": "https://www.zacks.com/stock/news/2380446/acadia-acad-down-29-since-last-earnings-report-can-it-rebound",
      "time_published": "20241206T163111",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default342.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.147587,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EXEL",
          "relevance_score": "0.203215",
          "ticker_sentiment_score": "0.056208",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.102449",
          "ticker_sentiment_score": "-0.002169",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Earnings Expected to Grow: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2228586/acadia-pharmaceuticals-acad-earnings-expected-to-grow-should-you-buy",
      "time_published": "20240220T150049",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default69.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.145869,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.129482",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Supercharged Growth Stocks Billionaires Can't Stop Buying",
      "url": "https://www.fool.com/investing/2023/08/28/2-supercharged-growth-stocks-billionaires-cant-sto/",
      "time_published": "20230828T220000",
      "authors": [
        "George Budwell"
      ],
      "summary": "A top hedge fund has been steadily buying these two growth stocks in 2023.",
      "banner_image": "https://media.ycharts.com/charts/bdced13a57b3a2e31e42e289347f51fa.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.370447,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ROIV",
          "relevance_score": "0.297061",
          "ticker_sentiment_score": "0.380502",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.151222",
          "ticker_sentiment_score": "0.104375",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.101154",
          "ticker_sentiment_score": "0.059385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Acadia  ( ACAD )  Up 1% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/1889856/why-is-acadia-acad-up-1-since-last-earnings-report",
      "time_published": "20220330T153029",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default259.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": -0.036407,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.101154",
          "ticker_sentiment_score": "0.04994",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Henry Schein  ( HSIC )  Set to Post Q3 Earnings: What Awaits?",
      "url": "https://www.zacks.com/stock/news/2174298/henry-schein-hsic-set-to-post-q3-earnings-what-awaits",
      "time_published": "20231030T124100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.262804,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MEDP",
          "relevance_score": "0.10087",
          "ticker_sentiment_score": "0.084072",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PODD",
          "relevance_score": "0.134214",
          "ticker_sentiment_score": "0.049907",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.10087",
          "ticker_sentiment_score": "0.089419",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSIC",
          "relevance_score": "0.417198",
          "ticker_sentiment_score": "0.410321",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Recap of Monday's Biotech Catalysts - End of the Day Summary",
      "url": "https://www.benzinga.com/general/biotech/22/07/28108177/recap-of-mondays-biotech-catalysts-end-of-the-day-summary",
      "time_published": "20220718T220744",
      "authors": [
        "Ragothaman Srinivasan"
      ],
      "summary": "Abbvie ABBV has submitted a marketing authorization application ( MAA ) to the European Medicines Agency ( EMA ) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/07/18/bz-pharma_0.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.897321"
        }
      ],
      "overall_sentiment_score": 0.23731,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "APYX",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.114001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACER",
          "relevance_score": "0.150592",
          "ticker_sentiment_score": "0.081236",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ELDN",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.166611",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RARE",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.114952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RYTM",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.188061",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EYPT",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.150484",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.071225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.045231",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MEIP",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.087245",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RXDX",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.129011",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ETON",
          "relevance_score": "0.100729",
          "ticker_sentiment_score": "0.153708",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Up 10% Since Last Earnings Report: Can It Continue?",
      "url": "https://www.zacks.com/stock/news/2332287/acadia-acad-up-10-since-last-earnings-report-can-it-continue",
      "time_published": "20240905T153106",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default4.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.141429,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.198628",
          "ticker_sentiment_score": "0.029458",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.100099",
          "ticker_sentiment_score": "0.06683",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",
      "url": "https://www.benzinga.com/general/biotech/22/08/28353376/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazenecas-lynparza-in-early-stage-breast-cancer",
      "time_published": "20220804T130628",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours: The European Union has approved AstraZeneca Plc AZN and Merck & Co Inc's MRK Lynparza ( olaparib ) for human epidermal growth factor receptor 2 ( HER2 ) -negative high-risk early breast cancer previously treated ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/04/cells-gdd37bc5d2_1920.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.116523,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SYRS",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "-0.014014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYGR",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADAP",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.198221",
          "ticker_sentiment_score": "0.276786",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CCXI",
          "relevance_score": "0.198221",
          "ticker_sentiment_score": "0.277157",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AGIO",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCRX",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTLA",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABUS",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TVTX",
          "relevance_score": "0.149346",
          "ticker_sentiment_score": "0.090442",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSTX",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "-0.040761",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PDSB",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "-0.022",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SELB",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EIGR",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AUPH",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "-0.062416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.110528",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGR",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.122289",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VIR",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?",
      "url": "https://www.zacks.com/stock/news/2462221/dentsply-sirona-to-post-q1-earnings-whats-in-store-for-the-stock",
      "time_published": "20250505T151200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.168082,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ANIP",
          "relevance_score": "0.099271",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.099271",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XRAY",
          "relevance_score": "0.29176",
          "ticker_sentiment_score": "0.201881",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COR",
          "relevance_score": "0.099271",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ANI Pharmaceuticals  ( ANIP )  to Post Q2 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2129956/ani-pharmaceuticals-anip-to-post-q2-earnings-whats-in-store",
      "time_published": "20230731T150600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999985"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.236232,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ANIP",
          "relevance_score": "0.466325",
          "ticker_sentiment_score": "0.244882",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.099066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.099066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.099066",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Incyte  ( INCY )  to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/1998863/incyte-incy-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20221027T170800",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/94/1507.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.186849,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "INCY",
          "relevance_score": "0.705998",
          "ticker_sentiment_score": "0.207323",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EDIT",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "0.049939",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "0.076285",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "0.072517",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Incyte  ( INCY )  to Report Q2 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2128877/incyte-incy-to-report-q2-earnings-whats-in-the-cards",
      "time_published": "20230727T142000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999965"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.189921,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "INCY",
          "relevance_score": "0.500227",
          "ticker_sentiment_score": "0.263056",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.146025",
          "ticker_sentiment_score": "0.142515",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.097655",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.097655",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors",
      "url": "https://www.benzinga.com/pressreleases/23/09/g34680558/aiviva-biopharma-appoints-lester-j-kaplan-phd-to-the-board-of-directors",
      "time_published": "20230918T100000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "COSTA MESA, Calif., Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Dr. Lester J. Kaplan, PhD to its board of directors.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.248916,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.097062",
          "ticker_sentiment_score": "0.0231",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NICXF",
          "relevance_score": "0.097062",
          "ticker_sentiment_score": "0.0231",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revvity to Report Q3 Earnings: What's in Store for the Stock?",
      "url": "https://www.zacks.com/stock/news/2362850/revvity-to-report-q3-earnings-whats-in-store-for-the-stock",
      "time_published": "20241101T181100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.145937,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PRVA",
          "relevance_score": "0.096671",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.096671",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.096671",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVTY",
          "relevance_score": "0.372912",
          "ticker_sentiment_score": "0.147266",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revvity to Report Q3 Earnings: What's in Store for the Stock?",
      "url": "https://www.zacks.com/stock/news/2362850/revvity-to-report-q3-earnings-whats-in-store-for-the-stock",
      "time_published": "20241101T171100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.145937,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PRVA",
          "relevance_score": "0.096671",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.096671",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.096671",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVTY",
          "relevance_score": "0.372912",
          "ticker_sentiment_score": "0.147266",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Analysts Estimate Acadia Pharmaceuticals  ( ACAD )  to Report a Decline in Earnings: What to Look Out for",
      "url": "https://www.zacks.com/stock/news/1909511/analysts-estimate-acadia-pharmaceuticals-acad-to-report-a-decline-in-earnings-what-to-look-out-for",
      "time_published": "20220427T190323",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": -0.020956,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.095688",
          "ticker_sentiment_score": "0.017055",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardinal Health to Report Q1 Earnings: What's in Store?",
      "url": "https://www.zacks.com/stock/news/2358053/cardinal-health-to-report-q1-earnings-whats-in-store",
      "time_published": "20241025T171500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999996"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.27239,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.09439",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.09439",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.40638",
          "ticker_sentiment_score": "0.355381",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.09439",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD",
      "url": "https://www.benzinga.com/pressreleases/22/07/g27938866/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-acadi",
      "time_published": "20220701T234632",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, July 01, 2022 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ( \"Acadia\" or the \"Company\" ) ACAD and certain of its officers.",
      "banner_image": "",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": -0.060759,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.094297",
          "ticker_sentiment_score": "-0.055074",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More",
      "url": "https://www.zacks.com/stock/news/2066904/biotech-stock-roundup-acads-drug-approval-sgen-to-be-acquired-by-pfe-more",
      "time_published": "20230316T152000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.156983,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MRSN",
          "relevance_score": "0.093836",
          "ticker_sentiment_score": "-0.068836",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.093836",
          "ticker_sentiment_score": "0.099587",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGEN",
          "relevance_score": "0.320081",
          "ticker_sentiment_score": "0.22787",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.046999",
          "ticker_sentiment_score": "0.044897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARDS",
          "relevance_score": "0.093836",
          "ticker_sentiment_score": "0.085542",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.140348",
          "ticker_sentiment_score": "0.14553",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.186378",
          "ticker_sentiment_score": "0.14961",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.046999",
          "ticker_sentiment_score": "0.044897",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs",
      "url": "https://www.benzinga.com/general/biotech/22/05/26958446/the-daily-biotech-pulse-fdas-adcomm-for-acadias-pimavanserin-review-issues-for-speros-tebipenem-a",
      "time_published": "20220503T130106",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nStocks In Focus\nAcadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis\nThe FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia Pharmaceuticals Inc  ( NASDAQ: ACAD )  resubmitted",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/05/03/cells-gdd37bc5d2_1920.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.014358,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GRPH",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.084375",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TARS",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.006643",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INFI",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "-0.000393",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.001889",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SESN",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.010203",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PHAT",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "9e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AQST",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "-0.000175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OCUL",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.000117",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ESPR",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.002993",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.001586",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSHA",
          "relevance_score": "0.185734",
          "ticker_sentiment_score": "0.00393",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VCYT",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "-0.004863",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KOD",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.216957",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BLTE",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.059115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BTAI",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.006528",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RYTM",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.000323",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTRN",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.000551",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLRX",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.034259",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRTX",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.125543",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "4.5e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.001098",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RIGL",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "-0.003217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.000267",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.000377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.093507",
          "ticker_sentiment_score": "0.00565",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Acadia  ( ACAD )  Down 13.9% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/1934161/why-is-acadia-acad-down-139-since-last-earnings-report",
      "time_published": "20220603T153142",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default14.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": -0.048966,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.089864",
          "ticker_sentiment_score": "-0.65572",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.089864",
          "ticker_sentiment_score": "-2e-06",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Down 0.6% Since Last Earnings Report: Can It Rebound?",
      "url": "https://www.zacks.com/stock/news/1977592/acadia-acad-down-06-since-last-earnings-report-can-it-rebound",
      "time_published": "20220907T153043",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.111959,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.089129",
          "ticker_sentiment_score": "0.19464",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ecolab's Set to Report Q3 Earnings: What's in Store for the Stock?",
      "url": "https://www.zacks.com/stock/news/2358075/ecolabs-set-to-report-q3-earnings-whats-in-store-for-the-stock",
      "time_published": "20241025T175400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ECL third-quarter results are likely to reflect continued segmental strength.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/3739.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        }
      ],
      "overall_sentiment_score": 0.289329,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GIC",
          "relevance_score": "0.132611",
          "ticker_sentiment_score": "0.187002",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.088635",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.088635",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.088635",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ECL",
          "relevance_score": "0.383578",
          "ticker_sentiment_score": "0.242675",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What's in Store for Gilead  ( GILD )  This Earnings Season?",
      "url": "https://www.zacks.com/stock/news/1997030/whats-in-store-for-gilead-gild-this-earnings-season",
      "time_published": "20221025T163900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default54.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999994"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.012027,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EDIT",
          "relevance_score": "0.132611",
          "ticker_sentiment_score": "0.047234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.088635",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.219213",
          "ticker_sentiment_score": "0.107848",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.132611",
          "ticker_sentiment_score": "0.068588",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
      "url": "https://www.zacks.com/stock/news/2127881/acadia-pharmaceuticals-acad-expected-to-beat-earnings-estimates-can-the-stock-move-higher",
      "time_published": "20230726T140227",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.13573,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EXAS",
          "relevance_score": "0.175859",
          "ticker_sentiment_score": "-0.024329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.088472",
          "ticker_sentiment_score": "0.116805",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Expected to Beat Earnings Estimates: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2087477/acadia-pharmaceuticals-acad-expected-to-beat-earnings-estimates-should-you-buy",
      "time_published": "20230501T140109",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default173.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.156535,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.088309",
          "ticker_sentiment_score": "0.116764",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALEC",
          "relevance_score": "0.175539",
          "ticker_sentiment_score": "-0.002855",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  May Report Negative Earnings: Know the Trend Ahead of Next Week's Release",
      "url": "https://www.zacks.com/stock/news/1961361/acadia-pharmaceuticals-acad-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release",
      "time_published": "20220801T140100",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default256.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.124474,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.088309",
          "ticker_sentiment_score": "0.159398",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CDXS",
          "relevance_score": "0.175539",
          "ticker_sentiment_score": "0.010111",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Earnings Expected to Grow: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2266098/acadia-pharmaceuticals-acad-earnings-expected-to-grow-should-you-buy",
      "time_published": "20240501T140121",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.121679,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "0.114648",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "-0.002079",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Expected to Beat Earnings Estimates: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2172803/acadia-pharmaceuticals-acad-expected-to-beat-earnings-estimates-should-you-buy",
      "time_published": "20231026T140223",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default298.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.165574,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "0.041775",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Iovance Biotherapeutics  ( IOVA )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
      "url": "https://www.zacks.com/stock/news/2314295/iovance-biotherapeutics-iova-expected-to-beat-earnings-estimates-can-the-stock-move-higher",
      "time_published": "20240801T140123",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.142664,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.087985",
          "ticker_sentiment_score": "0.03911",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "0.172591",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "url": "https://www.zacks.com/stock/news/2312027/acadia-pharmaceuticals-acad-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
      "time_published": "20240730T140115",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default53.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.126271,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.087985",
          "ticker_sentiment_score": "0.116683",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.174903",
          "ticker_sentiment_score": "-0.025672",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Analysts Estimate Moderna  ( MRNA )  to Report a Decline in Earnings: What to Look Out for",
      "url": "https://www.zacks.com/stock/news/1998637/analysts-estimate-moderna-mrna-to-report-a-decline-in-earnings-what-to-look-out-for",
      "time_published": "20221027T140225",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.119202,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "-0.015974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.087985",
          "ticker_sentiment_score": "-0.002078",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Earnings Preview: Acadia Pharmaceuticals  ( ACAD )  Q1 Earnings Expected to Decline",
      "url": "https://www.zacks.com/stock/news/2459056/earnings-preview-acadia-pharmaceuticals-acad-q1-earnings-expected-to-decline",
      "time_published": "20250430T140127",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.107596,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "YMAB",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "-0.002077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.041742",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Stoke Therapeutics, Inc.  ( STOK )  Expected to Beat Earnings Estimates: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2088128/stoke-therapeutics-inc-stok-expected-to-beat-earnings-estimates-should-you-buy",
      "time_published": "20230502T140211",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default224.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.14946,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.038066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.259267",
          "ticker_sentiment_score": "0.119585",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Expected to Beat Earnings Estimates: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/1997644/acadia-pharmaceuticals-acad-expected-to-beat-earnings-estimates-should-you-buy",
      "time_published": "20221026T140202",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.145067,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.041742",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HRMY",
          "relevance_score": "0.174587",
          "ticker_sentiment_score": "-0.002848",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "url": "https://www.zacks.com/stock/news/2360756/acadia-pharmaceuticals-acad-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
      "time_published": "20241030T140145",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default322.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.163378,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.173958",
          "ticker_sentiment_score": "-0.024145",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.087503",
          "ticker_sentiment_score": "0.124858",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals  ( ACAD )  May Report Negative Earnings: Know the Trend Ahead of Next Week's Release",
      "url": "https://www.zacks.com/stock/news/2056393/acadia-pharmaceuticals-acad-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release",
      "time_published": "20230220T150029",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default248.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.103047,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.087503",
          "ticker_sentiment_score": "0.114492",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRVB",
          "relevance_score": "0.173958",
          "ticker_sentiment_score": "-0.026999",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's in Store for Gilead  ( GILD )  This Earnings Season?",
      "url": "https://www.zacks.com/stock/news/1997030/whats-in-store-for-gilead-gild-this-earnings-season",
      "time_published": "20221025T163900",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default54.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999994"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.045697,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EDIT",
          "relevance_score": "0.130689",
          "ticker_sentiment_score": "0.110633",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.087344",
          "ticker_sentiment_score": "0.160107",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.216087",
          "ticker_sentiment_score": "0.241924",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.130689",
          "ticker_sentiment_score": "0.158053",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Insmed  ( INSM )  Expected to Beat Earnings Estimates: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2267122/insmed-insm-expected-to-beat-earnings-estimates-should-you-buy",
      "time_published": "20240502T140104",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default300.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.135663,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "INSM",
          "relevance_score": "0.256989",
          "ticker_sentiment_score": "0.118731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.087027",
          "ticker_sentiment_score": "0.038006",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lower Volume Likely to Hurt GE HealthCare's Q3 Earnings",
      "url": "https://www.zacks.com/stock/news/2358967/lower-volume-likely-to-hurt-ge-healthcares-q3-earnings",
      "time_published": "20241028T180200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GEHC's third-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line figure may reflect better pricing.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.25895,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GEHC",
          "relevance_score": "0.337427",
          "ticker_sentiment_score": "0.093146",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGIQ",
          "relevance_score": "0.043499",
          "ticker_sentiment_score": "0.089409",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.08687",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TXG",
          "relevance_score": "0.08687",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.08687",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Strong Segmental Performance to Drive Stryker's Q3 Earnings",
      "url": "https://www.zacks.com/stock/news/2358089/strong-segmental-performance-to-drive-strykers-q3-earnings",
      "time_published": "20241025T180700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999981"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.280415,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BRSYF",
          "relevance_score": "0.043499",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.08687",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.08687",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.48724",
          "ticker_sentiment_score": "0.345992",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Analysts Estimate Fortrea Holdings Inc.  ( FTRE )  to Report a Decline in Earnings: What to Look Out for",
      "url": "https://www.zacks.com/stock/news/2462131/analysts-estimate-fortrea-holdings-inc-ftre-to-report-a-decline-in-earnings-what-to-look-out-for",
      "time_published": "20250505T140020",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default353.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.137865,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FTRE",
          "relevance_score": "0.256089",
          "ticker_sentiment_score": "0.07422",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.086713",
          "ticker_sentiment_score": "0.039011",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biotech Investors: August's Key PDUFA Catalysts You Must Know",
      "url": "https://www.benzinga.com/general/biotech/22/07/28278314/biotech-investors-augusts-key-pdufa-catalysts-you-must-know",
      "time_published": "20220731T132123",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "Regulatory decisions have yet to pick up pace this year. July's calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/07/31/biotech8.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.067387,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FOLD",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BGNE",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "-0.088808",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.134356",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.105128",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "-0.408132",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYOV",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "-0.196316",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CRMD",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "-0.018789",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "-0.121533",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.084275",
          "ticker_sentiment_score": "0.134356",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Mersana Therapeutics  ( NASDAQ:MRSN ) , Dynavax Technologies  ( NASDAQ:DVAX ) , Pfizer  ( NYSE:PFE ) , BioLine Rx  ( NASDAQ:BLRX ) , BioNTech  ( NASDAQ:BNTX ) , Hepion Pharmaceuticals  ( NASDAQ:HEPA ) , Agenus  ( NASDAQ:AGEN ) , Horizon Therapeutics  ( NASDAQ:HZNP ) , Alector  ( NASDAQ:ALEC ) , Adamis Pharmaceuticals  ( NASDAQ:ADMP ) , Regulus Therapeutics  ( NASDAQ:RGLS ) , ACADIA Pharmaceuticals  ( NASDAQ:ACAD ) , Novavax  ( NASDAQ:NVAX ) , AVITA Medical  ( NASDAQ:RCEL )  - Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary",
      "url": "https://www.benzinga.com/general/biotech/22/09/28840130/important-biotech-catalysts-for-september-12-2022-end-of-the-day-summary",
      "time_published": "20220912T222944",
      "authors": [
        "Ragothaman Srinivasan"
      ],
      "summary": "The U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to Mersana Therapeutics' MRSN lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer ( TNBC ) .",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/09/12/bz-pharma_5.jpg?optimize=medium&dpr=2&auto=webp&width=3840",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.803643"
        }
      ],
      "overall_sentiment_score": 0.239854,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MRSN",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.120916",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HAE",
          "relevance_score": "0.16171",
          "ticker_sentiment_score": "0.128987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.080439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.089865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HEPA",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.099851",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.117345",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.042041",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALEC",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.202369",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ADMP",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.101896",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGLS",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.080179",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.113147",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVAX",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.151053",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RCEL",
          "relevance_score": "0.081276",
          "ticker_sentiment_score": "0.243608",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Is Iovance Biotherapeutics  ( IOVA )  Up 7.9% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/2105856/why-is-iovance-biotherapeutics-iova-up-79-since-last-earnings-report",
      "time_published": "20230608T153057",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default83.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.112896,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.061025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IOVA",
          "relevance_score": "0.388879",
          "ticker_sentiment_score": "0.345222",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel",
      "url": "https://www.benzinga.com/general/biotech/22/04/26469978/the-daily-biotech-pulse-thervance-gains-on-positive-late-stage-readout-bristol-myers-squibb-snags",
      "time_published": "20220405T114852",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nStocks In Focus\nTheravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy Patients\nTheravance Biopharma, Inc.  ( NASDAQ: TBPH )  announced results from the second Phase 3 stud",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2012/red-blood-cell-gc6575ac93_1920_2.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.002637,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TBPH",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.010273",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BTAI",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "-0.000402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FULC",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.000215",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HTGC",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.006435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISBC",
          "relevance_score": "0.120814",
          "ticker_sentiment_score": "0.013528",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RCUS",
          "relevance_score": "0.120814",
          "ticker_sentiment_score": "0.013528",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.012412",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.120814",
          "ticker_sentiment_score": "0.000542",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRDN",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.006435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.120814",
          "ticker_sentiment_score": "0.00812",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FLDM",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.013595",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TBBK",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.013528",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FUJIF",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.005119",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.010879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TFFP",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "6.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARGX",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.035774",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATRA",
          "relevance_score": "0.080715",
          "ticker_sentiment_score": "0.005119",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock",
      "url": "https://www.zacks.com/stock/news/2349805/labcorps-q3-earnings-looms-heres-what-to-expect-from-the-stock",
      "time_published": "20241014T132200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ea/78695.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999892"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.23713,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.080188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.080188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPK",
          "relevance_score": "0.040145",
          "ticker_sentiment_score": "0.076471",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "0JDB",
          "relevance_score": "0.040145",
          "ticker_sentiment_score": "0.16565",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.080188",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?",
      "url": "https://www.zacks.com/stock/news/2349806/dgx-gears-up-for-q3-earnings-what-lies-ahead-for-the-stock",
      "time_published": "20241014T132500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/57613.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.308363,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "III",
          "relevance_score": "0.038407",
          "ticker_sentiment_score": "0.140472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MASI",
          "relevance_score": "0.076724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.076724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGX",
          "relevance_score": "0.436634",
          "ticker_sentiment_score": "0.470919",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.076724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.038407",
          "ticker_sentiment_score": "0.258088",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Unexpected Challenge That Could Dig Into Pfizer's Covid Pill",
      "url": "https://www.investors.com/news/technology/enta-stock-launches-as-enanta-causes-a-kerfuffle-for-pfizer-paxlovid/",
      "time_published": "20220622T155200",
      "authors": [
        "Investor's Business Daily",
        "ALLISON GATLIN"
      ],
      "summary": "ENTA Stock Launches As Enanta Causes A Kerfuffle For Pfizer's Paxlovid Investor's Business Daily ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-Pfizer-04-shutt.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.977154"
        }
      ],
      "overall_sentiment_score": -0.116185,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.07509",
          "ticker_sentiment_score": "-0.020895",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALN",
          "relevance_score": "0.07509",
          "ticker_sentiment_score": "0.030529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ENTA",
          "relevance_score": "0.36254",
          "ticker_sentiment_score": "-0.314735",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.549154",
          "ticker_sentiment_score": "-0.178334",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings",
      "url": "https://www.zacks.com/stock/news/2349802/robust-analytical-instrument-segment-likely-to-aid-tmos-q3-earnings",
      "time_published": "20241014T121900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/14/2537.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999858"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.161612,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "TMDX",
          "relevance_score": "0.074809",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.074809",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DMAC",
          "relevance_score": "0.074809",
          "ticker_sentiment_score": "0.044352",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OLK",
          "relevance_score": "0.037446",
          "ticker_sentiment_score": "0.272577",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.292776",
          "ticker_sentiment_score": "0.179413",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More",
      "url": "https://www.zacks.com/stock/news/2240974/biotech-stock-roundup-amlx-acad-down-on-study-data-mrna-rgls-gain-on-updates-more",
      "time_published": "20240314T160700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.095539,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RGLS",
          "relevance_score": "0.070935",
          "ticker_sentiment_score": "0.104688",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.070935",
          "ticker_sentiment_score": "-0.016153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.106227",
          "ticker_sentiment_score": "0.126319",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMLX",
          "relevance_score": "0.106227",
          "ticker_sentiment_score": "-0.065031",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?",
      "url": "https://www.zacks.com/stock/news/2349822/edwards-lifesciences-to-report-q3-earnings-whats-in-the-cards",
      "time_published": "20241014T133900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/63046.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.311051,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.070725",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EW",
          "relevance_score": "0.374568",
          "ticker_sentiment_score": "0.418754",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.070725",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.070725",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.035397",
          "ticker_sentiment_score": "0.137323",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street",
      "url": "https://www.fool.com/investing/2023/08/16/this-under-the-radar-growth-stock-could-soar-by-27/",
      "time_published": "20230816T170000",
      "authors": [
        "George Budwell"
      ],
      "summary": "This small-cap biotech might be a hidden gem.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744354%2Fgrowth-curve.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.28219,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.0699",
          "ticker_sentiment_score": "-0.003043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.328798",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Is Acadia  ( ACAD )  Down 23.4% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/2247513/why-is-acadia-acad-down-234-since-last-earnings-report",
      "time_published": "20240328T153045",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default185.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.090078,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "-0.004045",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PRGO: Bolster Your Portfolio with These 3 Pharma Stock Buys",
      "url": "https://stocknews.com/news/prgo-acad-pcrx-bolster-your-portfolio-with-these-3-pharma-stock-buys/",
      "time_published": "20240215T172343",
      "authors": [
        "StockNews.com Staff"
      ],
      "summary": "The pharmaceutical industry's growth prospects appear promising due to factors including the adoption of advanced technologies, increased investment in research and development ( R&D ) , the prevalence of chronic diseases, a rapidly aging population, and the development of drugs for rare ...",
      "banner_image": "https://stocknews.com/wp-content/uploads/2023/07/ABhuyan.jpg",
      "source": "Stocknews.com",
      "category_within_source": "n/a",
      "source_domain": "stocknews.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.997405"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.277864,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.065775",
          "ticker_sentiment_score": "0.395213",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PINC",
          "relevance_score": "0.032916",
          "ticker_sentiment_score": "0.483938",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PCRX",
          "relevance_score": "0.195551",
          "ticker_sentiment_score": "0.270428",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.22731",
          "ticker_sentiment_score": "0.319209",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals",
      "url": "https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals",
      "time_published": "20231124T141000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.225302,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.064104",
          "ticker_sentiment_score": "0.045096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRSP",
          "relevance_score": "0.127795",
          "ticker_sentiment_score": "0.105904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KDNY",
          "relevance_score": "0.021388",
          "ticker_sentiment_score": "0.138084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.021388",
          "ticker_sentiment_score": "0.171316",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.064104",
          "ticker_sentiment_score": "0.045096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.0854",
          "ticker_sentiment_score": "0.090184",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRTX",
          "relevance_score": "0.021388",
          "ticker_sentiment_score": "0.138084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OABI",
          "relevance_score": "0.021388",
          "ticker_sentiment_score": "0.106821",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.021388",
          "ticker_sentiment_score": "0.138084",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ionis announces the appointment of Michael Yang to Board of Directors",
      "url": "https://www.prnewswire.com/news-releases/ionis-announces-the-appointment-of-michael-yang-to-board-of-directors-302014842.html",
      "time_published": "20231214T210500",
      "authors": [
        "Ionis Pharmaceuticals",
        "Inc."
      ],
      "summary": "CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS ) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10.",
      "banner_image": "https://mma.prnewswire.com/media/882077/Ionis_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.251294,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IONS",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "0.089996",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.063258",
          "ticker_sentiment_score": "0.049066",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia  ( ACAD )  Up 3.5% Since Last Earnings Report: Can It Continue?",
      "url": "https://www.zacks.com/stock/news/2024960/acadia-acad-up-35-since-last-earnings-report-can-it-continue",
      "time_published": "20221202T163141",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.073436,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NURPF",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.154074",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.084012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.244109",
          "ticker_sentiment_score": "0.032874",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus",
      "url": "https://www.zacks.com/stock/news/2349820/abbotts-q3-earnings-release-coming-up-epd-business-in-focus",
      "time_published": "20241014T132800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1479.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.282462,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.061394",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.122425",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.061394",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.061394",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer",
      "url": "https://www.globenewswire.com/news-release/2024/02/28/2836968/0/en/Lantheus-Announces-Promotion-of-Amanda-Morgan-to-Chief-Commercial-Officer.html",
      "time_published": "20240228T133000",
      "authors": [
        "Inc.",
        "Lantheus Holdings"
      ],
      "summary": "BEDFORD, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Lantheus Holdings, Inc. ( \"Lantheus\" ) ( NASDAQ: LNTH ) , the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7ff76065-4799-4307-9b3d-033643bacc35",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.258879,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LNTH",
          "relevance_score": "0.507932",
          "ticker_sentiment_score": "0.49985",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.060848",
          "ticker_sentiment_score": "0.166045",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Everest Group Recognizes ODAIA for Market Impact, Vision, and Capability",
      "url": "https://www.prnewswire.com/news-releases/everest-group-recognizes-odaia-for-market-impact-vision-and-capability-302036477.html",
      "time_published": "20240117T120500",
      "authors": [
        "ODAIA"
      ],
      "summary": "TORONTO, Jan. 17, 2024 /PRNewswire/ -- Cutting-edge AI company, , today announced it was named a Major Contender in the from Everest Group.",
      "banner_image": "https://mma.prnewswire.com/media/2320127/ODAIA_Wordmark_Black__1_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.450272,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EG",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.228653",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.314179",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates",
      "url": "https://www.benzinga.com/general/biotech/22/05/27484985/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates",
      "time_published": "20220531T194253",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/05/31/biotech13.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.062044,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FOLD",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "-0.613882",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.003354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMLX",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "4.3e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RYTM",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.000115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.00221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.146558",
          "ticker_sentiment_score": "-0.266568",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PHAT",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.00221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.146558",
          "ticker_sentiment_score": "0.019538",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "0.049455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACER",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "-0.002975",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRCA",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "-0.613882",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "-0.005128",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYOV",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "-0.613882",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "-0.093815",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVAX",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.000747",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "0.049455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.000135",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.000203",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.058903",
          "ticker_sentiment_score": "0.000135",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer - Lantheus Holdings  ( NASDAQ:LNTH ) ",
      "url": "https://www.benzinga.com/pressreleases/24/02/g37362345/lantheus-announces-promotion-of-amanda-morgan-to-chief-commercial-officer",
      "time_published": "20240228T133000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "BEDFORD, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Lantheus Holdings, Inc. ( \"Lantheus\" ) LNTH, the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.714479"
        }
      ],
      "overall_sentiment_score": 0.236484,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LNTH",
          "relevance_score": "0.573492",
          "ticker_sentiment_score": "0.494313",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.057628",
          "ticker_sentiment_score": "0.165994",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Should You Buy, Sell or Hold McKesson Before Q2 Earnings?",
      "url": "https://www.zacks.com/stock/news/2363728/should-you-buy-sell-or-hold-mckesson-before-q2-earnings",
      "time_published": "20241104T184700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.267388,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.056143",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.056143",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCK",
          "relevance_score": "0.352865",
          "ticker_sentiment_score": "0.304247",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BDX",
          "relevance_score": "0.056143",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as ... - PR Newswire",
      "url": "https://www.prnewswire.com/news-releases/quralis-expands-leadership-team-with-doug-williamson-md-as-chief-medical-officer-and-jason-brown-mba-as-chief-financial-officer-and-appoints-shafique-virani-md-to-board-of-directors-302166686.html",
      "time_published": "20240611T114500",
      "authors": [],
      "summary": "QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as ... PR ...",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.279946,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BBIO",
          "relevance_score": "0.02799",
          "ticker_sentiment_score": "-0.005629",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.055946",
          "ticker_sentiment_score": "0.054897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVDL",
          "relevance_score": "0.02799",
          "ticker_sentiment_score": "0.058539",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRTC",
          "relevance_score": "0.02799",
          "ticker_sentiment_score": "0.067916",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.02799",
          "ticker_sentiment_score": "0.067916",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?",
      "url": "https://www.zacks.com/stock/news/2350886/will-farapulse-line-aid-boston-scientifics-q3-earnings",
      "time_published": "20241015T160300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/66981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.360608,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MASI",
          "relevance_score": "0.055236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.055236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.244791",
          "ticker_sentiment_score": "0.287459",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PXXXF",
          "relevance_score": "0.027635",
          "ticker_sentiment_score": "0.241356",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.055236",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results",
      "url": "https://apnews.com/article/health-business-mental-schizophrenia-acadia-pharmaceuticals-inc-a7cae137f9fb486f84dace7930abfd8e",
      "time_published": "20221102T200345",
      "authors": [],
      "summary": "Acadia Pharmaceuticals Inc. ( Nasdaq: ACAD ) , today announced its financial results for the third quarter ended September 30, 2022.",
      "banner_image": "https://apnews.com/images/PaidContent3.png",
      "source": "Associated Press",
      "category_within_source": "Business",
      "source_domain": "apnews.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.109589,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.053449",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.02674",
          "ticker_sentiment_score": "0.141042",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "iShares Nasdaq Biotechnology Index Fund  ( IBB ) , SPDR S&P Biotech ETF  ( XBI )  - Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know",
      "url": "https://www.benzinga.com/general/biotech/22/08/28705100/bluebird-bio-seeks-back-to-back-nods-go-or-no-go-for-revances-botox-rival-amylyx-twin-hurdles-and",
      "time_published": "20220831T185235",
      "authors": [
        "Shanthi Rexaline"
      ],
      "summary": "After August's mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. New molecular entity approvals drew a blank in August.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/31/biotech6.jpg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.079121,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FOLD",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "-0.015994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLUE",
          "relevance_score": "0.104683",
          "ticker_sentiment_score": "0.193585",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMLX",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.131582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.078611",
          "ticker_sentiment_score": "0.211707",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AXSM",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.131582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.078611",
          "ticker_sentiment_score": "0.162924",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HRTX",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "-0.157599",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SPPI",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OBSV",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "-0.117582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FENC",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRMD",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "-0.015994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "-0.015994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "-0.195652",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "RVNC",
          "relevance_score": "0.052455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.104683",
          "ticker_sentiment_score": "-0.059021",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bitcoin, Ethereum, Dogecoin Surge, Crypto Market Cap Hits $2.5T While MicroStrategy Loads Up On BTC; Tesla's German Factory Back Online After Arson Attack Disrupts Production - Top Headlines Today While US Slept",
      "url": "https://www.benzinga.com/news/24/03/37626353/bitcoin-ethereum-dogecoin-surge-crypto-market-cap-hits-2-5t-while-microstrategy-loads-up-on-btc-tesl",
      "time_published": "20240312T160451",
      "authors": [
        "Akanksha Bakshi"
      ],
      "summary": "'BONK Killer' MILLI Skyrockets 20% In A Day, Outperforming Dogecoin, Shiba Inu: Targets $15M Market Cap Within Week Of Its Launch Staggering $47M Stolen In Crypto By Bitcoin, Dogecoin And Shiba Inu Phishers In February, Targeting 57K Victims On Elon Musk's X",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Cryptocurrency-Photo-by-stockphoto-graf-_3.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.271727,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "0.072032",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSTR",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.070049",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASAN",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.153659",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.176988",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.162445",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.101824",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABNB",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.131702",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.153659",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "0.086976",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OCUL",
          "relevance_score": "0.047465",
          "ticker_sentiment_score": "-0.153659",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.366061",
          "ticker_sentiment_score": "-0.113075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:ETH",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "-0.047985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:SHIB",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "-0.150645",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CRYPTO:DOGE",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "-0.144893",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Stoke Therapeutics  ( STOK )  Up on Upbeat Dravet Syndrome Study Data",
      "url": "https://www.zacks.com/stock/news/2246714/stoke-therapeutics-stok-up-on-upbeat-dravet-syndrome-study-data",
      "time_published": "20240327T125000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.128584,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ADMA",
          "relevance_score": "0.265859",
          "ticker_sentiment_score": "0.177975",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FGEN",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "-0.024735",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.045139",
          "ticker_sentiment_score": "0.022809",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOK",
          "relevance_score": "0.46648",
          "ticker_sentiment_score": "0.104928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACET",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "-0.026492",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alector Provides Executive Leadership Update - Alector  ( NASDAQ:ALEC ) ",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44545387/alector-provides-executive-leadership-update",
      "time_published": "20250328T200500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.185701,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.044885",
          "ticker_sentiment_score": "-0.00888",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALEC",
          "relevance_score": "0.601486",
          "ticker_sentiment_score": "0.262758",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright",
      "url": "https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright",
      "time_published": "20231122T130700",
      "authors": [
        "Ekta Bagri"
      ],
      "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.227746,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LGND",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.125054",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRSP",
          "relevance_score": "0.111281",
          "ticker_sentiment_score": "0.139072",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KDNY",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.061954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.172148",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.044634",
          "ticker_sentiment_score": "0.125054",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.066908",
          "ticker_sentiment_score": "0.125817",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRTX",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.061954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OABI",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.154669",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.022326",
          "ticker_sentiment_score": "0.061954",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bright Minds Biosciences Announces Non-Executive Director Appointment - Bright Minds Biosciences  ( NASDAQ:DRUG ) ",
      "url": "https://www.benzinga.com/pressreleases/23/02/g30957545/bright-minds-biosciences-announces-non-executive-director-appointment",
      "time_published": "20230217T115000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "VANCOUVER, British Columbia, Feb. 17, 2023 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.23817,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.170275",
          "ticker_sentiment_score": "0.230281",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LUMO",
          "relevance_score": "0.042876",
          "ticker_sentiment_score": "0.055717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HHC",
          "relevance_score": "0.042876",
          "ticker_sentiment_score": "0.055717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.042876",
          "ticker_sentiment_score": "0.055717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIFE",
          "relevance_score": "0.042876",
          "ticker_sentiment_score": "0.055717",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bright Minds Biosciences Announces Non-Executive Director Appointment",
      "url": "https://www.globenewswire.com/news-release/2023/02/17/2610514/0/en/Bright-Minds-Biosciences-Announces-Non-Executive-Director-Appointment.html",
      "time_published": "20230217T115000",
      "authors": [
        "Bright Minds Biosciences"
      ],
      "summary": "David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/a119dbec-a019-4ff2-be29-6a110f1088e6?size=1",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.253877,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.085173",
          "ticker_sentiment_score": "0.195807",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LUMO",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.05765",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HHC",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.05765",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.05765",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIFE",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.05765",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization",
      "url": "https://www.globenewswire.com/news-release/2022/06/27/2469321/0/en/Bright-Minds-Biosciences-Announces-Changes-to-its-Executive-Leadership-Team-Marking-the-Transition-to-a-Development-Organization.html",
      "time_published": "20220627T105000",
      "authors": [
        "Bright Minds Biosciences"
      ],
      "summary": "VANCOUVER, British Columbia, June 27, 2022 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences ( \"Bright Minds,\" \"BMB\" or the \"Company\" ) ( Nasdaq: DRUG ) ( CSE: DRUG ) , a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/a119dbec-a019-4ff2-be29-6a110f1088e6?size=1",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.468323,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.158728",
          "ticker_sentiment_score": "0.437405",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.039931",
          "ticker_sentiment_score": "0.523192",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alector Provides Executive Leadership Update",
      "url": "https://www.globenewswire.com/news-release/2025/03/28/3051632/0/en/Alector-Provides-Executive-Leadership-Update.html",
      "time_published": "20250328T200500",
      "authors": [
        "Alector LLC"
      ],
      "summary": "--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/cc1d53f9-03a6-42d4-aba2-ab4ce7b73508",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.167419,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACAD",
          "relevance_score": "0.039418",
          "ticker_sentiment_score": "-0.009724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALEC",
          "relevance_score": "0.599202",
          "ticker_sentiment_score": "0.24574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization",
      "url": "https://www.benzinga.com/pressreleases/22/06/g27858251/bright-minds-biosciences-announces-changes-to-its-executive-leadership-team-marking-the-transition",
      "time_published": "20220627T105000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "VANCOUVER, British Columbia, June 27, 2022 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences ( \"Bright Minds,\" \"BMB\" or the \"Company\" ) DRUG DRUG, a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced ...",
      "banner_image": "",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.427692,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRUG",
          "relevance_score": "0.155026",
          "ticker_sentiment_score": "0.443211",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.038988",
          "ticker_sentiment_score": "0.526732",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Sumo Logic Appoints John D. Harkey, Jr. to Board of Directors",
      "url": "https://www.globenewswire.com/news-release/2022/05/03/2435151/0/en/Sumo-Logic-Appoints-John-D-Harkey-Jr-to-Board-of-Directors.html",
      "time_published": "20220503T215400",
      "authors": [
        "Inc.",
        "Sumo Logic"
      ],
      "summary": "REDWOOD CITY, Calif., May  03, 2022   ( GLOBE NEWSWIRE )  -- Sumo Logic  ( Nasdaq: SUMO ) , the SaaS analytics platform to enable reliable and secure cloud-native applications, today announced that it has appointed John D. Harkey, Jr. to its Board of Directors, effective immediately. With this addit",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/e305eb9a-106f-4758-91fe-5089dcb384e4?size=1",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.174392,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.036716",
          "ticker_sentiment_score": "0.003794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.036716",
          "ticker_sentiment_score": "0.003794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SUMO",
          "relevance_score": "0.45045",
          "ticker_sentiment_score": "0.373291",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TSAT",
          "relevance_score": "0.036716",
          "ticker_sentiment_score": "0.003794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.036716",
          "ticker_sentiment_score": "0.003794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ET",
          "relevance_score": "0.036716",
          "ticker_sentiment_score": "0.003794",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors",
      "url": "https://www.benzinga.com/pressreleases/24/02/g37359279/axosim-appoints-two-biotech-industry-veterans-as-co-chairs-of-its-board-of-directors",
      "time_published": "20240228T120000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW ORLEANS, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- AxoSim, Inc., a leader in the development and application of 3D organoid neurodiscovery platforms, today announced that current directors Dale Pfost, PhD, and David Weiner, MD, have been appointed as Co-Chairs of AxoSim's Board of Directors.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.175774,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CMMB",
          "relevance_score": "0.0367",
          "ticker_sentiment_score": "0.020306",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LUMO",
          "relevance_score": "0.0367",
          "ticker_sentiment_score": "0.030365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HHH",
          "relevance_score": "0.0367",
          "ticker_sentiment_score": "0.030365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.0367",
          "ticker_sentiment_score": "0.030365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPK",
          "relevance_score": "0.0367",
          "ticker_sentiment_score": "0.020306",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LIFE",
          "relevance_score": "0.0367",
          "ticker_sentiment_score": "0.030365",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why This Top-Notch Solar Stock Is Outperforming Its Rivals",
      "url": "https://www.investors.com/research/the-new-america/enph-stock-why-this-highflying-solar-player-is-outperforming-its-rivals/",
      "time_published": "20220623T205900",
      "authors": [
        "ALLISON GATLIN",
        "Investor's Business Daily"
      ],
      "summary": "From solar panels to electric vehicles, green energy is booming, says Enphase Energy ( ENPH ) Chief Executive Badri Kothandaraman, as ENPH stock outperforms its rivals. The company was founded in 2006 and makes microinverters, plug-and-play devices that convert the electricity generated by ...",
      "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/wNAshipments062022.jpg",
      "source": "Investors Business Daily",
      "category_within_source": "n/a",
      "source_domain": "www.investors.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999922"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.030718,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENPH",
          "relevance_score": "0.343517",
          "ticker_sentiment_score": "0.006143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEDG",
          "relevance_score": "0.175987",
          "ticker_sentiment_score": "0.02832",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.070882",
          "ticker_sentiment_score": "0.061138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VALN",
          "relevance_score": "0.035476",
          "ticker_sentiment_score": "0.030529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GM",
          "relevance_score": "0.070882",
          "ticker_sentiment_score": "0.061138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.035476",
          "ticker_sentiment_score": "-0.020895",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DQ",
          "relevance_score": "0.070882",
          "ticker_sentiment_score": "0.060501",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.035476",
          "ticker_sentiment_score": "0.030529",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sumo Logic Appoints John D. Harkey, Jr. to Board of Directors",
      "url": "https://www.benzinga.com/pressreleases/22/05/g26980042/sumo-logic-appoints-john-d-harkey-jr-to-board-of-directors",
      "time_published": "20220503T215406",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "REDWOOD CITY, Calif., May  03, 2022   ( GLOBE NEWSWIRE )  -- Sumo Logic  ( NASDAQ:SUMO ) , the SaaS analytics platform to enable reliable and secure cloud-native applications, today announced that it has appointed John D. Harkey, Jr. to its Board of Directors, effective immediately. With this additi",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.179298,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.035397",
          "ticker_sentiment_score": "0.003339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.035397",
          "ticker_sentiment_score": "0.003339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SUMO",
          "relevance_score": "0.494385",
          "ticker_sentiment_score": "0.402655",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TSAT",
          "relevance_score": "0.035397",
          "ticker_sentiment_score": "0.003339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.035397",
          "ticker_sentiment_score": "0.003339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ET",
          "relevance_score": "0.035397",
          "ticker_sentiment_score": "0.003339",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS",
      "url": "https://www.prnewswire.com/news-releases/lipocine-announces-board-of-director-appointments-301521263.html",
      "time_published": "20220411T120000",
      "authors": [
        "Lipocine Inc."
      ],
      "summary": "SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Lipocine Inc.  ( NASDAQ: LPCN ) , a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors.",
      "banner_image": "https://mma.prnewswire.com/media/627654/Lipocine_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.103144,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SFTBF",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.030499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAX",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.030499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASRT",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.030499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.019477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPCN",
          "relevance_score": "0.506736",
          "ticker_sentiment_score": "0.159631",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MMM",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.030499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.019477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.034155",
          "ticker_sentiment_score": "0.019477",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bionomics appoints Spyridon \"Spyros\" Papapetropoulos as President and Chief Executive Officer",
      "url": "https://www.globenewswire.com/news-release/2022/12/15/2575165/0/en/Bionomics-appoints-Spyridon-Spyros-Papapetropoulos-as-President-and-Chief-Executive-Officer.html",
      "time_published": "20221215T233500",
      "authors": [
        "Bionomics Ltd"
      ],
      "summary": "Experienced biotech executive to lead the next phase of growth Experienced biotech executive to lead the next phase of growth ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/822aaa99-a2bd-4905-ab9c-07869668b7f7?size=1",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.111253,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VIGL",
          "relevance_score": "0.029256",
          "ticker_sentiment_score": "0.040331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNOX",
          "relevance_score": "0.558802",
          "ticker_sentiment_score": "0.169467",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.029256",
          "ticker_sentiment_score": "0.040331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.029256",
          "ticker_sentiment_score": "0.040331",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.029256",
          "ticker_sentiment_score": "0.040331",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio",
      "url": "https://www.prnewswire.com/news-releases/parkinsons-disease-psychosis-market-is-likely-to-increase-at-a-steady-growth-rate-by-2032-estimates-delveinsight--key-companies-working-to-develop-therapies---vanda-kyowa-kirin-sage-athira-aptinyx-cogstate-agenebio-301941331.html",
      "time_published": "20231002T210100",
      "authors": [
        "LLP",
        "DelveInsight Business Research"
      ],
      "summary": "Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight ... PR ...",
      "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.204202,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BIVI",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DNLI",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KRTX",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.073271",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CERE",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRTA",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.054983",
          "ticker_sentiment_score": "0.104827",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KNBWF",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.096754",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APTX",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.096754",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATHA",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.096754",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.054983",
          "ticker_sentiment_score": "0.057847",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANVS",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DNPUF",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.049131",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLNN",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSUMF",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.049131",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.096754",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VNDA",
          "relevance_score": "0.082393",
          "ticker_sentiment_score": "0.094921",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KYKOF",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.096754",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.027508",
          "ticker_sentiment_score": "0.032597",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bionomics appoints Spyridon \"Spyros\" Papapetropoulos as President and Chief Executive Officer - Bionomics  ( NASDAQ:BNOX ) ",
      "url": "https://www.benzinga.com/pressreleases/22/12/g30102460/bionomics-appoints-spyridon-spyros-papapetropoulos-as-president-and-chief-executive-officer",
      "time_published": "20221215T233525",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "ADELAIDE, Australia, Dec. 15, 2022 ( GLOBE NEWSWIRE ) -- Bionomics Limited BNOXBNO ) ) , ( Bionomics or the Company ) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous ...",
      "banner_image": "",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.12047,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VIGL",
          "relevance_score": "0.026241",
          "ticker_sentiment_score": "0.038711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.026241",
          "ticker_sentiment_score": "0.038711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AWON",
          "relevance_score": "0.026241",
          "ticker_sentiment_score": "0.070333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.026241",
          "ticker_sentiment_score": "0.038711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.026241",
          "ticker_sentiment_score": "0.038711",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Stocks That Hit 52-Week Highs On Thursday",
      "url": "https://www.benzinga.com/news/22/04/26526399/stocks-that-hit-52-week-highs-on-thursday",
      "time_published": "20220407T171622",
      "authors": [],
      "summary": "On Thursday, 75 stocks made new 52-week highs.\nInteresting Highlights From Today's 52-Week Highs:\nThe largest company by market cap to hit a new 52-week high was UnitedHealth Group  ( NYSE:UNH ) .\nThe smallest company in terms of market cap to set a new 52-week high was China Jo-Jo Drugstores  ( NAS",
      "banner_image": "https://cdn.benzinga.com/files/imagecache/story_image_685x375C/images/story/2022/movers_image_6081.jpeg",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.997787"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": -0.033332,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ACHC",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.001359",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IPI",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.010927",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCKT",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.005673",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STE",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.301993",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.349974",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BHSE",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.186751",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "IDA",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.000341",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.001096",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRY",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.016754",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNK",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.007037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LNT",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.190354",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ORLY",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.00224",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBF",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.49504",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "TRVI",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.02339",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KACL",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.001068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKH",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.000726",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GIA",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.041278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MGEE",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.00083",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ED",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.116147",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CEG",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-5.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.002383",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRCC",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.002047",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSY",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.196556",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "FCN",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.000318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.000563",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZO",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.000372",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VST",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.003623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MGPI",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.000451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMPH",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.002041",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VNOM",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.018862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.005714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WEYS",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.098337",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTAQ",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.003649",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EURN",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.001711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.048984",
          "ticker_sentiment_score": "0.036965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASC",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.004068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.00086",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MUSA",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.004653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LNTH",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.005074",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGML",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.000379",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UTAA",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.33201",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.098119",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCRX",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.055114",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PDS",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.059631",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.000882",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AON",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.002264",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BOCN",
          "relevance_score": "0.048984",
          "ticker_sentiment_score": "-0.198662",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SRRA",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.002133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AORT",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.005558",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.005495",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBFM",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.003473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZETA",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.008741",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.003391",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MIRM",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.016888",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCK",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.007374",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TK",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.007037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANTM",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.007595",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OGS",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "-0.003648",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.024504",
          "ticker_sentiment_score": "0.000834",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CJJD",
          "relevance_score": "0.073419",
          "ticker_sentiment_score": "0.069308",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "With 7.2% CAGR, Neurodegenerative Diseases Drugs Market Size to Surpass Around USD 62,786.2 Million by 2028",
      "url": "https://www.benzinga.com/pressreleases/22/06/g27894962/with-7-2-cagr-neurodegenerative-diseases-drugs-market-size-to-surpass-around-usd-62-786-2-million-",
      "time_published": "20220629T082959",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Pune, India, June 29, 2022 ( GLOBE NEWSWIRE ) -- The global neurodegenerative diseases drugs market is likely to gain traction from the rising incidence of neurodegenerative diseases worldwide. Such diseases pose a greater burden on the physical and mental health of the populaces, as well as on ...",
      "banner_image": "",
      "source": "Benzinga",
      "category_within_source": "Mergers",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.01564,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MSBHF",
          "relevance_score": "0.024",
          "ticker_sentiment_score": "0.001294",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.024",
          "ticker_sentiment_score": "0.001294",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.024",
          "ticker_sentiment_score": "0.001294",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ESALF",
          "relevance_score": "0.047979",
          "ticker_sentiment_score": "-0.027699",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.095784",
          "ticker_sentiment_score": "-0.027699",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Global Positive Allosteric Modulators Market to Grow at a Significant CAGR During 2022-2031; Market to Grow on the Back of the Increasing Prevalence of Chronic Mental Disorders, Upsurge in the Geriatric Population, and Advancement in R&D",
      "url": "https://www.benzinga.com/pressreleases/22/07/g28154556/global-positive-allosteric-modulators-market-to-grow-at-a-significant-cagr-during-2022-2031-market",
      "time_published": "20220721T152111",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, July 21, 2022 ( GLOBE NEWSWIRE ) -- As per the World Health Organization, anxiety and depressive disorders are estimated to be the most prevalent mental disorders, affecting 1 in 8 persons, or 970 million people worldwide, in 2019.",
      "banner_image": "",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.118894,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GIC",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.153095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NHGP",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.153095",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.023259",
          "ticker_sentiment_score": "0.104716",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation",
      "url": "https://www.prnewswire.com/news-releases/alkermes-publishes-investor-presentation-detailing-companys-transformation-and-value-creation-301846055.html",
      "time_published": "20230608T110000",
      "authors": [
        "Alkermes plc"
      ],
      "summary": "Alkermes Publishes Investor Presentation Detailing Company's ... PR ...",
      "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.178691,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.322255",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.277312",
          "ticker_sentiment_score": "0.20266",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.021778",
          "ticker_sentiment_score": "0.125225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.043539",
          "ticker_sentiment_score": "-0.097648",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ",
      "url": "https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di",
      "time_published": "20230613T110000",
      "authors": [
        "PRNewswire"
      ],
      "summary": "Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote \"FOR\" Alkermes' Director Nominees on Company's WHITE Proxy Card",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.165805,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRM",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.122763",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.028649",
          "ticker_sentiment_score": "0.027306",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INFI",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.177696",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PRTA",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ENDPQ",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.350825",
          "ticker_sentiment_score": "0.247017",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.047079",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.028649",
          "ticker_sentiment_score": "-0.042413",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDXG",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.048746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPTX",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.177696",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXLA",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.048746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IDXX",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "-0.112723",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZLAB",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.177696",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.122763",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.019102",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CYCN",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "-0.048746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.009551",
          "ticker_sentiment_score": "0.062837",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders",
      "url": "https://www.prnewswire.com/news-releases/recently-appointed-independent-directors-of-alkermes-issue-open-letter-to-shareholders-301862757.html",
      "time_published": "20230626T110000",
      "authors": [
        "Alkermes plc"
      ],
      "summary": "Recommend Shareholders Vote \"For\" Alkermes' Seven Director Nominees On Company's Proxy Card",
      "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.258622,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.234978",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.366061",
          "ticker_sentiment_score": "0.396186",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.018995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders - Alkermes  ( NASDAQ:ALKS ) ",
      "url": "https://www.benzinga.com/pressreleases/23/06/n33002604/recently-appointed-independent-directors-of-alkermes-issue-open-letter-to-shareholders",
      "time_published": "20230626T110000",
      "authors": [
        "PRNewswire"
      ],
      "summary": "Recommend Shareholders Vote \"For\" Alkermes' Seven Director Nominees On Company's White Proxy Card",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.251682,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.234378",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.322608",
          "ticker_sentiment_score": "0.344551",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.018439",
          "ticker_sentiment_score": "0.125498",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Earnings Scheduled For May 4, 2022",
      "url": "https://www.benzinga.com/news/earnings/22/05/26983503/earnings-scheduled-for-may-4-2022",
      "time_published": "20220504T083630",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Companies Reporting Before The Bell\n\u2022 Seres Therapeutics  ( NASDAQ:MCRB )  is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.\n\u2022 Obsidian Energy  ( AMEX:OBE )  is projected to report quarterly earnings at $0.41 per share on revenue of $156.00 million.\n\u2022 Internationa",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2022/earnings_image_5094.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": -0.019324,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SGFY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRIP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.034285",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CDE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.080282",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000233",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVST",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "9.5e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVID",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GDDY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000156",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NGVT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002391",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VIASP",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "-0.001015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DOCN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-5.7e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMSI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.078126",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PNW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INSG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.068836",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCMP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVRO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.079762",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STOR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000428",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WING",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001669",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.135974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EDIT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.098895",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SUM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.120782",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAND",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.188371",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SUN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-5.2e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TWO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000727",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPXC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000219",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EMKR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000752",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SUP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.020661",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JCI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.010034",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SOVO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLYM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.047269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RNWK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.097039",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MIR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.004926",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNCY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001018",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TTMI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001046",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001554",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VCEL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.039721",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASTE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCAB",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.025865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BDC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001702",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.006215",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOLD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.004027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SVC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.022563",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVEC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.003778",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TXG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.067828",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GNK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.032283",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CDAY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.020451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALGS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.009086",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DMAC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002571",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGLD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FATE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.093835",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "L",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ONL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.007641",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KIDS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.079451",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "O",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "-0.001161",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HNGR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.040575",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QLYS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "6.5e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.034363",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBOW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-9e-06",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LGND",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-8.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.026328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDVT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.007214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACEL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000545",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMYT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.028214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.005276",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UDMY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.010808",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SIMO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.004804",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCRB",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.026492",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CF",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000158",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STAA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DIN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNEX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001518",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SWM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000564",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RUN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.014944",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INSW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.032033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VMC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VICI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000373",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVOP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000243",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FTHM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.094966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SILK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.113261",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TIG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-5.9e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000642",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VATE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00332",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-7.2e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HDSN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.004283",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-2.4e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MANT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001128",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GTES",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WOLF",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.10971",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ATO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000601",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001044",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCCI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000666",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGU",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.010355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REV",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.051309",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CXW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001555",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLMR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001155",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.332341",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TCPC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000131",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EWCZ",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.003538",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HBB",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.0005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PAHC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000429",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PAY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000257",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVGI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.003864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BWA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LITE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.002384",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FNV",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001372",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MLR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001172",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00094",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NUVA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000553",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TALO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00035",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGNX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.132676",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LOPE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.027965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.033875",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GTHX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.069924",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AUR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.066892",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVNW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVNS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.003919",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNDM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.056651",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DCPH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00082",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HST",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "7.9e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EMR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00018",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001757",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ERII",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-3.8e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ES",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002757",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ET",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000218",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "YUM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TECH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.008098",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UMH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.004968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INVE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.036802",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QRVO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000159",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000294",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMST",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000404",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PAGP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000793",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BHG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.059664",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AFG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000119",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTVA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001884",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LHCG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000101",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPNT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.005552",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JHG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-4e-06",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LUMN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STWD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000102",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "0.000355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BHR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRTX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.031955",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GBT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.124909",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SDGR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.034718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MARA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.01323",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ONEM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.023797",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RYI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.005913",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RYN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.0007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSSS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.089978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALLO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.044002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MGNI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001309",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OSW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.095029",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLVS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.094165",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DGII",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000734",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LNC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.004348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TTEK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.030062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LOCO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000196",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NARI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.021156",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RMNI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "6.2e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EQC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-2.4e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTRA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.072221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PETQ",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000241",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVFM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00998",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QNST",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000245",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DOC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00113",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRBT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.115298",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KRMD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.097489",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TGLS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.003077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-3.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.141922",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSNL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.014517",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000176",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMPY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.002798",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GEL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.020219",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QUOT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-6.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CASA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.077969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCOR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.022751",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRTO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00046",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ECPG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.002357",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FTNT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "5.1e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMPL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.035448",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACLS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000417",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RCII",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EAT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000283",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TTEC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001193",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DIOD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-1.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KURA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.011268",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NMIH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.0001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSLY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.069955",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PXD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000652",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZYME",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.249968",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MAR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.004212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AXGN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.033494",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BLK",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "0.000131",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSGS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00045",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ROCK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FTS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TPC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000165",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.008732",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000759",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TPL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000171",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANSS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FDP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.011596",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CFMS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.024946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PING",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.102841",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBGI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.180633",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "KD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.005473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAVE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.012685",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PCRX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000121",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNMD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.017756",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FUN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.034569",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SITE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ISEE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.014194",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SITM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000445",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XYL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "2.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KW",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.003213",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NUS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CMLS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.019917",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CYTK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.072263",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FSNUF",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "0.000401",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PDCE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.004715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DRRX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.037553",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UPLD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002378",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ETSY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.004734",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.057626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALB",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADPT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.004494",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CPE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.0007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GNRC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.004724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IDXX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ROCC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000266",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-1e-06",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OTEX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.004174",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GXO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000414",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ICFI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000522",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LL",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "-0.00198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALL",
          "relevance_score": "0.005449",
          "ticker_sentiment_score": "-0.011251",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HBIO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MTG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.0002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ELVT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.016692",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CGAU",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "THRM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002428",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VMEO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.02363",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "USDP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000173",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSII",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.089001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LILA",
          "relevance_score": "0.016346",
          "ticker_sentiment_score": "-0.000495",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WHD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000251",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.145862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTVE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001742",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EYPT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.027626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "THRY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000232",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SIGI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000223",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDU",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-5.3e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DLHC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00093",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LSI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000614",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NWN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000298",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ORCC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TWNK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001561",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRKR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001838",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GIL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MUR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.002163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WEAV",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.084964",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PKI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00049",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DCP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.00043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000649",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RAIN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.015152",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LCI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.022388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBAY",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001249",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.018302",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NWPX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "5.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.033963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CENT",
          "relevance_score": "0.016346",
          "ticker_sentiment_score": "0.001833",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMRE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000399",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "1.2e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TREC",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.017159",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MET",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001571",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ESTE",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000187",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MNRL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "5.1e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKLZ",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.05282",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MNTX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.019013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPRX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.018236",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VAPO",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.033042",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADTN",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000175",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.001227",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MNTV",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.089965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.023996",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEPH",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.130859",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.061507",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXPI",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HEAR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.055083",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AEVA",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.072738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PARR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.072537",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EFX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-6.1e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.016367",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PRTK",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.009854",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKNG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.071073",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.058987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FBRT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-7.6e-05",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OM",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.088105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QDEL",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.000246",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OPAD",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.003347",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APLS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.136632",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NYT",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.006565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GKOS",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.033983",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "USER",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.08651",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTRX",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TUP",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.00023",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLNG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.086814",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APG",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "0.000381",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCOR",
          "relevance_score": "0.010898",
          "ticker_sentiment_score": "-0.001682",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value",
      "url": "https://www.prnewswire.com/news-releases/alkermes-files-definitive-proxy-statement-and-issues-letter-to-shareholders-detailing-business-execution-that-has-driven-strong-performance-and-delivered-shareholder-value-301835124.html",
      "time_published": "20230525T201500",
      "authors": [
        "Alkermes plc"
      ],
      "summary": "Alkermes Files Definitive Proxy Statement and Issues Letter to ... PR ...",
      "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
      "source": "PR Newswire",
      "category_within_source": "n/a",
      "source_domain": "www.prnewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.304093,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.137825",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.110344",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.136033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.463562",
          "ticker_sentiment_score": "0.421704",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.008968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value - Alkermes  ( NASDAQ:ALKS ) ",
      "url": "https://www.benzinga.com/pressreleases/23/05/n32584139/alkermes-files-definitive-proxy-statement-and-issues-letter-to-shareholders-detailing-business-exe",
      "time_published": "20230525T201500",
      "authors": [
        "PRNewswire"
      ],
      "summary": "Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.301909,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RARE",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.137791",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.110316",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IONS",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.135999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALKS",
          "relevance_score": "0.46204",
          "ticker_sentiment_score": "0.436007",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "UTHR",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PTCT",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HZNP",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EBS",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXEL",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACAD",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.008935",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}